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BILATERAL ADRENALECTOM Y AS TREATMENT FOR CUSHING'S DISEASE
In this thesis the results of bilateral adrenalectom y as treatm ent for Cushing's disease 
(p itu itary -dependen t bilateral adrenal hyperplasia) are studied. This first chapter contains a 
short in troduction  to the different forms of Cushing's syndrom e and reviews curren t knowledge 
of treatm ent modalities in  Cushing's disease.
1.1 C U S H IN G ’S S Y N D R O M E
On top of each kidney lies an adrenal gland, an organ that is only about one inch long, 
producing glucocorticoids, mineralocorticoids and adrenal sex hormones. Patients w ith Cushing's 
syndrome suffer from overproduction of the glucocorticoid hormone cortisol, leading to visible 
symptoms like filling out of the face (creating a so-called moonface) and the abdomen, skin changes 
such as easy bruising, poor wound healing, hirsutism, and striae. Excessive cortisol production can 
also lead to many other symptoms, such as fatigue and muscular weakness, hypertension, diabetes, 
menstrual disorders, impotence, infertility, osteoporosis, kidney stones and even psychological 
changes. As these symptoms often appear only gradually, and in the early stages are very vague, it 
often takes a long time before an accurate diagnosis can be made.
In 1912 Harvey Cushing described the first patien t w ith  th is disorder (1). This patient had 
rapidly acquired central obesity, hirsutism , am enorrhea, and muscle weakness. On physical 
exam ination she had a round  face, supraclavicular fat pads, and it was noted  th a t the skin was 
th in  and dry, w ith  considerable pigm entation, num erous ecchymoses and purp lish  striae. A t 
th a t time, Cushing was uncertain  as to w hether the symptoms were attributable to pituitary, 
adrenal, pineal, or ovarian influences. In 1932, Cushing published his classic m onograph, 'The 
Basophil Adenomas of the P itu itary  Body and Their Clinical M anifestations', w hich included a 
fu rther description of the patien t initially described in  1912, as well as reports on 11 other 
patients w ith  similar presenting sym ptom s (2). In Cushing's original series, three of eight 
patients who were autopsied had basophilic p itu itary  adenomas, two had chrom ophobe 
adenomas, and one had an 'adenom atous-like' structure. Cushing postulated th a t most patients 
w ith  features of chronic hypercortisolism  w ould have tum ors of the p itu itary  gland.
Nowadays, much more is know n about Cushing's syndrom e. Endogenous Cushing's 
syndrom e is a clinical state resulting from  prolonged, inappropriate endogenous secretion of 
cortisol and hence excess circulating free cortisol, characterized by loss of the norm al feedback 
mechanisms of the hypothalam o-pituitary-adrenal axis and the norm al circadian rhy thm  of cor­
tisol secretion (3). The cause of Cushing's syndrom e may be excessive ACTH production  from 
the p itu itary  gland (Cushing's disease), ectopic ACTH secretion by a non-p itu itary  tum or (e.g., 
bronchial carcinoid tum or, small-cell lung cancer, m edullary thyroid carcinoma), or excessive 
secretion of cortisol by an adrenocortical adenom a or carcinoma (4). In  addition, the syndrom e 
may be caused by ectopic CRH secretion (5), bilateral prim ary pigm ented m icronodular adrenal 
hyperplasia (6), prim ary m acronodular adrenal hyperplasia (7), w hich may be associated w ith  
expression of receptors for gastric-inhibitory peptide or catecholamines (8, 9, 10), or by adreno­
cortical hyperfunction  due to the M cCune-A lbright syndrom e (11). Pseudo-Cushing's states, 
w hich may have a similar clinical presentation and clear evidence of hypercortisolism , may be 
caused by alcohol abuse (12, 13, 14) and depression (15).
GENERAL IN TR O D U CTIO N  A N D  O U TLIN E OF T H E THESIS
1.2 T R E A T M E N T  M O D A L IT IE S  IN  C U S H IN G ’S D ISEASE
As this thesis is focussed on the treatm ent of patients w ith  ACTH-dependent bilateral 
adrenal hyperplasia (Cushing's disease) by bilateral adrenalectomy, we will now  review  curren t 
knowledge on treatm ent modalities in  Cushing's disease.
In  the past the only effective treatm ent in  patients w ith  Cushing's disease was bilateral 
total adrenalectom y w ith  life-long suppletion of gluco- and m ineralocorticoids afterw ards 
(16, 17, 18, 19). Later on, in  the seventies, new  treatm ent modalities were introduced, i.e., p itu ­
itary  m icrosurgery (20, 21, 22, 23, 24) and p itu itary  irradiation  (25, 26, 27, 28). Drug therapy 
w ith  adrenal enzyme inhibitors, such as ketoconazole, m etyrapone, or am inoglutethim ide, 
given alone or in  com bination (29), are sometimes useful as adjunctive therapy.
1.2.1 Pituitary surgery as trea tm ent modality for Cushing’s disease
Oscar H irsch and Harvey Cushing developed the classical transsphenoidal approach to the 
sella turcica in  hum ans (30, 31, 32, 33). Indeed nowadays the treatm ent of choice for patients 
w ith  Cushing's disease is transsphenoidal m icroadenom ectomy (23). The evolution of this sur­
gical technique and the developm ent of surgical instrum ents for endoscopic endonasal 
transsphenoidal p itu itary  surgery has made th is operation cleaner, easier and faster (34). 
However, p itu itary  surgery is not successful in  all patients. The rarity  of Cushing's disease pre­
cludes the collection of large series of patients undergoing transsphenoidal operation in  the 
same institu tion , thus m aking it difficult to assess the preoperative and postoperative factors 
influencing the immediate and late results of p itu itary  surgery. The European Cushing's Disease 
Survey Study Group reported  on 668 patients w ith  Cushing's disease from 25 institu tions 
th roughou t Europe treated w ith  transsphenoidal surgery betw een 1975 and 1990 (35). Early 
clinical and biochemical remission of hypercortisolism  after surgery occurred in  76.3% of 
patients. Recurrence of the disease, however, occurred in  12.7% of 510 patients in  remission 
after surgery at a mean time of 39.3 m onths. The d istribu tion  of the recurrences did no t show 
any plateau or cluster th roughou t the follow-up period, so it may be expected th a t w ith  longer 
follow-up more relapses will be observed. In  an Italian m ulticenter study transsphenoidal p itu ­
itary  m icrosurgery resulted in  com plete remission in  69%  of 236 patients w ith  Cushing's 
disease (36). The overall relapse rate after pitu itary  surgery was 17%. The relapse-free survival, 
as assessed by Kaplan-Meier analysis, was 95% at 12 months, 84% at 2 year, and 80% at 3 year 
in  this study. In the study of Sonino et al. (37) pitu itary  surgery was successful in  79 of 103 
patients (76.7%). The estimated cumulative percentage of patients remaining in  remission after 
successful pitu itary  surgery in  this study was 93.7%  after 2 years, 80.6% after 5 years, 78.5% 
after 7 years, and 74.1% after 10 years (follow-up period between 2 and 16 years, mean 7.3 +/-
3.4 years).
Clinical remission of Cushing's disease after p itu itary  surgery was found to be associated 
w ith  finding a m orning serum  cortisol level and a 24-hour u rinary  cortisol excretion postoper­
atively clearly below normal, especially w hen accom panied by sym ptom s of secondary adreno­
cortical insufficiency (35, 37). However, a small num ber of patients in  whom  p itu itary  surgery 
induces a remission of the disease are no t hypocortisolaem ic immediately after surgery, for 
example patients w ith  adrenal macronodules, periodic hypersecretion of cortisol, or patients
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BILATERAL ADRENALECTOM Y AS TREATMENT FOR CUSHING'S DISEASE
receiving medical treatm ent to lower the ir cortisol production  before surgery (38, 39, 40, 41). 
A bsent ACTH inh ib ition  after dexam ethasone, an exaggerated response to CRH testing (42), as 
well as persistence of the ACTH response to desm opressin in  the early postoperative period (43) 
were described as predictive factors for relapse of Cushing's disease. However, caution is needed 
in  the in terpretation  of the low-dose dexam ethasone test postoperatively. Failure to suppress 
serum  cortisol levels w ith  dexam ethasone in  the early postoperative period, b u t norm al 
suppressibility  later, and a course com patible w ith  cure have been reported  (44). On the other 
hand, persistent or recurren t Cushing's disease after operation, despite full suppression w ith  
dexam ethasone, have also been described (45, 46). V isualization of the adenom a on a preoper­
ative CT or MRI was strongly correlated w ith  remission of Cushing's disease after p itu itary  
surgery in  the series of Bochicchio et al. and Sonino et al. (35, 37), b u t not in  the series of Invitti 
e t al. (36). Cure rates tended  to be better w hen a p itu itary  adenoma was histologically 
confirmed (36, 47). Furtherm ore cure rates were h igher for microadenom as than  for macroade­
nomas in  some series (47), b u t no t in  others (35).
The risk  of relapse of Cushing's disease is also associated w ith  the early postoperative 
m orning serum  cortisol level as well as w ith  the 24-hour u rinary  cortisol excretion in  the imme­
diate postoperative period and also w ith  ACTH hyperresponsiveness in  an early postoperative 
CRH test (36, 47), although  there is considerable overlap in  responses betw een patients who do 
and those who do no t relapse (46, 48).
Surgical m ortality  after transsphenoidal surgery for Cushing's disease is low (0 to 1.9%), 
while major m orbidity  (cerebrospinal fluid rhinorrhea, meningitis, vascular in jury  or profuse 
bleeding, and pulm onary embolism) has been reported  in  4.5%  of patients (35, 49). P itu itary  
insufficiency after transsphenoidal surgery seems to be determ ined by the ex ten t of surgery. In 
an overview of 6 series of postoperative p itu itary  function after transsphenoidal adenomectomy 
for Cushing's disease, secondary hypogonadism  occurred in  3 to 48% , hypothyroidism  in 13 to 
40%  and persistent diabetes insipidus in  3 to 47%  (47).
1.2.2 Pituitary radiotherapy as trea tm ent modality for Cushing’s disease
For patients w ith  Cushing's disease not cured by, or relapsing after transsphenoidal 
surgery, p itu itary  irradiation  nowadays is considered as the most appropriate second line treat­
m ent w ith  long-term  response rates varying from  46 to 67%  (27, 28, 50, 51, 52). In the study 
of Sonino et al. (37) 42 patients w ith  Cushing's disease were treated w ith  p itu itary  irradiation, 
including 19 for w hom  it was the first treatm ent. Remission was defined as norm alization of 
24-hour urinary  cortisol excretion and adequate dexamethasone suppressibility while off medical 
therapy. A fter a follow-up period of 2 years, irradiation  w ith  45 to 50 Gy resulted in  remission 
in  23 patients (54.8%). A fter cure by p itu itary  irradiation and w ith  a follow-up period of 2-18 
years, in  this series the estim ated cum ulative percentages of patients rem aining in  remission 
were 100% after 2 years, 81.8%  after 5 years, 71.6%  after 7 years, and 65.1%  after 10 years. 
Estrada et al. (54) reported  on 30 patients treated w ith  external p itu itary  radiation  w ith  50 ± 1  
Gy, for persistent or recurren t Cushing's disease after transsphenoidal surgery. Like in  the study 
of Sonino et al. (37), remission was defined as the regression of sym ptom s and signs of 
Cushing's syndrom e, norm al 24-hour urinary  cortisol excretion, and adequate dexam ethasone 
suppressibility. Twenty-five patients (83%) had a remission after a median follow-up of 42
GENERAL IN TR O D U CTIO N  A N D  O U TLIN E OF THE THESIS
months (range 18 to  114 months). The remission started between 6 and 60 m onths after radiation 
therapy, b u t in  most cases remission occurred during  the first 2 years. None of these patients 
had a relapse of Cushing's disease after remission was achieved.
Previous p itu itary  surgery, although unsuccessful, appeared to be a protective factor for 
relapse (37), whereas factors like age, sex, the pretreatm ent 24-hour u rinary  cortisol excretion, 
the pretreatm ent plasma ACTH level, the interval between surgery and radiotherapy, the finding 
of a p itu itary  adenom a by pathological exam ination, or tum or size, did not attain  statistical 
significance (37, 53).
Sandler et al. (54) reported  on 82 patients w ith  Cushing's disease treated w ith  in terstitial 
irradiation  (by needle im plantation w ith  yttrium -90 or gold-198) as the sole therapy. One year 
after treatm ent 77% achieved remission. Of 54 patients in  remission, who were followed for 
3-26 years, no one relapsed. Newer forms of stereotactic radiotherapy - the 'pho ton  knife' (55) 
or the 'gamma knife' (56, 57, 58) - may be more effective, b u t experience w ith  them  is still 
lim ited. These are one-day procedures th a t expose the surrounding neuronal tissues to less irra­
diation than  conventional radiotherapy.
P itu itary  dysfunction  is the most common side effect of p itu itary  irradiation. Of the 30 
patients in  the study of Estrada et al. (53), who were irradiated  for Cushing's disease (median 
follow-up 42 months), 17 (57%) developed a deficiency of grow th horm one, 10 (33%) a defi­
ciency of gonadotropins, 4 (13%) a deficiency of thyrotropin , and 1 (3%) a deficiency of corti­
cotropin. Sandler et al. (54) reported  th a t 14 of 54 (26%) patients required corticosteroid or 
thyroid horm one replacem ent therapy, 3 to 26 years after interstitial irradiation. In  smaller 
studies p itu itary  irradiation for Cushing's disease also frequently  resulted in  p itu itary  dys­
function, i.e. grow th horm one deficiency in  50% , gonadotropin deficiency in  7 to 25% , and 
TSH deficiency in  12.5 to 14% (50, 59).
During the time required  to achieve the maximal benefit from irradiation, hypercortisolism  
can be controlled w ith  adrenal enzym e inhibitors, such as ketoconazole, m etyrapone, or 
am inoglutethim ide, given alone or in  com bination.
1.2.3 Bilateral adrenalectomy as trea tm en t modality for Cushing’s disease
Prior to the in troduction of transsphenoidal pitu itary  microsurgery, bilateral adrenalectomy 
was the treatm ent of choice for Cushing's disease in  most centers. Currently, indications for 
bilateral adrenalectom y in patients w ith  Cushing's disease are (a) severe hypercortisolism , 
persisting after p itu itary  surgery, w hich is no t reversible w ith  adrenal enzym e inhibition , tha t 
requires prom pt reversal of symptoms, and (b) hypercortisolism , persisting despite p itu itary  
surgery and radiotherapy, as alternative for long-term  treatm ent w ith  adrenal enzyme 
inhibitors. The consequences of total adrenalectomy are the need for life-long replacement therapy 
w ith  gluco- and m ineralocorticoids, the risk  of life-threatening acute adrenal insufficiency 
(Addisonian crisis) and the risk  of developm ent of Nelson's syndrome.
M ost series of adrenalectom y report a high cure rate, b u t persistence or recurrence of cor­
tisol hypersecretion after bilateral adrenalectomy, due to adrenal rem nants or ectopic adrenal 
tissue, has been described (60, 61, 62). M ajor causes of adrenal rem nants after total adrenalec­
tomy are technical difficulties during adrenalectom y such as bleeding, w hich can make it 
difficult to remove the gland as a whole. In older series a h igh  perioperative m orbidity  (63, 64)
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and a rather unacceptable perioperative m ortality  (5.0-7.4%) (16, 17, 65) were reported  in 
hypercortisolem ic patients after adrenalectomy. In later series lower m ortality  rates of about 2% 
were reported  (19, 66, 67, 68, 69), b u t there rem ained considerable perioperative morbidity, 
such as throm boem bolic events and w ound infections in  th is group of patients (66, 67, 69, 70). 
Nowadays adrenalectom y by the laparoscopic technique seems to have reduced perioperative 
m orbidity  (71, 72, 73, 74, 75).
Open adrenalectom y
The adrenal gland can be approached by various routes. Originally the transabdom inal 
approach was considered to be the preferred approach for adrenal cancer and phaeochrom ocy- 
toma because it perm its w ide exposure for 'en  bloc' excision in  m alignancy and allows explo­
ration of the contralateral adrenal gland and extra-adrenal sites in  case of phaeochrom ocytom a. 
However, im proved preoperative localization techniques, like CT, MRI, and m etaiodobenzyl- 
guanidine (MIBG)-scanning have reduced the need for exploring beyond the ipsilateral adrenal 
g land in  these cases, as they allow for preoperative assessment of local and d istan t disease.
The posterior or lateral lum bar extraperitoneal approach then  became the preferred 
approach for removal of benign adrenal disease. This route allows direct access to the adrenals, 
avoiding intraperitoneal dissection and the risk of injuries of the liver, the pancreas, or the 
spleen. In literature the incidence of iatrogenic in jury  of the spleen necessitating splenectomy 
for the an terior approach varied from 8 to 28% , whereas it was virtually  zero in  patients 
adrenalectom ized by the lum bar approach (63, 64, 76). The rate of hem orrhagic complications 
after the lateral lum bar approach was reported  to be lower (69, 76, 77). Furtherm ore using this 
approach postoperative respiratory  and digestive com plications were less frequen t (69) and the 
average duration  of postoperative hospital stay was shorter (76, 77) than  using the anterior 
approach. However, the posterior and lateral position during  adrenalectom y makes manage­
m ent of dysrhythm ia or circulatory failure more difficult and prolonged scar pain and w ound 
com plications after the lum bar approach were described (69).
Laparoscopic adrenalectom y
Nowadays laparoscopic surgery is the preferred m ethod in  case of benign unilateral adre­
nal tum ors or bilateral adrenal hyperplasia, since it showed excellent success rates, low peri­
operative m orbidity  and decreased hospital stay (71, 78, 79, 80). Laparoscopic techniques are 
ideally suited for adrenal surgery in  many ways: laparoscopic skin incisions are small and most 
procedures require only three or four port sites. The incisions generally do no t need to be 
enlarged for removal of the glands. Laparoscopic u ltrasound  imaging allows a highly focussed 
dissection (71). Laparoscopic access to the adrenal gland may be transperitoneal or retroperi­
toneal and can be obtained anteriorly, laterally, or posteriorly (75, 78, 81, 82). The anterior 
approach allows exploration of the abdom inal cavity and access to bo th  glands, b u t the expo­
sure of bo th  glands is somewhat more difficult from this angle, due to the difficult retraction 
of the abdom inal viscera away from  the operative field (71). The lateral laparoscopic approach 
is also a transperitoneal approach and gives the easiest access to the adrenal glands for dissec­
tion, b u t does no t allow a contralateral exploration. Bilateral adrenalectom y requires reposi­
tioning of the patient intraoperatively, and a second set of port sites. The posterior approach,
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
w hich is a retroperitoneal technique, also allows an easy identification of the gland. 
Postoperative pain and ileus after the lateral approach are reduced in comparison w ith  the 
anterior approach, bu t are slightly increased in comparison w ith  the posterior approach. The 
laparoscopic posterior approach is associated w ith  the least am ount of pain and perioperative 
morbidity. By no t opening the peritoneal cavity this retroperitoneal approach minimizes post­
operative ileus and other intestinal complications, reduces bacterial contam ination and limits 
postoperative fluid collection to the retroperitoneal space (75, 83). However, this approach is 
technically more difficult because of difficulty in w idening and dissecting the peri-adrenal 
retroperitoneal space. This approach also allows a bilateral dissection, w ith  a second set of port 
sites, bu t w ithout repositioning the patient. Some institu tions consider the laparoscopic poste­
rior approach as the standard adrenal surgery procedure for tum ors less than  5 to 6 cm in dia­
meter, while preferring the lateral approach for tum ors larger than  6 cm (75, 83, 85). In 
Cushing's syndrom e the posterior laparoscopic approach is described as a more difficult proce­
dure than  the transabdom inal approach because of abundant and poorly distensible retroperi­
toneal fat complicating the creation of an adequate w orking space in  the retro-peritoneum  (81).
In  patients w ith  Cushing's syndrom e laparoscopic surgery has proved to be successful in 
several series (69, 78, 85, 86, 87, 88, 89, 90, 91). Patients w ith  a glucocorticoid-producing 
adenoma or w ith  p itu itary-dependent adrenal hyperplasia represent particular challenges for 
surgical resection. These patients bare an increased risk  for significant metabolic abnormalities, 
have a chance to infection and display marked im pairm ents in w ound healing. M orbid obesity 
also complicates laparoscopic adrenalectomy. Avoidance of a large incision in laparoscopic 
adrenalectomy is a major advance in the management of Cushing's patients.
In several studies the average length of stay in the hospital after laparoscopic adrenalectomy 
is shorter than  after open procedures, and mean intraoperative blood loss and postoperative 
com plications appear to be lower in patients undergoing laparoscopic adrenalectom y 
(71, 72, 73, 74, 75, 92, 93). Finally, in studies exam ining postoperative analgesic requirem ents, 
it appeared tha t patients undergoing open adrenalectomy required three- to fourfold higher 
doses of narcotic analgesia in one study (72) and nearly tenfold higher total doses of analgesics 
in another (73).
Perioperative m orbidity  rates of laparoscopic bilateral adrenalectomy for Cushing's disease 
vary from 0 to 17%. M orbidity  includes intraoperative hemorrhage, abdominal wall hematoma 
and subphrenic abscess (82, 89, 90, 94, 95, 96). In experienced hands patients w ith  Cushing's 
disease can undergo successful laparoscopic adrenalectomy.
1.2.4 Unilateral adrenalectomy followed by external pituitary irradiation 
as treatment modality for Cushing’s disease
There are a few reports on the results of unilateral adrenalectomy followed by external 
p itu itary  irradiation (UAPI) as treatm ent for Cushing's disease (97, 98). In  the study of Nagesser 
et al. (98) long-term  results of UAPI and transsphenoidal p itu itary  surgery were reported in 85 
and 41 patients w ith  Cushing's disease, respectively. The mean follow-up periods were differ­
ent: 21.4 years for UAPI and 8.5 years for p itu itary  surgery. Remission of hypercortisolism  was 
identical for both  treatm ent modalities (64%). Cumulative relapse rates were also comparable 
(17% and 22% , respectively). Cumulative disease-free survival curves after both  treatm ent
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modalities were identical un til 5 years of follow-up, b u t diverged thereafter indicating more 
sustained remissions following UAPI. P itu itary  dysfunction in this study was defined as a sub­
normal response of one or more p itu itary  hormones following dynamic testing (CRH or 
m etyrapone adm inistration; TRH-test; GnRH-test), subnorm al levels of the respective peri­
pheral target hormones, or the need for replacem ent therapy. The incidence of p itu itary  
dysfunction following UAPI (36%) and p itu itary  surgery (55%) did not differ significantly. 
A fter p itu itary  surgery it was an immediate event, whereas it developed after a mean interval 
of 17.8 years (range 6 to 34 years) following UAPI. The authors concluded tha t unilateral 
adrenalectomy followed by external p itu itary  irradiation is a valid therapeutic m odality for the 
treatm ent of Cushing's disease, and could be considered as alternative to bilateral adrenalectomy 
and under some circumstances to transsphenoidal p itu itary  surgery. It is regrettable tha t there 
is no study comparing the results of UAPI w ith  p itu itary  irradiation alone.
1.3 O UTL IN E OF THE PRESENT THESIS
A lthough transsphenoidal p itu itary  surgery nowadays is the treatm ent of first choice in 
patients w ith  Cushing's disease, bilateral adrenalectomy certainly will rem ain of value in the 
management of this disease. In  this thesis, detailed attention  is given to the short- and long­
term  results and complications of bilateral adrenalectomy for Cushing's disease. Our data 
provides inform ation tha t is of help in  deciding w hether bilateral adrenalectomy or p itu itary  
irradiation is most appropriate as the second treatm ent of Cushing's disease after unsuccessful 
p itu itary  surgery.
Chapter one
In the in troduction  we described the clinical symptoms of Cushing's disease and reviewed 
the literature w ith  regard to treatm ent modalities in Cushing's disease.
Chapter two
Short-term m orbidity and m ortality of bilateral adrenalectomy for Cushing's disease were 
evaluated in 64 patients treated in our hospital between 1962 and 2002. Sixty patients underw ent 
an open procedure and 4 a laparoscopic procedure. The data were compared w ith  literature.
Chapter three
The incidence of residual, functioning adrenal tissue in patients treated by total bilateral 
adrenalectomy for Cushing's disease is not know n. We evaluated the incidence of persistent 
cortisol producing tissue and recurren t Cushing's disease after bilateral adrenalectomy in  our 
hospital in 37 patients, and compared our data w ith  literature.
Chapter four
In chapter four, the development of Nelson's syndrome after bilateral adrenalectomy is dis­
cussed. Chapter 4.1 contains a review of the literature on the incidence, pathogenesis and treatment 
modalities of Nelson's syndrome. In chapter 4.2 we investigated which factors may predict the
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development of Nelson's syndrome. We found that age at the time of bilateral adrenalectomy is a 
prognostic factor for the development of Nelson's syndrome. In chapter 4.3, the long-term results 
of different treatment modalities for Nelson's syndrome in our hospital are reviewed and compared 
with literature data. Chapter 4.4 contains a case-report of a patient w ith Nelson's syndrome, in 
whom the pituitary adenoma appeared to progress into a pituitary carcinoma during follow-up.
Chapter five
It is the clinical impression tha t patients bilaterally adrenalectom ized for Cushing's disease 
have an abnormal body composition. Body composition, however, had never been studied w ith  
objective methods in this group of patients. We report on aspects of body composition - body 
fat, body fat distribution, fat-free mass and bone m ineral density  - determ inated by six differ­
ent methods, in 14 women bilaterally adrenalectom ized for Cushing's disease.
Chapter s ix
Summary section.
Chapter seven
Samenvatting
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In this retrospective study we describe the operative m orbidity  and m ortality in 64 
patients bilaterally adrenalectom ized for treatm ent of Cushing's disease in our hospital.
PATIENTS
From 1962 to January 1st, 2002, in  our hospital a total of 64 patients (53 women and 11 
men) w ith  p itu itary-dependent Cushing's syndrom e (Cushing's disease) underw ent bilateral 
adrenalectomy. Between 1962 and 1980, bilateral adrenalectomy was the preferred treatm ent in 
our hospital for this disease. Thereafter p itu itary  m icrosurgery via the transsphenoidal route 
became the therapy of choice in patients w ith  Cushing's disease, w ith  bilateral adrenalectomy 
as second choice treatm ent in case of unsuccessful p itu itary  surgery. A fter 1995 p itu itary  irra­
diation became second choice treatm ent w hen p itu itary  surgery had failed. Before total 
adrenalectomy, 34 of the 64 patients had undergone unsuccessful p itu itary  surgery, one p itu ­
itary  surgery and irradiation, and 3 had undergone p itu itary  irradiation as monotherapy. Six 
patients were referred to our hospital (5 betw een 1962 and 1970, and one in 1997), after un i­
lateral adrenalectomy in  o ther institutions as initial treatm ent for Cushing's disease. Two 
patients first underw ent unilateral adrenalectomy in  our hospital because of suspicion of a un i­
lateral adrenal macroadenoma. In  these 8 patients extirpation  of the contralateral adrenal gland 
was perform ed in our hospital because of persistent or recurrent Cushing's disease. The mean 
age of the patients at the time of total adrenalectomy was 35.5 ± 11.6 (range 16 to 55) years. The 
mean duration  of Cushing's disease at the time of adrenalectomy was 2.3 ± 3.7 (range 1/12 to 
19) years. Staff-urological surgeons of the D epartm ent of Urology of our hospital perform ed all 
operations.
Before surgery most patients were no t treated medically to control m anifestations of hyper- 
cortisolism. Only 11 of the 64 patients (17%) received drug therapy preoperatively (cyprohep­
tadine (n=1), brom ocriptine (n=5), m etyrapone (n=3) or ketoconazole (n=2)), because of a 
severely increased operative risk (severe hypertension, severe obesity, severe depletion of muscle 
mass, uncontrolled diabetes mellitus). Routine electrocardiograms and chest roentgenograms 
were obtained preoperatively in all patients. Replacement steroid therapy was started at the 
time of surgery and continued after bilateral adrenalectomy. Prophylactic antibiotics were 
given during the first 24 hours after surgery. (Low-molecular-weight) heparin  was given to 
prevent throm boembolic complications.
OPERATIVE PROCEDURES
Open adrenalectom y
In two patients, in  1962 and 1969 respectively, adrenalectomy was perform ed by an ante­
rior transabdom inal approach by a transverse incision. In the latter patient the righ t adrenal 
could not be exposed by lum bar approach, and therefore a transabdom inal operation had to be 
perform ed to complete the adrenalectom y.
Fifty-eight patients underw ent bilateral adrenalectomy by a retroperitoneal approach via
BILATERAL ADRENALECTOMY FOR CUSHING'S DISEASE; SURGICAL TECHNIQUES AND EARLY POSTOPERATIVE MORBIDITY AND MORTALITY IN 64 PATIENTS
lum botom y (108 adrenalectomies; in  8 patients unilateral adrenalectomy was perform ed earlier 
as first treatm ent for Cushing's disease). A fter induction  of anesthesia, the patient was placed 
in the lateral decubitus position. A supracostal incision at the level of the 10th or 11th in ter­
costal space was made. The latissimus dorsi, external oblique, internal oblique, transversus 
abdominis, and intercostal muscles were divided along the upper border of the rib. The course 
of the intercostal nerve was followed to dissect the pleura from the inner aspect of the rib. The 
cleavage plane betw een the diaphragm  and the retroperitoneal space was mobilized, and the 
retroperitoneum  was entered. After removal of the adrenal gland the patient was tu rned  on the 
other side to remove the contralateral adrenal gland.
Laparoscopic adrenalectom y
Since 1993 in  five patients bilateral adrenalectomy was perform ed by a laparoscopic pro­
cedure via the transperitoneal lateral approach as described by Gagner et al. (1). In  one of them  
the laparoscopic procedure had to be converted to open adrenalectomy by lum bar approach 
because of inadequate exposure of the adrenal gland.
PERIOPERATIVE M O RBID ITY  A N D  MORTALITY
Open adrenalectom y
Of the 58 patients adrenalectom ized by the lateral lum bar approach, in 11 (19%) pleural 
drainage had to be perform ed because of peroperative opening of the pleura, in 3 of them  bilat­
erally. Six patients (10%) were treated for throm boembolic complications (pulm onary embolism 
in 4 and deep venous throm bosis in 2). Serious w ound infection and/or delayed w ound healing 
occurred in 16 patients (28%), in 2 of them  bilaterally. Pulm onary infection occurred in 5 
patients (9%), whereas urinary  tract infections were diagnosed in 7 patients (12%). One patient 
suffered from septic shock of unknow n origin, whereas in 4 others fever of unknow n cause 
occurred. One patient developed erysipelas after the adrenalectomy. In  2 patients signs of cor­
ticosteroid insufficiency occurred in spite of steroid replacem ent. One of the 2 patients adrena- 
lectomized by the abdominal approach developed pleuritis postoperatively.
A fter open adrenalectomy, one of the 60 patients (1.7%) died due to massive pulm onary 
embolism, 9 days after bilateral adrenalectomy by lum bar approach in  1979.
Laparoscopic adrenalectom y
In  the 4 patients treated for Cushing's disease by laparoscopic bilateral adrenalectomy. No 
perioperative m orbidity  or m ortality were noted.
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D ISCU SS IO N
Open adrenalectom y
Of our 58 patients adrenalectom ized by the lum bar route, in 19% pleural drainage had to 
be perform ed because of pleural in ju ry  during the operation. In literature the incidence of 
pleural drainage after retroperitoneal adrenalectomy has been reported to be lower (0-13%) 
(Table 1), although small pleural injuries, sutured during operation, occurred in 43%  (2). The 
h igher incidence of pleural injuries necessitating postoperative pleural drainage in our series 
probably can be explained by the more cranial location of the incision at the level of the 10th 
or 11th intercostal space, whereas in  most o ther studies the incision was made at the level of 
the 11th or 12th intercostal space.
Thromboembolic complications occurred in 10% of our patients adrenalectomized by the 
lum bar approach, w hich is in agreement w ith  the 0 to 12% incidence in patients adrenalec- 
tomized by posterior or lateral retroperitoneal approaches in  literature (Table 1). In patients 
w ith  Cushing's syndrom e a h igh incidence of throm boem bolic complications has been observed 
due to increased factor VIII activity, w hich may be responsible for a hypercoagulable state (3, 
4). Perioperative prevention by (low-molecular-weight) heparin  obviously does no t prevent 
throm boem bolic complications in all patients (this series; 5) W ound infection and delayed 
w ound healing also were a considerable problem  in  our series w ith  an incidence of 28% . In lit­
erature w ound infection rates after adrenalectomy have been reported to be betw een 1.5 and 
18% in hypercortisolemic patients (Table 1). However, in most series definitions for w ound 
complications were lacking. In  a smaller series Brunicardi et al. (6) reported impaired w ound 
healing in  43%  of their patients. W ound complications were observed more frequently  after 
posterior than  after the anterior approach (5). M oreover postoperative complications, including 
w ound complications, were reported by some authors to be related to the severity of the hyper- 
cortisolism rather than  to the surgical route (5), bu t no t by others (7). In the past it was clear­
ly dem onstrated tha t the anti-inflam m atory action of endogenous or exogenous steroids leads 
to a decrease in the strength  of the skin, interference w ith  w ound contraction, and delayed re- 
epithelialization and angiogenesis (8, 9, 10). In the light of the serious m orbidity  associated 
w ith  bilateral adrenalectomy for Cushing's syndrom e, pretreatm ent w ith  adrenal enzyme 
inhibitors is now used routinely in  our hospital to ensure tha t patients are eucortisolemic for 
several m onths before bilateral adrenalectomy.
In our series only one patient (1.7%) died w ith in  six weeks after adrenalectomy because 
of massive pulm onary embolism. In older series after adrenalectomy by posterior or lateral lum ­
bar approach for Cushing's syndrom e or Cushing's disease a rather h igh perioperative mortali­
ty  rate (2.3-7.4%) was reported (11, 12, 13, 14, 15, 16, 17, 18, 19). Pulm onary embolism and 
intractable abdominal hemorrhage were the most common causes of perioperative death in 
these studies. The h igh m ortality rate probably was mostly a result of operation on severely 
Cushingoid patients, w ith  problems of infection, w ound healing and cardiovascular disease. In 
more recent reports from the last decade, the m ortality rate after adrenalectomy by the poste­
rior or lateral retroperitoneal approach for Cushing's disease or Cushing's syndrom e was about 
2% (2, 5, 7). However, in the series of Lo et al. (20) an operative m ortality of 10.5% was report­
ed in 19 older patients w ith  Cushing's syndrom e, aged 65 years and older.
BILATERAL ADRENALECTOMY FOR CUSHING'S DISEASE;SURGICAL TECHNIQUES AND EARLY POSTOPERATIVE MORBIDITY AND MORTALITY IN 64 PATIENTS
Tab le  1. Morbidity and mortality after open lumbar bilateral adrenalectomy for Cushing’s disease in literature
A uthor (Ref.) Pleural drainage
Number (%)
Throm boem bolic
complications
Number (%)
W ound  infections 
and/or delayed 
wound healing
Number (%)
M ortality
Number (%)
Pezzulich 1970 (28) 18/136 (13.2) 1/136 (0.7) 2/136 (1.5)
Ernest 1972 (12) 0/44 (0) 2/44 (4.5) 3/44 (6.8)
Blichert-Toft 1972 (29) 1/17 (5.9) 2/17 (11.8) 1/17 (5.9)
Hradec 1973 (14) 1/22 (4.5) 4/22 (18.2) 1/38 (2.6)
Hasner 1983 (30) 4/156 (2.6) 6/156 (3.8)
Kelly 1983 (15) 2/43 (4.7)
Pelkonen 1983 (16) 2/27 (7.4)
Welbourn 1984 (17) 2/51 (3.9)
Manolas 1984 (18) 3/73 (4.1)
Brunicardi 1985 (6) 3/7 (43)
Proye 1993 (2) 0/37 (0) 1/37 (2.7)
Favia 1994 (31) 6/43 (13.5) 2/43 (3.6)
Heerden 1995 (7) 0/91 (0) 3/91 (3.3) 2/91 (2.2)
Chapuis 1996 (5) 3/82 (3.7) 9/82 (11.0) 2/82 (2.4)
Lo 1996 (20) 2/19 (10.5)
Present series 11/58 (19.0) 6/58 (10.3) 16/58 (27.6) 1/58 (1.7)
Laparoscopic adrenalectom y
In  our hospital laparoscopic surgery has replaced open adrenalectomy in case of benign adre­
nal disorders since 1993. In  this series 4 patients were adrenalectomized by a laparoscopic proce­
dure. Bilateral adrenalectomy for Cushing's disease, however, became a less frequent treatm ent 
modality, w hen in 1995 pituitary irradiation became second choice treatm ent in case of failure of 
pituitary surgery. In these few cases there was no perioperative m orbidity or mortality.
In  literature available data from multiple institu tions imply tha t laparoscopic adrenal sur­
gery is safe and efficacious, also in patients w ith  Cushing's disease. Compared to open surgery 
laparoscopy provides equally effective treatm ent, while m inim izing patient m orbidity. 
Laparoscopic adrenalectomy is also financially favorable to open adrenalectomy. For adrenal 
cancer, however, open surgery currently  remains the treatm ent of choice for some authors (21, 
22, 23), while others reported laparoscopic adrenalectomy as a save procedure in case of adre­
nal m alignant masses (24, 25, 26, 27).
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ABSTRACT
The incidence of residual, functioning adrenal tissue in patients treated by total bilateral 
adrenalectomy for Cushing's disease is no t know n. Between 1962 and May 1988 50 patients 
w ith  Cushing's disease were treated by bilateral adrenalectomy. Of these patients, 29 underw ent 
surgery betw een 1962 and 1980, w hen bilateral adrenalectomy was the treatm ent of first choice 
in our hospital in patients w ith  p itu itary-dependent Cushing's syndrom e. In  37 patients the 
presence or absence of cortisol-producing tissue could be evaluated (follow-up period, median 
and range, 8.3 and 0.1 - 18.9 yr). Evidence of functioning cortisol-producing tissue (plasma cor­
tisol level >50 nmol/L after stopping glucocorticoid and mineralocorticoid substitu tion  thera­
py for 24 h) was found in 9 patients (24%). Plasma cortisol levels in  these 9 patients varied 
betw een 60 and 330 nmol/L (mean ± SD, 180 ± 100 nmol/L). Signs and symptom s of recurrent 
Cushing's syndrom e were present in only one patient. There was no difference in  plasma ACTH 
levels and duration  of follow up betw een the patients w ith  and w ithout evidence of functio­
ning cortisol-producing tissue. In  all 9 patients detectable aldosterone levels indicated endoge­
nous mineralocorticoid production, whereas in only one patient adrenaline was detectable in 
the circulation. In  8 of the 9 patients suspected of functioning cortisol-producing tissue we 
perform ed a stim ulation test w ith  synthetic ACTH (1-24). In  2 patients plasma cortisol levels 
rose, in 6 they rem ained virtually  unchanged.
A lthough we found clinically relevant signs and symptom s of Cushing's syndrom e in only 
one of the 50 patients, the relatively high incidence of residual, functioning adrenal tissue after 
“total” adrenalectomy for p itu itary-dependent Cushing's syndrom e necessitates continuous 
surveillance for recurrent Cushing's syndrome. There is no place for routine adm inistration of 
full replacem ent doses of glucocorticoids after total adrenalectomy.
IN TR O D U C T IO N
A t the present time bilateral adrenalectomy is no longer the treatm ent of first choice for 
Cushing's disease. Nevertheless, in the light of the still lim ited results of p itu itary  surgery [cure 
rates varying from 60 to 89% , (1)] and because the incidence of recurrences after prim ary suc­
cessful p itu itary  surgery seems to increase w ith  a longer follow up (1,2), there rem ain many 
patients w ith  Cushing's disease who may benefit from bilateral adrenalectomy.
Patients treated by total adrenalectomy for p itu itary-dependent Cushing's syndrom e 
expectedly have no residual adrenocortical function. However, there are case reports of persis­
ten t or recurren t endogenous cortisol production after bilateral adrenalectomy, even leading to 
persistent or recurrent Cushing's syndrom e. The true incidence of residual functioning adrenal 
tissue after bilateral adrenalectomy - either due to accessory adrenal tissue or adrenal rem nants 
inadvertently  left behind at surgery - is no t know n. We investigated the incidence of residual 
adrenocortical function in 37 patients bilaterally adrenalectomized for p itu itary-dependent 
Cushing's syndrom e betw een 1962 and 1988.
RESIDUAL ADRENOCORTICAL FUNCTION AFTER BILATERAL ADRENALECTOMY FOR PITUITARY DEPENDENT CUSHING'S SYNDROME.
SUBJECTS A N D  M ETH O DS
Patients
Between 1962 and May 1988, 80 patients w ith  p itu itary-dependent Cushing's syndrom e 
were treated in  our hospital of whom 50 were bilaterally adrenalectomized. Between 1962 and 
1980, 29 patients were bilaterally adrenalectomized; 3 of them  had undergone transfrontal p itu ­
itary surgery before adrenalectomy because of a macroadenoma. Between 1962 and 1980 bilateral 
adrenalectomy was the preferred treatm ent in our hospital in these patients. Since 1981 p itu ­
itary m icrosurgery via the transsphenoidal route is therapy of first choice in patients w ith  
Cushing's disease in our hospital. W hen during this operation an adenoma is found, it is removed 
selectively. W hen no adenoma is found, resection of the anterior lobe is perform ed. The cure 
rate by transsphenoidal p itu itary  m icrosurgery at our institu tion  is about 60% (1). Between 
1981 and 1988, 21 patients underw ent bilateral adrenalectomy; 16 of them  had undergone 
unsuccessful p itu itary  surgery before adrenalectomy. In  all 50 patients who underw ent total 
adrenalectomy, cure of signs and symptom s of hypercortisolism  was achieved. The patients 
were operated on via two lum bar incisions, in  most patients at the level of the 10th or 11th 
intercostal space.
The presence or absence of cortisol-producing tissue was evaluated in 37 of these patients 
(of the rem aining patients 5 had died, 6 used estrogen-containing drugs, and 2 refused to 
participate in this study). The age of the 37 patients at the time of adrenalectomy varied 
betw een 16 and 55 y r (mean ± SD, 37 ± 1 1  yr). The time interval betw een the diagnosis 
Cushing's disease and total adrenalectomy varied betw een 1 m onth and 19 y r (median, 5 
months). Tw enty-nine patients were adrenalectom ized in a one-stage procedure, 8 patients in a 
two-stage procedure. Fourteen of these 37 patients had previously undergone p itu itary  surgery.
Methods
Basal p lasm a levels o f  adrenal hormones and o f  A C TH . In  all 37 out-patients who partici­
pated in this study blood was sampled betw een 0900 and 1100 h  for determ ination of plasma 
levels of cortisol, aldosterone, adrenaline, and ACTH via an iv catheter. A fter insertion of the 
catheter the patients were supine for half an hour before blood samples were collected. The 
patients were fasting and had stopped glucocorticoid and mineralocorticoid substitution therapy 
for 24 h. None of the patients used drugs interfering w ith  steroid horm one metabolism. This 
part of the study was carried out betw een February and December 1988. A t tha t time the pe­
riod after bilateral adrenalectomy ranged from 1 m onth to 18.9 y r (median 8.3 yr).
Plasm a cortisol and aldosterone levels before and a fter adm inistration o f  synthetic A C T H  
(1-24) in p a tients suspected o f  cortisol-producing tissue a fter bilateral adrenalectomy. After in ter­
preting the rather unexpected data on basal horm one levels, in patients w ith  a basal plasma cor­
tisol level greater than 50 nmol/L an ACTH-stimulation test was performed 5 - 34 months (median 
27 months) later. Unfortunately, one patient (No. 5) refused participation in this test. 
The patients were fasting and had stopped glucocorticoid and mineralocorticoid therapy for 24
h. Over a period of 10 min, 0.25 mg synthetic ACTH (1-24) dissolved in  100 mL of 0.9%  saline
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was adm inistered iv, starting at 0900 h. Blood samples for determ inations of plasma levels of 
cortisol and aldosterone were taken at t=  -15, 0, 30, 60, 90, and 120 min. In  addition, at 
t=  0 min, blood was sampled for measurement of plasma ACTH.
H orm one assays. Plasma cortisol and aldosterone were measured after extraction and paper 
chromatography, as described previously (3). The sensitivity of the RIA for cortisol was
9 fm ol/tube, i.e. 0.6 nmol/L w hen 0.2 mL plasma was assayed. The lower lim it of detection of 
the aldosterone RIA was 6.2 fm ol/tube, i.e. 0.04 nmol/L plasma w hen 2 mL plasma were 
assayed. Plasma adrenaline was determ ined by a catechol-O-methyl-transferase-based radioen- 
zymatic m ethod w ith  a th in  layer chromatographic separation (4,5). Plasma ACTH was deter­
m ined by a specific RIA, as described previously (6).
S ta tis tica l analyses. Statistical analyses were perform ed using Wilcoxon's two sample test 
(P denoted by P), Fisher's exact test (P denoted by P') and Spearman's rank  correlation test (P 
denoted by P").
Tab le  1. Fasting morning plasma levels o f cortisol, aldosterone, adrenaline, and ACTH in 9 patients with residual adrenocortical 
function after bilateral adrenalectomy for pituitary-dependent Cushing’s syndrome.
Patient Cortisol
(nmol/L)
Aldosterone
(nmol/L)
Adrenaline
(nmol/L)
A C T H
(pmol/L)
1. 200 0.08 <0.05 23.1
2. 290 0.18 <0.05 7.7
3. 80 0.14 <0.05 105.8
4. 170 0.14 <0.05 88.2
5. 250 0.16 <0.05 54.3
6. 60 0.07 <0.05 54.6
7. 110 0.08 0.08 264.4
8. 120 0.10 <0.05 34.1
9. 330 0.09 <0.05 732.2
Glucocorticoid and mineralocorticoid substitution therapy had been stopped for 24 h. Patients 6,7, and 8 had under­
gone pituitary surgery before bilateral adrenalectomy. Normal values at 0900 h: cortisol, 190-550 nmol/L; aldosterone, 
0.08-0.69 nmol/L; adrenaline, 0.06-0.30 nmol/L;ACTH, 2.2-15.0 pmol/L.
RESIDUAL ADRENOCORTICAL FUNCTION AFTER BILATERAL ADRENALECTOMY FOR PITUITARY DEPENDENT CUSHING’S SYNDROME.
RESULTS
Basal plasma hormone levels.
In  the 37 patients in whom  the presence or absence of cortisol-producing tissue could be 
evaluated, evidence of functioning cortisol-producing tissue (morning plasma cortisol level 
>50 nmol/L after stopping substitu tion  therapy for 24 h) was found in 9 patients (24%). Plasma 
cortisol levels in these 9 patients varied betw een 60 and 330 nmol/L (mean ± SD, 180 ± 100 
nmol/L; Table 1). In  all patients w ith  residual cortisol production after bilateral adrenalectomy 
there was also evidence of endogenous aldosterone production (morning plasma aldosterone 
level >0.07 nmol/L after stopping substitu tion  therapy for 24 h). In the 28 patients w ithout 
residual cortisol production the m orning plasma aldosterone level was 0.07 nmol/L or more in 
only 10 patients (P* <0.001). In  only one of the 9 patients w ith  evidence of residual cortisol- 
producing tissue adrenaline could be detected in the circulation (plasma adrenaline >0.05 
nmol/L).
In  the whole group of 37 patients there was a significant correlation betw een the plasma 
cortisol and the plasma aldosterone levels (r=0.66; P “ <0.01). There was no statistically signif­
icant correlation between the plasma ACTH and the plasma cortisol levels or between the plasma 
ACTH and the plasma aldosterone levels, neither betw een duration  of follow up and the plas­
ma levels of ACTH, cortisol, or aldosterone. W hen the group of patients w ith  evidence of 
functioning cortisol producing tissue is compared w ith  the group of 28 patients w ithout residual 
cortisol production, both  groups did no t differ significantly w ith  respect to duration  of 
follow-up (mean ± SD, 90 ± 38 vs. 104 ± 68 m onths; P  >0.10), plasma ACTH (151.8 ± 230.8 vs. 
342.8 ± 750.4 pmol/L; P  >0.10), adrenal w eight (combined w eight of both  removed adrenals 
24.1 ± 15.5 vs. 20.9 ± 14.8 g; P  >0.10), incidence of m acronodular hyperplasia (4/9 vs. 6/28; P' 
>0.10), or incidence of Nelson's syndrom e (0/9 vs. 2/28; P ' >0.10). Patients w ith  residual 
cortisol production had a significantly higher mean plasma aldosterone level (0.12 ± 0.04 vs.
0.07 ± 0.02 nMol/L; P< 0.0005). Only in the patient w ith  the h ighest plasma cortisol level were 
signs and symptom s of recurrent Cushing's syndrom e present. A 131I-adosterol (6ß-iodom ethyl- 
19-norcholesterol) scan revealed a left adrenal rem nant. Nine years after bilateral adrenalectomy 
this patient was treated by transsphenoidal surgery. Remarkably, in  the absence of clinical 
Cushing's syndrom e, 14 m onths later a righ t scrotal painful tum or was removed containing 
adrenal tissue and 25 m onths later a similar left one was removed. Apparently, this patient had 
both  residual and ectopic adrenal tissue. None of the 13 patients who could no t be screened for 
the presence of cortisol-producing tissue showed signs or symptom s of recurren t Cushing's 
syndrom e at the time of the last follow-up visit.
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Tabel 2. Plasma levels o f cortisol and aldosterone before and after administration o f 0.25 mg o f synthetic ACTH (1-24) in 8 o f 
the 9 patients with residual adrenocortical function after bilateral adrenalectomy for pituitary dependent Cushing’s syndrome.
Patients
I 2 3 4 6 7 8 9
A C T H  (pmol/L)
t= 0min I7.8 I2.3 I0.4 II2.0 85.0 252.0 I3.8 629.8
Cortisol (nmol/L)
t= -I5min 350 470 70 I 70 60 I20 II0 280
t= 0min 3I0 370 80 I50 60 I20 70 320
t= 30min 380 480 70 I80 50 I20 II0 3I0
t= 60min 390 520 70 I70 50 I30 II0 330
t= 90min 480 560 80 I80 50 I30 II0 320
t= I20min 440 550 70 I80 40 I20 II0 340
Aldosterone (nmol/L)
t= -I5min 0.I4 0.97 0.I0 0.I4 <0.07 0.II 0.09 0.II
t= 0min 0.I3 0.84 0.2I 0.23 0.08 0.I7 <0.07 0.08
t= 30min 0.I6 I.33 0.I9 0.2I <0.07 0.I8 <0.07 0.I0
t= 60min 0.II 0.79 <0.07 0.32 <0.07 0.09 <0.07 0.08
t= 90min 0.II 0.83 <0.07 0.II <0.07 0.08 <0.07 0.07
t= I20min 0.I2 0.93 <0.07 0.I5 <0.07 0.09 <0.07 0.I0
Months between 
determination of basal 
hormone levels and 
ACTH-stimulation test. 28 30 27 27 33 34 9 5
Glucocorticoid and mineralocorticoid substitution therapy had been stopped for 24 h.The plasma A C T H  level was 
determined before administration of synthetic A C T H  (1-24). Normal values at 0900 h :ACTH , 2.2-15.0 pmol/L; corti­
sol, 190-550 nmol/L;aldosterone,0.08-0.69 nmol/L.
RESIDUAL ADRENOCORTICAL FUNCTION AFTER BILATERAL ADRENALECTOMY FOR PITUITARY DEPENDENT CUSHING'S SYNDROME.
ACTH  stimulation test.
In  eight of the nine patients w ith  plasma cortisol levels greater than  50 nmol/L a stimula­
tion  test w ith  synthetic ACTH (1-24) could be performed (Table 2). In  all 8 patients, t= 0  plasma 
cortisol levels were again greater than  50 nmol/L. It is of note tha t a close correlation was found 
betw een basal plasma cortisol levels in this test and  the m orning plasma cortisol values found 
5-34 months earlier (r=0.90, P"<0.01). Plasma cortisol levels increased after adm inistration of 
ACTH only in patients 1 and 2. Both patients had relatively low ACTH levels and relatively high 
basal cortisol levels, and basal cortisol levels had increased considerably compared w ith  those 
earlier measured.
In  six of the eight patients (Nos. 1, 2, 3, 4, 7, and 9) we found plasma aldosterone levels 
greater than  or equal to 0.07 nmol/L. In most of the patients the aldosterone levels were com­
parable w ith  those measured at the earlier occasion. Only in patient 2 was the plasma aldos­
terone level significantly h igher than  30 m onths earlier.
D ISC U SS IO N
Even after bilateral total adrenalectomy persistence or recurrence of cortisol secretion has 
been described (7-15). Chalmers et al. (16) reported on 6 patients w ith  this complication and 
found 41 o ther cases described by 19 authors. Based upon assessment of adrenocortical func­
tion in patients w ith  clinical suspicion of persistent or recurrent Cushing's syndrom e, Ernest 
and Ekman (17) found 4 cases in  a series of 39 survivors of bilateral adrenalectomy and Glenn 
et al. (18) found 2 cases out of a group of 42 patients. Using a similar approach, Pelkonen et al. 
(19) and Bergan et al. (8) found incidences of 1/27 and 2/47, respectively.
The true incidence of residual adrenocortical function after bilateral adrenalectomy for 
Cushing's disease is not known. We determ ined plasma levels of adrenal hormones after stopping 
glucocorticoid and mineralocorticoid substitution therapy for 24 h  in a series of bilaterally adre­
nalectomized patients and found that in a surprisingly high num ber of patients (9 of 37) there was 
suspicion of residual cortisol producing tissue (morning plasma cortisol >50 nmol/L). However, 
in only one patient w ith  rather high plasma cortisol levels, signs and symptoms of recurrent Cus­
hing's syndrome were present. In all patients suspected of residual cortisol production after bilat­
eral adrenalectomy there was also evidence of endogenous aldosterone production, whereas in 
only one of these 9 patients adrenaline could be detected in the circulation.
A fter stim ulation w ith  synthetic ACTH virtually  no response of plasma cortisol levels was 
seen in six of eight patients w ith  evidence of cortisol-producing tissue after bilateral adrena­
lectomy. It seems tha t cortisol production in these patients was already maximally stim ulated 
by endogenous ACTH. It is remarkable tha t in  the rem aining two patients - w ith  relatively low 
ACTH and high cortisol levels - the plasma cortisol levels increased after adm inistration of 
synthetic ACTH. Apparently, in these two patients cortisol production was not maximally stim­
ulated by endogenous ACTH.
Residual adrenocortical function after bilateral adrenalectomy can be caused by the pres­
ence of accessory adrenal tissue or adrenal rem nants left behind at surgery. Ectopic adrenal 
tissue has been dem onstrated in as much as 32% of autopsies (20) and is localized in  the coeliac
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region, the mediastinum, the kidney, the bladder, the uterus, the broad ligament, the gonads, 
and in the vagina and the scrotum  (16). This accessory adrenal tissue may contain cortical or 
both  cortical and m edullary tissue (16). It is of practical im portance tha t adrenal rem nants occur 
more frequently  at the righ t side, because complete extirpation  of the righ t adrenal gland is 
technically more difficult than  removal of the left adrenal (7). The location of the functional 
adrenocortical tissue can be determ ined by selective venous sampling (15) or, preferably, 
by scanning following adm inistration of 131I-19-iodocholesterol (7,8,11,16). Of the 17 cases in 
the survey of Chalmers et al. (16), in  w hich the location was established, unequivocal ectopic 
adrenal tissue was found in 5 and in the rem aining 12, either adrenal rem nants or ectopic nod­
ules close to the adrenal sites were discovered. Using 131I-adosterol we demonstrated a left adrenal 
rem nant as the source of residual cortisol production in  1 patient. Later on we found ectopic 
adrenal tissue in both  right and left scrotum. The o ther 8 patients w ith  evidence of residual 
adrenocortical function were reviewed w ith  regard to the operative note or pathologic findings. 
In 3 of them  it seemed likely tha t an adrenal rem nant had been left behind, as the histological 
exam ination of the removed adrenals revealed tha t one of the excized glands was incom plete or 
fragm ented.
The following conclusions can be draw n from our study. First, after a median follow up of 
8 y r of 50 patients bilaterally adrenalectomized for p itu itary  dependent Cushing's syndrome, 
we found only 1 patient w ith  clinically relevant signs and symptoms of recurrent Cushing's 
syndrom e. Second, the relatively h igh incidence of residual, functioning cortisol-producing 
tissue after bilateral total adrenalectomy for p itu itary-dependent Cushing's syndrom e, neces­
sitates lifelong surveillance for recurrent Cushing's syndrom e, as recurrences have been 
described as late as 18 y r postoperatively (13). We agree w ith  Chalmers a t al. (16) tha t to avoid 
long-term  adverse effects, substitu tion  therapy should be prescribed individually. There is no 
place for routine adm inistration of full replacem ent doses, especially of glucocorticoids, after 
bilateral adrenalectomy.
RESIDUAL ADRENOCORTICAL FUNCTION AFTER BILATERAL ADRENALECTOMY FOR PITUITARY DEPENDENT CUSHING'S SYNDROME.
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ABSTRACT
Nelson's syndrom e is the clinical progression of an ACTH-secreting p itu itary  adenoma that 
occurs in patients adrenalectomized for Cushing's disease. These p itu itary  tum ors differ from 
those before adrenalectom y by their sometimes agressive grow th potential. Additional, their 
ACTH secretion is much less suppressible by adm inistration of glucocorticoids than  in  the stage 
of Cushing's disease. Nelson's tum or cells differ to some degree from those from Cushing's 
tum ors. Recent research underscores the intriguing possibility tha t somatic mutations in the 
glucocorticoid receptor gene m ight contribute to its pathogenesis. The incidence of Nelson's 
syndrom e after adrenalectomy is still a m atter of dispute, in part explained by lack in  unifor­
m ity of definition of the syndrome. Because Nelson tum ors are often locally invasive, neuro­
surgery, either trans- or suprasphenoidally, is the treatm ent of first choice. Postoperative radio­
therapy is indicated in  patients w ith  residual tum or or extrasellar extension. Recent reports 
claim benefit from long-acting somatostatin analogues, although long-term  success remains to 
be assessed. N otw ithstanding improved treatm ent, Nelson's syndrom e shares w ith  Cushing's 
disease the inevitable tendency to recur. Therefore, life-long management of these patients is 
mandatory.
IN TR O D U C T IO N
In 1958, Nelson described a new syndrom e characterized by the developm ent of a p itu ­
itary  macroadenoma, nonsuppressible high plasma ACTH levels, and hyperpigm entation of the 
skin in a woman adrenalectom ized 3 years earlier for Cushing's disease (1, 2). A t tha t time 
adrenalectomy was perform ed much more often than  it is now because of poor visualisation of 
p itu itary  microadenomas by conventional radiology and lack of adequate neurosurgical tech­
nique. The p itu itary  tum ors in Nelson's syndrome differ from those in Cushing's by the higher, 
sometimes aggressive, grow th potential in the tumor, and ACTH secretion by these tum ors is 
much less suppressible by adm inistration of glucocorticoid. In  the early days of Nelson's syn­
drome, opinions among endocrinologists diverged as to the pathogenesis of both  Cushing's 
disease and Nelson's syndrome. A lthough the m ajority agreed tha t in both  conditions the p rin ­
cipal cause should be sought in  a pathologically changed pituitary, others cherished the notion 
tha t an abnormal functioning hypothalam us m ight provide the drive for p itu itary  hyperplasia 
to start w ith, ending up in the form ation of more or less autonom ously functioning ACTH- 
secreting adenoma. W ith the advance of m odern radiology (computed tom ography and mag­
netic resonance imaging), petrosal sinus sampling, and refined neurosurgical technique, almost 
all agree tha t Cushing's disease - except for extrap itu itary  ACTH-sources - is almost always 
caused by a prim ary p itu itary  abnorm ality leading to adenoma formation. W ith  respect to 
Nelson's syndrom e, it is of note tha t this disorder in the natural h istory of Cushing's disease,
i.e., before total adrenalectomy was practized, has never been reported.
NELSON'S SYNDROME:A REVIEW
PATHOGENESIS OF N E LSO N ’S SYNDRO M E
Nelson's syndrome is an obligatory consequence of adrenalectomy in a m inority of patients 
w ith Cushing's disease, and, therefore, its pathogenesis is discussed against the background of the 
pathogenesis of the latter. The two most obvious differences between these disorders are the 
sometimes aggressive growth potential in Nelson's tum ors and their much lower capacity to 
respond to adm inistration of glucocorticoid w ith  restrained ACTH secretion. In his authorative 
Kober lecture in 1980, Grant Liddle discussed 'the fundamental disorder in Cushing's disease' (3). 
He was the first to suppose that a defect in the mechanism by which a pituitary cell becomes a tar­
get for normal cortisol action could lead to insufficiently restrained secretion of ACTH w ith hyper- 
cortisolism as its consequence. He suggested that in Cushing's disease, a clone of defective pituitary 
cells has developed that is capable of secreting ACTH even in the absence of hypothalamic stimula­
tion and that is only partially responsive to the inhibitory effect of glucocorticoid.
W ith ever growing insight into the action of steroid horm ones (4), recent reports suggest 
tha t Nelson's syndrom e as well as Cushing's disease m ight be the consequence of somatic muta­
tions in the glucocorticoid receptor gene (5). One can envisage a m ultitude of molecular abnor­
malities tha t render cortisol in normal concentrations unable to restrain  ACTH secretion in 
Cushing's disease, or grow th factors such as corticotrophin releasing horm one leading to pro­
liferation of clones of abnormal corticotrophs such as in Nelson's syndrom e. Indeed, Nelson's 
syndrom e may reflect the intrinsic proliferative activity  of some p itu itary  adenomas once free 
of the inhibitory  effect of glucocorticoid excess after adrenalectomy for Cushing's disease.
Nelson's syndrom e and Cushing's disease seemingly are based on similar adenomas indis­
tinguishable by light microscopy. By electron microscopy, however, m orphom etry can differ­
entiate betw een these tum or types (6). Perinuclear cytofilaments are typical features of ACTH- 
producing tum ors in Cushing's disease, whereas these are significantly fewer in ACTH-secret- 
ing adenomas in  Nelson's syndrome. Hypercortisolism  per se seems to account for the increased 
num bers of cytofilaments in ACTH-cell adenomas in  Cushing's disease, whereas its absence 
leads to fewer perinuclear cytofilaments in the tum or in Nelson's syndrom e (7). In  adenomas of 
patients w ith  Nelson's syndrome, a greater num ber of free ribosomes and larger prosecretory 
granules are found (6). These findings are in terpreted  to indicate accelerated synthesis and 
increased secretion of prosecretory granules due to lack of 'suppressive' hypercortisolism. In 
both  Cushing's disease and Nelson's syndrom e, more secretory granules and larger sized prose- 
cretory granules characterize the w ell-differentiated ACTH-cell adenomas (6). Undifferentiated 
adenomas show a greater content of nucleoli and prosecretory granules. The polyhormonal 
activity  of undifferentiated adenomas in Cushing's disease (7) was no t demonstrable in undif­
ferentiated adenomas in Nelson's syndrom e (6).
The presence of pro-opiom elanocortin mRNA can be dem onstrated in p itu itary  adenomas 
from both  patients w ith  Cushing's disease and Nelson's syndrom e, w ith  a significant higher 
intensity  of the signal in  the latter and a trend toward a greater proportion of positive cells in 
Nelson's syndrom e (8). This probably reflects relative inhibition  of pro-opiom elanocortin gene 
expression by hypercortisolism  in Cushing's disease.
A part from electron microscopic differences betw een p itu itary  adenomas in  Cushing's 
disease and Nelson's syndrom e, there are functional differences. Plasma ACTH responses to
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ovine corticotropin-releasing factor in patients w ith  Nelson's syndrom e are increased and pro­
longed compared to the responses of patients w ith  Cushing's disease (9). These differences can 
be explained by the greater size of the tum or and the reduced glucocorticoid feedback in 
adrenalectom ized patients w ith  Nelson's syndrom e. Goverde et al. (10) postulated that, in 
Nelson's syndrom e, ACTH secretion by the p itu itary  gland does no t differ, at least qualitative­
ly, from tha t in normal subjects. By analyzing plasma from patients w ith  Nelson's syndrom e and 
extracts of hum an pituitaries obtained from allegedly healthy subjects (traffic victims) by high 
perform ance liquid chrom atography and m easuring corticosteroidogenic bioactivity and ACTH 
immunoreactivity, they detected three bioactive forms of ACTH in both  plasma samples and 
pitu itary  extracts. The bioactive to immunoreactive ratio of these ACTH forms did no t differ 
betw een the plasma samples and the p itu itary  extracts.
IN C ID EN C E  OF N ELSO N ’S SYNDRO M E
In the late '60s it was estimated tha t 10% or less of patients w ith  Cushing's disease would 
develop Nelson's syndrome after bilateral adrenalectomy (11). In  later studies, up to 38 % of sub­
jects adrenalectomized for Cushing's disease subsequently developed Nelson's syndrome. In chil­
dren the incidence of Nelson's syndrome is reported to be much higher - up to 25-75% (12, 13).
As we reported earlier (14) in a group of 48 patients bilaterally adrenalectomized for p itu ­
itary-dependent Cushing's syndrome, eight (16%) developed Nelson's syndrome 1.5-13 years 
after adrenalectomy. None of these patients was treated w ith  radiotherapy after surgery. The 
mean age at adrenalectomy in the group of patients who developed Nelson's syndrome was sig­
nificantly lower than  tha t in the group w ithout Nelson's syndrome. In the patients adrenalec­
tomized before the age of 35 yr, 8 of 27 (30%) developed Nelson's syndrome, whereas in  the 
patients older than  35, none did. In concordance w ith  our findings, Horky et al. (15) report tha t 
age at the time of adrenalectomy is a predictive factor for development of Nelson's syndrome. In 
a group of 66 patients bilaterally adrenalectomized for pituitary-dependent Cushing's syndrome, 
15 (23%) developed Nelson's syndrome after a complete follow-up of 7.7 ± 1 .1  years. The mean 
age at adrenalectomy was significantly lower in the group w ith  Nelson's syndrome than  in the 
group w ithout. These authors state tha t in patients adrenalectomized before the age of 20, devel­
opment of Nelson's syndrom e was the rule (100%). Between 20 and 39 years, it appeared in 35% , 
and patients older than  40 years at the time of adrenalectomy never developed Nelson's syn­
drome. Kasperlik-Zaluska et al. (16) also mention tha t Nelson's syndrom e is age-related. In  a 
group of 50 patients, 14 developed Nelson's syndrome. All these patients were bilaterally adrena­
lectomized before the age of 30 years. Other factors, such as the duration of Cushing's disease 
before adrenalectomy (14, 15, 17, 18), the plasma ACTH level before adrenalectomy (12, 14, 15, 
19-21), or preoperative radiological evidence of a microadenoma of the p itu itary  (15) or substi­
tu tion  therapy afterw ard (12, 17), had no predictive value w ith  regard to the development of 
Nelson's syndrome. Sonino et al. (22), however, very recently presented results of long-term out­
come in pitu itary  dependent Cushing's disease and reported tha t in  their series of patients, age 
was not a predictive factor. Their paper contains insufficient data to substantiate their statement.
It is also unclear w hether or not prophylactic p itu itary  radiotherapy at the time of
NELSON'S SYNDROME:A REVIEW
adrenalectomy can prevent Nelson's syndrome. Orth and Liddle (23) report no cases of Nelson's 
syndrome in 28 adrenalectomized patients, most of whom had received p ituitary irradiation 
before adrenalectomy. Moore et al. (18) found no difference in the proportion of patients devel­
oping Nelson's syndrome, w hether receiving prior radiotherapy or not. Twenty of their 120 
patients had p ituitary irradiaton as the initial treatm ent for Cushing's disease. Two of them devel­
oped Nelson's syndrome after later adrenalectomy vs. 7 of the 100 not-irradiated patients. In a 
more recent study, Kuhn et al. (24) report the effect of radiotherapy after bilateral adrenalectomy 
in 31 patients. In 10, this treatm ent did not prevent development of Nelson's syndrome. In two 
other studies, prophylactic p ituitary radiotherapy also failed to prevent the development of 
Nelson's syndrome (25, 26). In contrast, Jenkins et al. (20) state tha t prophylactic p ituitary irra­
diation reduces the incidence of subsequent Nelson's syndrome by 50%. They described 56 
patients adrenalectomized for Cushing's disease. Twenty of them received prophylactic pituitary 
radiotherapy, five of whom (25%) developed Nelson's syndrome. Of the remaining 36 patients 
who had not received radiotherapy, 18 (50%) developed this complication. In their definition, 
Nelson's syndrome was diagnosed on the basis of the association of hyperpigm entation and a 
plasma ACTH value greater than  200 ng/L, regardless w hether a p ituitary tum or was demon­
strated or not. W hen the effects of prophylactic radiotherapy were compared in the patients w ith  
a pituitary tum or at the time of the diagnosis of Nelson's syndrome (n=12), the results were simi­
lar: 4 patients of the 20 (20%) who received radiotherapy developed a tum or vs. 8 of the 36 (22%) 
who did not. From all these studies we conclude that prophylactic p ituitary radiotherapy has not 
definitively been proven to prevent Nelson's syndrome after adrenalectomy for Cushing's disease.
THERAPY OF N ELSO N ’S SYNDRO M E
Classically Nelson tumors are large and often locally invasive, frequently defying all attempts 
of treatment (27). However, increasing clinical awareness allied w ith recent improvements in imag­
ing techniques permits earlier diagnosis w ith the corresponding benefits of better control. Pituitary 
surgery, either by the transsphenoidal or a suprasphenoidal approach, is the treatment of choice. 
Large-sized tumors usually are not completely resectable and have the propensity to recur (28). Only 
4 of Wilson's 19 cases (21%) were cured by pituitary surgery (29). Fukushima describes a 70% cure 
after radical selective transsphenoidal resection (30), and Wislawski et a l. (31) claim that 8 of their
10 patients are in remission, although in 2 of them radiation therapy was used to complement sur­
gical treatment. Others report improvement of hyperpigmentation in 50% of patients, but normal­
ization of plasma ACTH levels in only 20-25% (32). Conventional radiotherapy is employed post­
operatively in all patients w ith residual tum or or extrasellar extension (25).
It has been dem onstrated tha t p itu itary  irradiation successfully achieves long-term  control 
of the hyperpigm entation and tum or enlargement of Nelson's syndrom e (18, 25). In  the study 
of Howlett et al. (25), irradiation w ith  a total dose of 4500 cGy (rad) in 5 weeks resulted in  pro­
gressive decline of plasma ACTH levels in 14 of the 15 patients w ith  Nelson's syndrom e, accom­
panied by progressive depigm entation. An em pty p itu itary  fossa developed in 7 of them. 
A nterior p itu itary  function  was well preserved, and only one patient developed TSH and 
gonadotrophin deficiency due to radiotherapy (follow up 1.5 to 17.3 years; median 9.3 years).
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In the rem aining patient, an initial fall in plasma ACTH was followed by massive tum or recur­
rence at 6 years, leading to death at 11 years after radiotherapy. Using a dose of 5000 cGy, Tran 
et al. (33) describe a re tu rn  of serum  ACTH to normal levels in three of five patients w ith  
Nelson's syndrom e and subjective im provem ent in  all five patients. In  contrast w ith  these 
results, Kuhn et al. (24) report no significant decrease in  ACTH levels after p itu itary  radiation 
therapy (4500 to 5000 cGy) in  eight patients w ith  Nelson's syndrome.
The reported incidence of hypopituitarism  after p itu itary  irradiation varies w idely (25, 34) 
and seems to be dose-dependent (35). W hen considering possible nonendocrine adverse effects 
of p itu itary  radiotherapy, particular a ttention  has been paid to the nervous system because the 
radiation tolerance of the hypothalamus, optic pathways, brain-stem , and tem poral lobes is the 
dose-lim iting factor for megavoltage therapy (36). So far, no study using a lesion dose of 4500 
cGy given in 25 fractions over 35 days by an isodose-planned, three-field technique, has reported 
any late complications affecting the optic pathways or brain, or other nonendocrine adverse 
effects(25). To avoid damage of the optic pathways, so-called Gamma Knife irradiation of pituitary 
adenomas has been advised. This stereotactic radiosurgical procedure facilitates the delivery of a 
h igh-target radiation dose, saving the surrounding structures (37). Combining surgery and 
radiotherapy seems to offer the best regimen for control of Nelson's syndrome.
Until now there is no effective drug therapy for Nelson's syndrom e. There was consider­
able interest in the early reports showing tha t sodium valproate, a GABA agonist, was effective 
in Nelson's syndrom e by lowering plasma ACTH and decreasing skin pigm entation (38). Later 
studies showed tha t short-term  therapy w ith  sodium valproate reduced plasma ACTH concen­
trations in patients w ith Nelson's syndrome, but after continuing the drug during longer periods 
(1 year), mean plasma ACTH increased to values not significantly different from basal values 
(39, 40). Others showed failure of acute and chronic treatm ent w ith  sodium valproate to lower 
ACTH levels (19, 41) and to reduce tum or size (42). There are case reports describing decreasing 
ACTH levels in  patients w ith  Nelson's syndrom e after short-term  treatm ent w ith  magnesium 
valproate (43). Naloxone, an opiate antagonist know n to be involved in  the control of p itu itary  
horm one secretion (44), and indom ethacin, an inh ib ito r of ACTH secretion in  man (45), failed 
to suppress plasma ACTH levels in Nelson's syndrome. In  vitro, ketoconazole decreases ACTH 
secretion and release in p itu itary  adenoma cells from patients w ith  Nelson's syndrom e (46). 
Native som atostatin is know n to suppress corticotropin secretion (47). The efficacy of the 
som atostatin analogue O ctreotide[Reg] in Nelson's syndrom e was reported in several cases; in 
two patients, a single dose was effective, w ith  a significant decrease of ACTH in both  (48). In 
another patient, short-term  octreotide treatm ent decreased corticotropin levels by more than  
50% . An additional 10 day treatm ent w ith  continuous subcutaneous injection of 0.5 mg daily 
proved to be effective (50). In two cases, long-term  treatm ent was dramatically effective, w ith  
normalization of corticotropin levels w ithin 6 weeks, normalization of the visual field and acuity, 
and no tum or extension during two years of treatm ent (48, 49).
M odern neurosurgery after careful pre- and perioperative surveillance including medical 
and pharmacological measures, has improved treatm ent results impressively. N otw ithstanding 
cure rates approaching 70 to 90% , Nelson's syndrom e shares w ith  Cushing's disease an 
inevitable tendency to recur over the long term, i.e., over periods 10 years and longer. 
Therefore life-long surveillance of these patients is essential for optimum management.
NELSON'S SYNDROME:A REVIEW
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ABSTRACT
Reportedly betw een 8 and 38% of patients who receive bilateral adrenalectomy for treat­
m ent of Cushing's disease will develop Nelson's syndrom e. We investigated w hich factors may 
predict the developm ent of the syndrom e.
Eight of 48 patients, bilaterally adrenalectom ized for p itu itary-dependent Cushing's syn­
drome 1 to 30 y r previously, developed Nelson's syndrom e 1.5 to 13 years (6.6 ± 4.3 yrs) after 
adrenalectomy. The mean age at adrenalectomy in the group of patients who developed Nelson's 
syndrom e was significantly lower than  tha t in  the group w ithout the syndrom e (mean ± SD, 
26.0 ± 6.0 and 35.6 ± 11.7 y r respectively; P<0.02). In the patients adrenalectom ized before the 
age of 35 yr, 8 of 27 (30%) developed Nelson's syndrom e, whereas in  the patients older than  35 
yr, no one did (P<0.02). No statistically significant differences betw een the two groups were 
found in sex ratio, duration  of disease before adrenalectomy, or duration  of follow-up there­
after. There were no statistically significant differences betw een the two groups in mean plas­
ma cortisol and ACTH levels before adrenalectomy, cortisol suppressibility after the adm inis­
tration  of 8 and 16 mg dexamethasone, or cortisol responses to CRH, TRH, and LR-releasing 
hormone before adrenalectomy. We conclude that age at the time of adrenalectomy is an important 
predictive factor for the developm ent of Nelson's syndrome.
IN TR O D U C T IO N
Pitu itary  surgery is the treatm ent of choice for p itu itary-dependent Cushing's syndrome, 
w ith  cure rates varying from 60-89% (1). W ith  longer follow-up, recurrences after prim ary 
successful p itu itary  surgery increase. Therefore, there rem ain patients w ith  Cushing's disease 
who may benefit from bilateral adrenalectomy. A fter bilateral adrenalectomy, betw een 8 and 
38% of these adrenalectom ized subjects will subsequently  develop Nelson's syndrom e (2, 3).
It is still unclear w hether clinical or biochemical data at the time of adrenalectomy may 
predict the risk  of developm ent of Nelson's syndrom e after total adrenalectomy. There is some 
discussion on the relationship betw een the incidence of Nelson's syndrom e and age at the time 
of adrenalectomy. We, therefore, investigated a num ber of possibly predictive factors in the 
developm ent of Nelson's syndrom e, w ith  special attention  to the age of the patients at the time 
of adrenalectomy.
PATIENTS A N D  M ETH O DS
Between 1962 and 1991, 54 patients, aged 16 to 55 yr, were bilaterally adrenalectomized 
in our hospital because of p itu itary-dependent Cushing's syndrome. One patient died w ith in  9 
days postoperatively, probably from pulm onary embolism. In 5 o ther patients, total adrenalec­
tomy was preceded or followed by p itu itary  irradiation (5000 Rad). The rem aining 48 patients 
are presented in this study. None of these patients had evidence of a macroadenoma at the time 
of adrenalectomy.
PATIENTS AGE IS A SIMPLE PREDICTIVE FACTOR FOR THE DEVELOPMENT OF NELSON'S SYNDROME AFTER TOTAL ADRENALECTOMY FOR CUSHING'S DISEASE
The follow-up period ranged from 1 to 30 y r (median, 9.5 yr). A cure of signs and symptoms 
of hypercortisolism  was achieved in all patients after bilateral adrenalectomy. Twenty-two 
patients had previously undergone p itu itary  surgery w ithout success. All patients received 
conventional corticosteroid supplem entation. Nelson's syndrom e was diagnosed in the presence 
of fasting ACTH levels of more than  200 pmol/L, w ith  hyperpigm entation of the skin and 
radiological evidence of a p itu itary  tum or of more than  1 cm.
In the period immediately before adrenalectomy, basal cortisol, ACTH, and prolactin levels 
were calculated from the mean of three samples taken on separate days at 0800 h  after overnight 
bed rest and fasting. TRH (200 |o,g; Roche, Basel, Switzerland), LH-releasing hormone (LRH, 100 
Hg; Hoechst, F rankfurt am Main, Germany), and ovine or hum an CRH [100 |o,g; Bachem 
(Torrance, CA) and Bissendorf, (Hannover, Germany), respectively] tests were perform ed as 
described previously  (4, 5). A h igh  dose dexam ethasone suppression test was 
performed as described by Liddle (6). Plasma ACTH, cortisol, and prolactin levels were measured 
by specific radioimmunoassays as described previously (4).
STATIST ICAL ANALYSES
Statistical analyses were perform ed using Wilcoxon's two sample test (P ) and Fisher's exact
X2 test (P ).
RESULTS
Eight of the 48 adrenalectom ized patients developed Nelson's syndrom e (17%) 1.5 to 13 y r 
(mean ± SD; 6.6 ± 4.3 yr) after adrenalectomy (group 1). The rem aining 40 patients formed 
group 2.
Table 1 shows no statistically significant differences in sex ratio, duration  of disease before 
adrenalectomy, and duration  of the follow-up thereafter. In group 2, w ithout Nelson's 
syndrome, 20 of the 40 patients underw ent unsuccessful p ituitary surgery before adrenalectomy
*compared to 2 out of the 8 in group 1 (P >0.10). The mean age at adrenalectomy in  group 1 was 
rem arkably lower than  in group 2 (26.0 ± 6.0 vs. 35.6 ± 11.7; P<0.02). Figure 1 illustrates tha t 
in the patients bilaterally adrenalectomized before the age of 35 y r 8 of 27 (30%) developed
*Nelson's syndrom e, whereas in the group older than  35 y r no one did (P <0.02).
In  Table 2, a num ber of preoperative biochemical data in  both  patient groups have been 
collected. There were no statistically significant differences in  mean plasma cortisol and mean 
plasma ACTH levels. The 2 groups did no t differ in cortisol suppressibility after the adm inis­
tration  of 8 and 16 mg dexamethasone or in the cortisol response to CRH. In  the group w ithout 
Nelson's syndrome, 11 of 32 patients showed a paradoxical rise of cortisol and ACTH levels after 
TRH and/or LRH (4). In the group w ith  Nelson's syndrom e, this paradoxical reaction never 
occurred. The plasma prolactin levels before adrenalectomy did not differ significantly in the 
two groups.
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Tab le  1. Preoperative clinical characteristics o f 48 patients, adrenalectomized for pituitary-dependent Cushing’s syndrome.
W ith  Nelson’s syndrome W ith o u t Nelson’s syndrome P
No. of patients 8 40
Sex ratio (women:men) 8:0 36:4 NS
Duration of disease before adrenalectomy (yr) 2.7 ± I.8 (I-6)a 4.4 ±4.2 (I-20)a NS
Prior pituitary surgery 2 (25)b 20 (50)b NS*
Median follow-up after adrenalectomy (yr) I2.5 (I-30)a 9 (I-23)a NS
Age at adrenalectomy (yr) 26.0 ±6.0 (I6-34)a 35.6 ± II.7  (I6-55)a <0.02
a Mean ± SD; range is in parentheses 
b Percentage is in parentheses
p = Wilcoxon two sample test, p* = Fisher's exact test.
F ig . I . Age at adrenalectomy o f the patients with and without Nelson’s syndrome
Nelson ( + ) Nelson ( - )
PATIENTS AGE IS A SIMPLE PREDICTIVE FACTOR FOR THE DEVELOPMENT OF NELSON'S SYNDROME AFTER TOTAL ADRENALECTOMY FOR CUSHING'S DISEASE
D ISC U SS IO N
From this study it appears tha t age at adrenalectomy is an im portant predictive factor for 
the developm ent of Nelson's syndrome. It is know n tha t Nelson's syndrome after adrenalectomy 
occurs frequently  in children (7, 8). In  adults, age at the time of adrenalectomy has rarely been 
m entioned as a prognostic factor for Nelson's syndrome. We reviewed all published series of 
adult patients w ith  Nelson's syndrom e. In  concordance w ith  our findings, Horky et al. (9) 
recently reported (in Czech) tha t age at the time of adrenalectomy is a predictive factor for 
developm ent of Nelson's syndrom e after adrenalectomy. In  a group of 66 patients, including 
many children, who had undergone bilateral adrenalectomy for p itu itary-dependent Cushing's 
syndrome, 15 patients (23%) developed Nelson's syndrome after 2.7 ± 1.0 y r (complete follow-up 
7.7 ± 1 .1  yr). The mean age at adrenalectomy was significantly lower in  the group w ith  Nelson's 
syndrome. These researchers stated that in  patients who underw ent adrenalectomy before the 
age of 20 yr, the developm ent of Nelson's syndrom e is the rule (100%); betw een 20 and 39 yr, 
it appeared in  34.7% of operated cases, whereas patients older than  40 y r at the time of adrena­
lectomy never developed Nelson's syndrome. Kasperlik-Zaluska et al. (10) also mentioned that 
Nelson's syndrome seems to be age related. In a group of 50 patients, 14 developed Nelson's 
syndrome (28%). All of these patients were bilaterally adrenalectomized before the age of 30 yr. 
From 2 other reports we could not derive a statistically significant age dependency for the 
developm ent of Nelson's syndrom e (11, 12).
There are o ther groups who report on the developm ent of Nelson's syndrom e and the age
Tab le  2. Preoperative biochemical characteristics o f 48 patients, adrenalectomized for pituitary-dependent Cushing’s syndrome.
W ith  Nelson’s syndrome W ith o u t Nelson’s syndrome P
Plasma cortisol (nmol/L)a 
Plasma ACTH (pmol/L)a
Cortisol suppression by 8 mg dexamethasone (%)a 
Cortisol suppression by I6 mg dexamethasone (%)a 
Cortisol increase after CRH (nmol/L)a 
Paradoxical cortisol response to TRH and/or LRH (%) 
Plasma prolactin (mU/L)b
630 ± I30 (8) 590 ± I50 (40) NS
25 ± I4 (5) I8 ± II (33) NS
62 ± 30 (6) 6I ± 32 (32) NS
75 ± 29 (4) 7I ± 29 (29) NS
350 ± 200 (3) 370 ± 250 (I9) NS
0 (6) 34 (32) NS*
I00-350 / I75 (5) 30-I550 / 225 (27) NS
Normal values at 0900 h: cortisol, I90-550 nmol/L;ACTH, 2-I5 pmol/L; prolactin, I00-480 mU/L (female) and I40-360 mU/L 
(male). P = Wilcoxon's two sample test; P* = Fisher's exact test.The number of subjects is in parentheses. 
a Mean ± SD. 
b Range/median.
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at the time of diagnosing Cushing's syndrom e (2, 3, 13). It appears from these studies that 
patients who developed Nelson's syndrom e were younger than  patients who did not, although 
the difference was no t statistically significant.
In our study in the group older than  35 y r at the time of adrenalectomy, no one developed 
Nelson's syndrom e. From the reviewed literature (2, 3, 9, 11-13), including our own data, it 
appeared tha t of the 61 patients who developed Nelson's syndrom e, only 6 (9.8%) had under­
gone bilateral adrenalectomy at an age older than  35 yr. The rem aining 55 patients w ith  Nelson's 
syndrom e were 35 y r or younger at the time of adrenalectomy. Unfortunately, we are only 
informed about the ages of the patients w ith  and w ithout Nelson's syndrom e from the studies 
of Ernest et al. (12) and Cohen et al. (3). W hen we scrutinize these studies, including our own, 
in the group of patients adrenalectomized at an age older than  35 yr, 3 out of 52 (5.8%) developed 
Nelson's syndrome; in the group adrenalectom ized at the age of 35 y r or younger, 17 out of 56 
patients (30.4%) developed Nelson's syndrom e (P<0.001).
In agreement w ith  previous reports (9, 11), we found no difference betw een the two 
groups in duration  of disease before adrenalectomy or follow-up thereafter. It is know n that 
Nelson's syndrom e can occur up to 16 years after adrenalectomy (2).
The ACTH level before adrenalectomy seems to be no predictive factor, as no difference in 
this value was found betw een patients who developed Nelson's syndrom e after adrenalectomy 
and those who did not. The same conclusion was draw n by Barnett et al. (13).
Several researchers dem onstrated a paradoxical ACTH response to LRH or TRH in Nelson's 
syndrom e (14, 15). It has even been suggested tha t a paradoxically stim ulatory influence of LRH 
on Nelson's adenomas may play an im portant role in their horm onal activity  and, perhaps, 
grow th (15). However, we never observed paradoxical responsiveness before adrenalectomy in 
any patient who developed Nelson's syndrome.
W ith  Horky et al. (9) we conclude tha t none of the usual preoperative biochemical tests is 
of predictive value for the developm ent of Nelson's syndrom e after adrenalectomy.
In the past, bilateral adrenalectomy was though t to be the treatm ent of choice in young 
people w ith  p itu itary-dependent Cushing's syndrom e, because of the risk of developm ent of 
hypopituitarism  and its subsequent deleterious effects on grow th and sexual m aturation after 
p itu itary  surgery (7). Now, the m orbidity  of transsphenoidal resection of microadenomas is 
low; therefore, this is the treatm ent of choice in p itu itary-dependent Cushing's syndrome. 
Adrenalectomy in patients younger than  35 y r bears a substantial risk  of developm ent of 
Nelson's syndrome.
PATIENTS AGE IS A SIMPLE PREDICTIVE FACTOR FOR THE DEVELOPMENT OF NELSON'S SYNDROME AFTER TOTAL ADRENALECTOMY FOR CUSHING'S DISEASE
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BILATERAL ADRENALECTOMY AS TREATMENT FOR CUSHING'S DISEASE
ABSTRACT
O bjective . To analyze the results of different treatm ent modalities for Nelson's syndrome, 
w hich was defined as radiological evidence of a p itu itary  macroadenoma, fasting plasma ACTH 
levels of more than  200 pmol/l after stopping glucocorticoid substitu tion  for at least 24 hours 
in a patient who had undergone bilateral adrenalectomy for Cushing's disease.
D esign . The medical reports of all Nelson's patients know n in  our hospital were studied 
w ith  regard to treatm ent modalities and result of treatm ent. Clinical remission of Nelson's 
syndrom e was defined as a reduction  of tum or size to a diam eter of 10 mm or less and fasting 
plasma ACTH levels less than  200 pmol/l after stopping glucocorticoid substitu tion  for at least 
24 hours.
Patien ts. Fifteen women w ith  Nelson's syndrom e were studied. Bilateral adrenalectomy had 
been performed 1 to 29 years before Nelson's syndrome was diagnosed. Before adrenalectomy 
eight patients had undergone unsuccessful transsphenoidal p itu itary  surgery.
R esults. Eight patients were initially followed w ithout surgical or radiotherapeutical 
intervention  during 1 to 7 years. In seven of them, plasma ACTH levels and tum or volumes 
increased progressively during this rather short observation period, w ith  developm ent of 
extrasellar extension in four patients. In one of these patients, who was planned for elective 
p itu itary  surgery, massive p itu itary  haem orrhage occurred w hich was fatal despite emergency 
pitu itary  surgery.
Elective p itu itary  surgery was perform ed in eleven patients, of whom  three were operated 
twice. Clinical remission was docum ented in  five patients in the first year after operation. In 
one patient postoperative MR-imaging revealed no residual tum or mass bu t the postoperative 
plasma ACTH level was still elevated. In  another patient a residual intrasellar macroadenoma 
and an increased plasma ACTH level rem ained stable for 22 years. The rem aining four patients 
received postoperative radiotherapy because of residual tum or masses. Of these patients, one 
had a clinical remission. In tw o others relatively small residual intrasellar tum or masses remain, 
w ith  a fasting plasma ACTH level of more than  200 pmol/l in one of them . The fourth  patient 
died of the consequences of progressive tum or growth. Radiotherapy was the only treatm ent in 
two patients and did not result in clinical remission.
Tumor volumes and plasma ACTH levels at the time of diagnosis of Nelson's syndrom e 
were positively correlated (r=+0.61, P<0.05). This correlation was stronger at the moment of 
decision of either p itu itary  surgery or radiotherapy (r=+0.85, P<0.001). A t the end of the 
follow-up period the correlation betw een tum or volumes and plasma ACTH levels in the 
combined pitu itary  surgery and/or irradiation only group was +0.77 (P<0.001). In  the p itu itary  
surgery group tum or volumes before and after surgery were directly correlated (r=+0.70, 
P <0.05).
C onclusions. Our results dem onstrate tha t p itu itary  surgery of Nelson's macroadenomas 
is more successful w hen Nelson's adenomas are relatively small. P itu itary  surgery should be 
perform ed before extrasellar expansion of the tum or occurs in  order to attain  long lasting remis­
sions. P itu itary  irradiation should be perform ed postoperatively in all patients w ith  residual 
tum or. Our data also illustrate tha t in patients w ith  Nelson's syndrome, plasma ACTH levels can 
reliably be used as an indirect approxim ation for tum or volume.
MANAGEMENT OF NELSON'S SYNDROME: OBSERVATIONS IN FIFTEEN PATIENTS
IN TR O D U C T IO N
Nelson's syndrom e was first described in 1958 and was defined as the developm ent of a 
p itu itary  macroadenoma, m arkedly elevated plasma ACTH levels, and hyperpigm entation of 
the skin in a patient bilaterally adrenalectom ized for p itu itary-dependent hypercortisolism 
(Cushing's disease) (1). A t tha t time, adrenalectomy for Cushing's disease was perform ed much 
more often than  it is now because of the lim itations of conventional radiological techniques to 
detect p itu itary  microadenomas and the lack of adequate neurosurgical techniques. Nowadays, 
p itu itary  surgery is the treatm ent of choice for Cushing's disease. Cure rates, however, are still 
not higher than  60 to 90% (2) and w ith  longer follow-up times recurrence rates after initially 
successful p itu itary  surgery increase. Therefore, there rem ain patients w ith  Cushing's disease 
who may benefit from bilateral adrenalectomy.
Between 8 and 38% of bilaterally adrenalectom ized subjects will develop Nelson's 
syndrom e (3, 4, 5). Classically, Nelson's tum ors are large and often locally invasive, frequently 
defying all attem pts at treatm ent (6). P itu itary  surgery, either by the transsphenoidal or by the 
transfrontal approach, has been advocated as the treatm ent of choice (6, 7). However, large 
tum ors are usually not completely resectable and have the propensity  to recur. Postoperative 
radiotherapy has been advocated in patients w ith  residual tum or or extrasellar extension (8). 
Untill now, there is no effective drug therapy for Nelson's syndrom e, although there are few 
case reports in w hich long-term  efficacy is described for treatm ent w ith  the somatostatin ana­
logue octreotide (9, 10).
In  the present report we review  the results of treatm ent in 15 patients w ith  classical 
Nelson's syndrom e and we discuss the optimal treatm ent mode, especially the optimal time to 
initiate surgical treatm ent.
PATIENTS A N D  M ETH O DS
Between 1969 and 1998 in  our hospital fifteen cases of Nelson's syndrom e were diagnosed. 
We defined Nelson's syndrom e as the presence of fasting plasma ACTH levels of more than  200 
pmol/l after stopping glucocorticoid substitu tion  for at least 24 hours, hyperpigm entation of 
the skin and radiological evidence of a p itu itary  adenoma of more than  10 mm in diameter. All 
patients were women, bilaterally adrenalectom ized for Cushing's disease w ith  a median follow- 
up of 7 years (range 1-29 years) before Nelson's syndrom e was diagnosed. In seven patients, in 
whom Cushing's disease was diagnosed before 1981, roentgenogram s of the skull revealed no 
enlargement or destruction of the sella turcica before adrenalectomy. In eight patients, diag­
nosed as having Cushing's disease in or after 1981, CT-scanning and/or MR-imaging of the p itu ­
itary gland revealed no macroadenoma at tha t time. Before adrenalectomy, in one patient (num­
ber 3) transsphenoidal cryocoagulation of the p itu itary  was perform ed in  1968. Seven other 
patients (numbers 8, 9, 11-15) had undergone unsuccessful transsphenoidal p itu itary  surgery 
before adrenalectomy. Histological exam ination revealed adenom atous tissue in five, and only 
normal p itu itary  tissue in two of them. Cure of signs and symptom s of hypercortisolism  was
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Tab le  I . Clinical characteristics, plasma ACTH levels, results of radiological examinations of the sellar region and treatment modalities in 15 patients with Nelson’s syndrome.
Patient number Interval in 
years between 
A D X  and N S
Age at 
diagnosis N S
Plasma A C T H  
at diagnosis 
N S#
Radiological sellar examination Treatm ent Modalities
(years) (pmol/l)
Tumor volumef-
(mm3)
Tumor
extension
Year$ Modes of treatm ent
1* 7 30 n.a n.a. Destruction 1969
1985
Pituitary surgery (TF) 
Pituitary surgery (TF) + RT
2 27 57 3900 1680 I.S 1991
1998
Observation 
Pituitary surgery (ETN)
3. 29 60 420 1014 I.S 1998 Pituitary surgery (ETN)
4. 8 32 >1750 n.a. I.S 1977 Pituitary surgery (FT)
5* 7 34 7750 9500 I.P 1978
1979
Pituitary surgery (FT) 
Pituitary surgery (FT) + RT
6. 18 49 640 1872 I.S, P 1997
1999
Observation 
Pituitary surgery (ETN)
7. 2 37 225 1800 I.S 1982
1985
Pituitary surgery (TE) 
Pituitary surgery (TF) + RT
8* 2 26 930 2820 I.P 1986 RT
9. 10 36 280 180 1 1994
1996
1997
Observation
Pituitary surgery (ESO)
RT
10* 7 33 475 1040 1 1991
1992
Observation
RT
11* 10 51 11000 1980 1 1995 Observation
12 9 51 200 616 I.S 1998 Pituitary surgery (ESO)
13. 1 29 510 384 1 1992
1999
Observation 
Pituitary surgery (ETN)
14. 6 29 250 1073 I.S, P 1997
1999
Observation 
Pituitary surgery (ETN)
15. 2 51 335 560 1 1994
1999
Observation 
Pituitary surgery (FT)
(Massive pituitary haemorhage)
MANAGEMENT OF NELSON'S SYNDROME: OBSERVATIONS IN FIFTEEN PATIENTS
Legends to  Tab le  1.
#, Plasma ACTH was measured in the fasting state and after stopping glucocorticoid substitution for at least 24 hours; only in 
patients 6 and 9 plasma ACTH was measured in the non-fasting state and less than 12 hours after the last dose o f glucocorti­
coid substitution.
f,Tumor volumes in mm3 were approximated by multiplying the maximal tumor diameters measured in three directions x 0.5. 
$ The first figure is the year o f diagnosis o f Nelson’s syndrome.
* Drug therapy failed to control Nelson’s syndrome in 5 patients (see text).
ADX, bilateral adrenalectomy; NS, Nelson’s syndrome; I, intrasellar mass; S, suprasellar extension; P, parasellar extension; n.a., not 
available; TF, transfrontal approach; ETN, endoscopic transnasal approach; FT, frontotemporal approach; TE, transethmoidal 
approach; ESO, endoscopic-assisted supra-orbital approach; RT, radiotherapy (40-50 Gy).
achieved in  all patients after bilateral adrenalectomy. All patients received conventional gluco- 
and mineralocorticosteroid supplem entation.
The medical records of the fifteen Nelson's patients were reviewed w ith  regard to treat­
m ent strategies used, pre- and post-treatm ent plasma ACTH levels, developm ent of ophthalm o­
logic complications and pitu itary  insufficiency. Unless stated otherw ise, only fasting plasma 
ACTH levels after stopping glucocorticoid substitu tion  for at least 24 hours are used in this 
report. Plasma ACTH was determ ined as described previously (11). Pre- and post-treatm ent 
radiological exam inations were evaluated w ith  regard to tum or size and extrasellar extension of 
the Nelson's adenomas. Tumor volumes were approxim ated by m ultiplying the maximal tum or 
diameters measured in three directions x 0.5 (12). A t present the median follow-up period after 
the diagnosis of Nelson's syndrom e is 6 years (range 0.3 to 29 years). Clinical remission was 
defined as fasting plasma ACTH levels less than  200 pmol/l after stopping glucocorticoid sub­
stitu tion  for at least 24 hours, and a tum or size less than  10x10x10 mm. Statistical analysis was 
perform ed by using Spearman's rank  correlation test.
RESULTS OF TREATMENT OF N ELSO N ’S SYNDROM E
Clinical characteristics and plasma ACTH levels of the patients at the time of diagnosis of 
Nelson's syndrom e are show n in  Table 1. The age at the time of diagnosis of Nelson's syndrom e 
was 40.3 ±  11.5 years (mean ±  SD). The first patient w ith  Nelson's syndrom e (num ber 1) was 
diagnosed in 1969 w hen plasma ACTH measurements were not yet available. This woman was 
darkly pigm entated and a roentgenogram  of the skull showed severe destruction of the sella 
turcica. In the o ther fourteen patients, Nelson's syndrom e was diagnosed betw een 1977 and 
1998. In all of them  hyperpigm entation of the skin was present. CT and/or MRI showed an 
intrasellar macroadenoma in  five of them  and supra- and /or parasellar extension of the 
macroadenoma in nine of them. Tumor volumes ranged from 180 to 9500 mm3. A t the time of 
diagnosis of Nelson's syndrom e, only two of the fifteen patients had ophthalmological sym p­
toms (bitem poral hemianopsia, oculomotor nerve and abducens nerve paresis in patient 5; 
oculomotor nerve paresis in patient 8) and three (numbers 4, 7 and 10) had mild hyperpro­
lactinemia most probably due to compression of the p itu itary  stalk by the macroadenoma. The
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Tab le  2. The course o f  plasma A C T H  levels and o f  tumor size after observation only, pituitary surgery and radiotherapy in 15 patients with Nelson’s  syndrome.
Patient
number
Treatm ent
modality
Follow-up 
in years
Plasma A C T H #
(pmol/l)
Tumor vo lum ef (m m 3) and radiological extension
tl t2 tl t2
2. Observation 7 3900 9500 1680 I.S 3278 I.S, P Chiasm compression, cavernous sinus
6. Observation 1.5 640a 820 1872 I.S. P 4590 I.S, P Chiasm compression, cavernous sinus
9. Observation 2 280a 4420a 180 1 3640 I.P Cavernous sinus
10. Observation 1.5 475 4280 1040 1 8960 I.P Cavernous sinus
11. Observation 3 11000 1500 1980 1 1366 I.S
13. Observation 6 510 1650 384 1 2016 I.P Cavernous sinus
14. Observation 2 250 900 1073 I.S. P 1248 I.S. P Cavernous sinus
15. Observation 5 335 3380 560 1 6760 I.S Chiasm compression, internal carotic artery
1. Surgery (1st) 16 n.a. 96800 n.a. n.a. I.S, P Thalamus, sphenoidal sinus, lentiform nucleus
Surgery (2nd) 2/12b 96800 162800 n.a. 32250 I.S, P Thalamus, sphenoidal sinus, lentiform nucleus
2. Surgery 3/12 9500 520 3278 I.S. P 0
3. Surgery 3/12 420 10 1014 I.S 38 1
4. Surgery 22 >1750 1770 n.a 2380 1
5. Surgery (1st) 1 7750 34750 950 I.P 7834 I.P Cavernous sinus
Surgery (2nd) 2/12b 34750 1410 7834 I.P 6363 I.P Cavernous sinus
6. Surgery 3/12 820 63 4590 I.S. P 0
7. Surgery (1st) 3 225 5030 1800 I.S 5750 I.S Infundibulum 3rd ventricle
Surgery (2nd) 2/12b 5030 265 5750 I.S 1112 1
9. Surgery 6/12b 4420a I90a 3640 I.P 500 1
12. Surgery 3/12 200 120 616 I.S 2 1
13. Surgery 3/12 1650 540 2016 I.P 720 1
14. Surgery 3/12 900 57 1248 I.S. P 0
1. Surgery + RT 10 162800 I5800a 32250 I.S. P 11813 I.S, P Sphenoidal sinus
5. Surgery + RT 19 1410 50 6363 I.P 125 p
7. Surgery + RT 13 265 15 1112 1 910 1
9. Surgery + RT 1.5 190* 520 500 1 512 1
8. RT 12 930 2400 2820 I.P 6292 p Cavernous sinus
10. RT 7 4280 130 8960 I.P 728 p
MANAGEMENT OF NELSON'S SYNDROME: OBSERVATIONS IN FIFTEEN PATIENTS
Legends to  Tab le  2.
f,Tumor volumes were approximated by multiplying the maximal tumor diameters measured in three directions x 0.5;
#, Plasma ACTH was measured in the fasting state and after stopping o f glucocorticoid substitution for at least 24 hours. Only 
when indicated with a, plasma ACTH was measured in the non-fasting state and less than 12 hours after the last dosage o f glu­
cocorticoid substitution.
b, Pituitary surgery was followed by pituitary irradiation.
t l, time o f diagnosis o f Nelson's syndrome; t2, time at the end o f follow-up; RT, radiotherapy; I, intrasellar mass; S, suprasellar exten­
sion; P, parasellar extension, n.a., not available.
treatm ent modalities used for the 15 patients w ith  Nelson's syndrom e are outlined in  Table 1 
and the results of these are described in  Table 2.
In itia lly  no surgical or radiotherapeutical trea tm en t.
A fter diagnosing Nelson's syndrom e, eight patients were followed w ithout surgical or 
radiotherapeutical intervention  during 1.5 to 7 years (Table 2). In  six of them  (numbers 2, 6, 9, 
10, 13 and 14) elective p itu itary  surgery or radiotherapy had to be perform ed after 1.5 to 7 years 
because of grow th of the tum or, neurological complications due to the tum or, or rapid increase 
of plasma ACTH levels. In the seventh patient (num ber 15), who was planned for elective p itu ­
itary surgery because of p itu itary  tum or growth, massive p itu itary  hemorrhage occurred 5 
years after the diagnosis of Nelson's syndrom e and this patient died despite emergency p itu ­
itary surgery one day after hospital admission. In  the eighth  patient (num ber 11) up  till now an 
expectative policy has been followed for 4 years because the patient refuses p itu itary  surgery.
In  seven of the eight patients both  plasma ACTH levels and tum or volumes increased d u r­
ing the observation period (Table 2), w ith  a huge progression of tum or volume in  four patients 
(numbers 9, 10, 13, and 15) over a time period of 1.5 to 7 years. In five of the patients (numbers 
9, 10, 11, 13, and 15) supra- and /or parasellar extension of the p itu itary  tum or developed d u r­
ing the expectative period. These five patients had only an intrasellar macroadenoma at the 
time of diagnosis of Nelson's syndrome. Only patient 11 showed no progression of tum or volume 
during follow-up. In  this case plasma ACTH decreased during 18 m onths of treatm ent w ith  
quinagolide (0.075 mg/day).
In  all cases hyperpigm entation persisted. In  spite of supra- and/or parasellar extension of 
the tum or in most cases, neurological symptom s appeared only in patient 10 and included acute 
and progressive headache, complete ophthalm oplegia of the righ t eye w ith  ptosis and a dilated 
pupil. In  patient 11 levothyroxin substitu tion  had to be started for secondary hypothyroidism . 
None of the other patients developed thyroidal, adrenal or gonadal insufficiency.
E lective p itu ita ry  surgery.
In  11 patients elective p itu itary  surgery was performed as treatm ent for the ir Nelson's syn­
drome (Table 2). In  five patients (numbers 2, 3, 6, 12, and 14), operated recently for the ir Nelson's 
syndrome, postoperative MR-imaging showed virtually no residual tumor, whereas fasting plasma 
ACTH levels declined to a level of less than  200 pmol/l in four of them. H yperpigm entation 
decreased or even disappeared in all of them. Clinical remission of Nelson's syndrome, as defined
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above, was achieved after p itu itary  surgery in these four patients.
Of the remaining six patients, in three (numbers 1, 5, 7) reoperation of the p itu itary  tum or 
had to be performed, 1 to 16 years after the first neurosurgical procedure, because of progres­
sion of tum or volume (all), increasing plasma ACTH levels (numbers 5 and 7) and ophthalmologic 
complications (visual field defects in patients 1 and 7; progression of oculomotor nerve paresis 
in patient 5). Postoperatively, CT-scanning revealed residual intrasellar tum or mass in all three 
patients, w ith  parasellar extension in  tw o of them . Plasma ACTH levels also remained elevated 
(162800, 1410 and 265 pmol/l, respectively) postoperatively. Therefore in all three patients p itu ­
itary  reoperation was followed by radiotherapy. In the patients 9 and 13 the postoperative MRI 
revealed also residual intrasellar tum or, although plasma ACTH levels were decreased postoper­
atively. In patient 9 radiotherapy was given six m onths after pituitary surgery, as will be done 
in patient 13. In patient 4 - during a postoperative follow-up of 22 years - there remained an 
enlarged and bulging p itu itary  gland w ithout supra- or parasellar extension and w ithout tum or 
progression. Plasma ACTH levels remained high but showed no increase during follow-up.
After p itu itary  surgery patient 4 developed an incom plete H orner's syndrome, bu t her 
visual fields rem ained normal up till now. In three of the patients substitu tion  therapy had to 
be given for diabetes insipidus (numbers 2 and 3) and for secondary hypogonadism  and 
hypothyroidism  (num ber 4), respectively.
Radiotherapy.
In six cases p itu itary  radiotherapy was given in  2 Gy fractions, using 10-18 MeV linear
Tab le  3. Summary o f results o f different treatment modalities for Nelson’s syndrome.
Plasma A C T H
<200 pmol/la
Tum or size
<10x10x10 mm
Clinical
remissionb
Observation 0/8 0/8 0/8
Drug therapy 0/5 0/5 0/5
Pituitary surgery 5/11 5/11 4/11
Radiotherapy given after surgery 2/4 1/4 1/4
Radiotherapy as single therapy 1/2 0/2 0/2
All therapeutical modalities 8/15 6/15 5/15
a, Plasma ACTH was measured in the fasting state and after stopping of glucocorticoid substitution for at least 24 hours.
b,Clinical remission was defined as fasting plasma ACTH levels less than 200 pmol/l,after stopping glucocorticoid substitution for at 
least 24 hours, and a tumor size less than 10x10x10 mm.
MANAGEMENT OF NELSON'S SYNDROME:OBSERVATIONS IN FIFTEEN PATIENTS
accelerators in  a three-field technique. In  four patients (numbers 1, 5, 7 and 9) p itu itary  sur­
gery preceded radiotherapy (total dose 46-50 Gy), while in two (numbers 8 and 10) p itu itary  
irradiation was given as first-line treatm ent (total doses 45 and 40 Gy, respectively) (Table 2). Of 
the four patients treated w ith  the com bination of p itu itary  surgery and irradiation, one (num­
ber 5) is in clinical remission up till now (follow-up 19 years) w ith  plasma ACTH levels less than  
200 pmol/l, and a small residual parasellar tum or mass (Table 3). In two others (numbers 7 and
9) relatively small residual intrasellar tum or masses remain, w ith  a plasma ACTH level of more 
than  200 pmol/l in  one of them. In  the fourth  patient (number 1) there was progressive tum or 
grow th despite p itu itary  surgery (twice) and radiotherapy and she died 10 years after the sec­
ond pitu itary  operation because of w idespread puru len t leptom eningitis. Autopsy revealed a 
large adenohypophyseal carcinoma in the sellar region w ith  extensive destruction of the sella 
turcica and a circum scribed metastasis attached to the dura (13).
Of the two patients irradiated for Nelson's syndrome as first-line treatm ent (numbers 8 and
10), plasma ACTH levels declined to a level of less than  200 pmol/l in  one (number 10), although 
there remained a residual parasellar tum or mass in this case. In patient 8, after an initial decrease 
of plasma ACTH levels and tum or mass, progression of the volume of the Nelson's adenoma 
occurred w ith  parasellar extension into the cavernous sinus and to the apex of the orbit. 
Treatment w ith  octreotide during 9 m onths was not successful and p itu itary  surgery is planned.
A fter radiotherapy, hyperpigm entation persisted in two patients (numbers 1 and 8) bu t 
disappeared in the o ther patients. A fter p itu itary  irradiation ophthalmological complications 
persisted in four patients (visual field disturbances in  patients 1 and 9, oculomotor nerve pare­
sis in patients 1, 5 and 10, and abducens nerve paresis in  patient 10). P itu itary  substitu tion  
therapy had to be started for secondary hypogonadism  and hypothyroidism  in patients 1, 5, 7 
and 10, and for grow th horm one deficiency in patients 8 and 10. Fifteen years after treatm ent 
for Nelson's syndrom e, patient 5 had developed a frontal psychosyndrom e w ith  amnesia and 
bradyfrenia and a pseudobulbar and pyram idal syndrom e most probably caused by the earlier 
treatm ent.
D rug therapy.
Drug therapy w ith  cyproheptadine in  a daily dose of 12 mg (num ber 1), brom ocriptine in 
a daily dose of 10 to 15 mg (numbers 5 and 10) or octreotide in a daily dose of 0.3 to 0.5 mg 
(numbers 8 and 11) failed to control Nelson's syndrom e in  five patients. Only in  one patient 
(number 11) plasma ACTH decreased from 11000 to 1500 pmol/l after 18 m onths of treatm ent 
w ith  quinagolide (0.075 mg/day). Tumor volume in this patient decreased slightly during treat­
m ent w ith  quinagolide (Table 2).
Considering all treatm ent modalities clinical remission was attained in only five out of 
fifteen patients (Table 3).
P lasm a  A C T H  and  tum or volum e.
At the time of diagnosis of Nelson's syndrome, tum or volumes ranged from 180 to 95003mm3 and plasma ACTH levels from 200 to 11000 pmol/l. Tumor volumes and plasma ACTH lev­
els were significantly correlated (r=+0.61, P<0.05). This correlation was stronger at the 
moment of the decision of either p itu itary  surgery or radiotherapy (r=+0.85, P<0.001). A t the
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end of the follow-up period the correlation betw een tum or volumes and plasma ACTH levels in 
the patients who were treated w ith  p itu itary  surgery, irradiation or w ith  both  treatm ent modal­
ities was +0.77 (P<0.001). Considering all patients irrespective of treatm ent (pituitary surgery 
w ith  or w ithout irradiation, irradiation only or observation), the correlation betw een plasma 
ACTH and tum or volume at the end of follow-up was as h igh as +0.86 (P<0.001). In the p itu­
itary surgery group, tum or volumes before and after surgery were significantly correlated 
(r=+0.70, P<0.05).
D ISCU SS IO N
Between 8 and 38% of adu lt subjects adrenalectom ized for Cushing's disease will develop 
Nelson's syndrom e (14), sometimes many years after adrenalectomy (in this study betw een 1 and 
29 years). The natural h istory of Nelson's syndrom e is no t well know n, bu t p itu itary  tum ors in 
these patients are reported to differ from those in  Cushing's disease by their higher, sometimes 
aggressive, grow th potential (14). Of the eight evaluable patients in our study in whom  an 
expectative policy was chosen after the diagnosis of Nelson's syndrom e was made, seven had 
clear progression of tum or volume w ith  developm ent of extrasellar extension in four of them  
w ith in  a rather short period of 1.5 to 7 years. Therefore w hen the diagnosis of Nelson's syn­
drome is made, p itu itary  surgery and/or radiotherapy should be seriously considered.
Of the eleven patients who underw ent p itu itary  surgery for Nelson's syndrom e in  our 
study, in  four cases clinical remission, defined as a reduction  of tum or size to a diameter of 10 
mm or less and fasting plasma ACTH levels less than  200 pmol/l after stopping glucocorticoid 
substitu tion  for at least 24 hours, was docum ented in the first year after operation (Table 3). All 
our patients had p itu itary  macroadenomas w ith  supra- or parasellar extension at the time of 
p itu itary  surgery. In  the series of Kasperlik-Zaluska et al. (5) transsphenoidal surgery resulted 
in clinical im provem ent in seven out of nine patients, albeit tha t two of them  were given addi­
tional p itu itary  irradiation postoperatively. The results of this study are, however, difficult to 
interpret as postoperative plasma ACTH levels or tum or sizes were not reported. The difficulties 
in treating Nelson's macroadenomas are clearly illustrated by another report in w hich improve­
m ent of hyperpigm entation only occurred in 50% of patients w ith  Nelson's macroadenomas 
after p itu itary  surgery, and norm alization of plasma ACTH levels was achieved in  only 25% 
(15). Furhermore, W ilson et al. (16) reported tha t in none of 10 patients w ith  Nelson's macroade­
nomas plasma ACTH decreased to normal levels after p itu itary  surgery.
More favourable results of pituitary surgery were achieved in Nelson's patients w ith smaller, 
intrasellar adenomas. Fukushim a (17) claimed cure following selective transsphenoidal resection 
in seven out of 10 Nelson's patients w ith intrasellar adenomas. Wislawski et al. (18) reported that 
eight of 10 patients w ith  intrasellar adenomas were in  remission postoperatively. However, in 
two of them  radiation therapy was used to complement surgical treatm ent. In both  series 
patients w ith  microadenomas were included, whereas we and colleagues defined Nelson's 
tum ors as macroadenomas. Obviously, a more pronounced decline of plasma ACTH levels after 
selective transsphenoidal surgery can be achieved in patients w ith  intrasellar Nelson's adenomas 
than  in those w ith  extrasellarly extending tum ors (19). Furtherm ore, cavernous sinus invasion
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by a p itu itary  tum or has been related to a low surgical cure rate because of the complexity of 
surgical exploration (20). These results strongly support early selective adenomectomy in 
patients w ith  Nelson's syndrom e, preferably before supra- or parasellar extension has occurred.
Conventional p itu itary  radiotherapy has been advocated postoperatively in all patients 
w ith  residual tum or or extrasellar extension (8) and may achieve long-term  control of hyper­
pigm entation and tum or grow th in Nelson's syndrom e (3, 8). We treated two patients w ith  
radiotherapy alone. In  one of them  there is no progression of the parasellar tum or during a fol­
low-up of 7 years, whereas in the o ther patient there was again tum or grow th 4 years after 
radiotherapy. A t present, only one of four patients treated w ith  both  p itu itary  surgery and 
radiotherapy is in clinical remission. The total dose of irradiation varied betw een 40 and 50 Gy 
in our patients. In the study of H owlett et al. (8), p itu itary  irradiation w ith  a total dose of 45 
Gy over 5 weeks as single therapy resulted in a progressive decline of plasma ACTH levels and 
progressive depigm entation in 14 of 15 patients w ith  Nelson's syndrom e w ith  or w ithout radi­
ologic evidence of a p itu itary  tum or. An em pty sella developed in  seven of them. In  the 
fifteenth patient of H owlett et al. (8), an initial fall in plasma ACTH was followed by massive 
tum or recurrence after 6 years, leading to death at 11 years after radiotherapy. In another study 
pitu itary  irradiation w ith  a total dose of 50 Gy, given after p itu itary  surgery, was reported to 
normalize plasma ACTH levels in three of five patients w ith  Nelson's syndrom e (21). Kuhn et al. 
(22), however, reported lack of a significant decrease in  plasma ACTH levels after p itu itary  radi­
ation therapy (45 to 50 Gy) as the single treatm ent m odality in eight patients w ith  Nelson's 
syndrome. Recently, Gamma Knife irradiation was reported to achieve clinical im provem ent and 
reduction of tum or size in p itu itary  adenomas including Nelson's adenomas (23). This stereo­
tactic radiosurgical procedure facilitates the delivery of a high-target radiation dose, saving the 
surrounding structures and avoiding damage of the optical pathways.
In  five of our patients drug therapy (bromocriptine, cyproheptadine or octreotide) was not 
successful in the treatm ent of Nelson's syndrom e. Currently, there is no really effective drug 
therapy for Nelson's syndrom e. Sodium valproate (24, 25, 26), brom ocriptine (27, 28) and cypro­
heptadine (29) have been tried alone or in com bination (30), bu t none of these drugs has 
achieved w idespread use, due to the lim ited data on the ir abilities to normalize ACTH secretion 
and to reduce tum or size for longer periods. Efficacy has only been reported for the somato­
statin analogue octreotide in the treatm ent of cases w ith  Nelson's syndrom e (9, 10, 31).
In our study after p ituitary surgery and/or radiotherapy in eight of 10 patients pituitary 
replacement therapy had to be given for diabetes insipidus (n=2), hypogonadism (n=5), hypothy­
roidism (n=5) or grow th hormone deficiency (n=2). In the literature the reported incidence of 
hypopituitarism  after p ituitary irradiation varies widely and seems to be dose dependent (32). In 
the study of Howlett et a l . (8) of 15 patients irradiated w ith  a total dose of 45 Gy, only one devel­
oped TSH and gonadotrophin deficiency (follow-up 1.5 to 17.3 years; median 9.3 years).
There is no agreement on the optimal time of in tervention  in  patients w ith  Nelson's 
syndrome. Several argum ents advocate for early treatm ent. Nelson's tum ors are recognized for 
their large size and aggressive and invasive grow th (6, 7, 33). In some Nelson's patients there is 
considerable progression of the tum or volume in a relatively short period (as in this report) w ith  
supra- and parasellar expansion leading to ophthalmological and neurological symptoms. 
Parasellar expansion, especially cavernous sinus invasion, by a p itu itary  tum or has been related
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to a low surgical cure rate because of the com plexity of surgical exploration (20), whereas far 
better results of p itu itary  surgery have been reported in patients w ith  smaller intrasellar 
Nelson's adenomas (17, 18). Moreover, in large Nelson's tum ors spontaneous haem orrhage in the 
tum or can occur (5, 19), w hich can lead to neurological complications and even death as was 
dram atically illustrated by the course of disease in  one of our Nelson's patients. Furtherm ore, 
large Nelson's adenomas usually are no t completely resectable and have the propensity to recur 
(7). Therefore in these cases radiotherapy has to be given postoperatively to complement surgical 
treatm ent. The incidence of p itu itary  insufficiency after non-selective p itu itary  surgery and 
radiotherapy for treatm ent of these large tum ors will be much higher than  in patients cured 
after selective transsphenoidal p itu itary  surgery for an intrasellar adenoma.
Our study is the first dem onstrating a strong relation betw een plasma ACTH levels and 
tum or volumes both  at diagnosis of Nelson's syndrom e and after p itu itary  surgery and/or irra­
diation. This strong association betw een tum or volume and circulating ACTH suggests tha t the 
latter can be used as an indirect measure for tum or load. Furtherm ore, it appeared tha t in the 
surgery group tum or volume at diagnosis may have a predictive value for the chance of 
completeness of tum or excision: the larger the tum or before surgery, the lower its remission 
rate, again suggesting an argument to treat Nelson's adenoma early and aggressively. This finding 
is in line w ith  similar data on grow th horm one and prolactin in acromegaly and prolactinoma, 
respectively (34, 35).
In conclusion, in our opinion, based upon experience in  15 patients, p itu itary  surgery of 
Nelson's macroadenomas should be perform ed before extrasellar expansion of the tum or occurs. 
P itu itary  surgery seems to be more successful w hen a Nelson's adenoma is lim ited to the 
intrasellar region. P itu itary  irradiation has to be perform ed postoperatively in all patients w ith  
residual tum or in  order to attain  long lasting remission.
MANAGEMENT OF NELSON'S SYNDROME:OBSERVATIONS IN FIFTEEN PATIENTS
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ABSTRACT
A 25-year-old w om an developed Nelson's syndrom e, 3 years after successful bilateral 
adrenalectom y for Cushing's disease. Despite p itu itary  surgery and radiotherapy the tum our 
showed invasive growth, leading to visual d isturbance, paresis of the oculom otor nerve and, 34 
years after adrenalectomy, to death  by w idespread pu ru len t leptom eningitis. A utopsy revealed 
a large adenohypophyseal carcinoma w ith  a metastasis attached to the dura, bo th  tum ours 
showing immunocytochem ical staining for ACTH and TSH.
We review  the literature on m etastatic adenohypophyseal carcinoma in Cushing's disease 
and Nelson's syndrom e and discuss the role of proliferation markers as indicators of m alignant 
progression.
IN TR O D U C T IO N
Nelson's syndrom e is the clinical m anifestation of an adrenocorticotropic horm one (ACTH) 
secreting adenohypophyseal neoplasm  th a t occurs in  patients adrenalectom ized for Cushing's 
disease. In its typical form, the syndrom e is characterized by the developm ent of a p itu itary  
macroadenoma, fasting ACTH levels exceeding 200 pmol/l, and hyperpigm entation  of the skin
(1). A lthough p itu itary  tum ours in  Nelson's syndrom e are recognized for the ir large size and 
aggressive and invasive growth, they rarely undergo m alignant transform ation (2). We present 
a patien t w ith  Nelson's syndrom e w ith  a 30-year interval betw een the diagnosis of Cushing's 
disease and th a t of a m etastatic p itu itary  carcinoma. Additionally, we review  the literature on 
adenoma-to-carcinoma transform ation in  Cushing's disease and Nelson's syndrom e, the role of 
proliferation markers as indicator of m alignant progression, and discuss the clinical relevance 
of this transform ation.
CASE REPORT
Propositus, a woman, underw en t bilateral adrenalectom y in  1962 at the age of 22 years, 
because of p itu itary -dependen t Cushing's syndrom e and was substitu ted  by glucocorticoids 
and mineralocorticoids. A preoperative X-ray showed a normal configuration of the sella turcica. 
One and a half year after adrenalectom y m arked hyperpigm entation  developed and renewed 
radiological exam ination showed enlargem ent and destruction  of the sella. Carotic angiography 
and cysternography were compatible w ith  the presence of a p itu itary  macroadenoma and a diag­
nosis of Nelson's syndrom e was made. Ophthalmologic exam ination showed normal visual fields.
In  1969, X-ray planigraphy showed progressive enlargement of the sella w ith  destruction  of 
the dorsum sellae. A lthough visual fields were still intact, p itu itary  surgery was perform ed by 
a suprasphenoidal approach. A largely suprasellar, soft tum our, displacing both optical nerves, 
was removed by suction. Histologic exam ination revealed a p itu itary  adenoma, the tum our cells 
showing chrom ophobic or slightly eosinophilic cytoplasm, slight nuclear atypia, but no mitotic 
activity. Postoperatively the patient developed hypothyroidism  and hypogonadism.
PROGRESSION OF A NELSON’S ADENOMA TO PITUITARY CARCINOMA;A CASE REPORT AND REVIEW OF THE LITERATURE
Figure 1b
Figure 1c
Figure 1. Macroscopy of the pituitary carcinoma (a) and of the metastasis attached to the inside of the parietal dura (b); lat- 
ero-lateral diameter o f carcinoma 3.5 cm; maximum diameter o f metastasis 1.2 cm. Microscopically, the tumour cells showed 
strong cytoplasmic immunohistochemical staining for ACTH in both the sellar/suprasellar lesion (not shown) and in the metasta­
sis (c;note the negative fibrous tissue (FT),surrounded by positive tumour cells;original magnifcation in c  x200).
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Figure 2. Extensive purulent leptomeningitis (a) and focal purulent myocarditis (b);note the dense accumulation of neutrophilic 
granulocytes in the leptomenin-ges (LM ) but not in the cerebral cortex (CX ) and the scattered presence of these cells in between 
the cardiac muscle fibers (a, b: hematoxylin and eosin staining; original magnification x100 resp. x200).
In 1979, w hen ACTH m easurem ents became available, plasma ACTH levels were 12,320 
pmol/l and rose w ith in  6 m onths to 110,000 pmol/l (normal values 2.2-15 pmol/l). Cypro- 
hep tad in  failed to suppress ACTH-production. CT-scanning was refused because of clau­
strophobia.
In 1985 opthalmologic exam ination revealed almost complete hom onym ous hem ianopsia at 
the righ t side and paresis of the left oculom otor nerve. Com puterized tom ography of the skull 
revealed a suprasellar expanded mass w ith  a diam eter of at least 50 mm. Again p itu itary  sur­
gery was perform ed by a suprasphenoidal approach. The left carotid artery  and the left optical 
nerve were displaced and surrounded  by tum our. The tum our, th a t could only partially be 
removed because of fixation to the carotid artery, showed essentially the same histological 
features as in  1969. Additionally, m oderate nuclear atypia and occasional mitoses were present. 
Paresis of the left oculom otor nerve and hem ianopsia of the left eye persisted w ith  a reduced 
visual acuity  (0.6). P itu itary  surgery was followed by irradiation  w ith  a total dose of 46 Gy. 
CT-scanning showed a decrease of the p itu itary  tum our size to 40 mm and ACTH levels declined 
slowly to a minimum of 3,520 pmol/l in  1993.
PROGRESSION OF A NELSON’S ADENOMA TO PITUITARY CARCINOMA;A CASE REPORT AND REVIEW OF THE LITERATURE
In  1995 CT-scanning revealed grow th of the p itu itary  tum our w ith  extension to the left 
parasellar region and into the left sphenoidal sinus. Plasma ACTH levels had increased again to 
15,840 pmol/l. Since there was no progression of the know n visual field defects, a th ird  p itu ­
itary  operation was no t indicated at tha t moment. In 1996, after a w eek suffering from a com­
mon cold w ithou t fever, the patient was found unconscious at home and she died in  the hospi­
tal after unsuccessful resuscitation, because of acute electrom echanical dissociation. She 
appropriately had taken her glucocorticoid and m ineralocorticoid substitu tion  therapy.
A utopsy revealed a large tum our in  the sellar region (max. diam. 3.5 cm) w ith  extensive 
destruction  of the sella turcica and w ith  incorporation and atrophy of the left optic nerve 
(Fig.1a). A second, circum scribed tum our w ith  a maximum diam eter of 1.2 cm was attached to 
the dura in  the righ t parietal region (Fig.1b). Both the sellar and the dural tum our showed sim­
ilar histological features as the adenohypophyseal tum our in  1985, in  the sellar tum our focal 
necrosis was present. There was no macroscopic or microscopic invasion of the brain. 
Furtherm ore, w idespread pu ru len t leptom eningitis around bo th  the brain  and spinal cord 
(Fig.2a), and focal pu ru len t inflam m ation in  the myocard was found (Fig.2b). Cultures for 
microorganisms were not perform ed, since these inflam m ations were only detected during 
microscopic exam ination. The leptom eningitis could very well be explained by the extensive 
destruction  of the base of the skull in  the sellar region, while the pu ru len t myocarditis was 
tentatively in te rp re ted  as haem atogenous spread of the leptom eningeal inflammation.
Im m unohistochem istry was perform ed on the sellar and dural tum our obtained at autopsy, 
as well as on tissue of the adenohypophyseal tum our removed in  1969 and 1985, using avidin- 
biotin  techniques on formalin-fixed, paraffin-em bedded material. All these tissues showed dif­
fuse cytoplasmic staining for ACTH (Fig.1c) and focal positiv ity  for TSH. Occasional cells 
showed cytoplasmic staining for LH, whereas the stainings for GH, PRL, and FSH were nega­
tive. The MIB-1 labeling index (MIB-1 LI) (Imm unotech Inc. France; monoclonal; 1:100 dilution) 
was 5.7% resp. 2.6%  in the biopsy tissue removed in  1969 and 1985, and 0.6%  resp. 0.7%  in 
the sellar and dural tum our tissue obtained at autopsy (for this MIB-LI at least 500 nuclei of 
tum our cells were counted in  the area w ith  a h igh  percentage of positive nuclei). In  all tissues 
p53-staining (Neomarkers Corp. USA; monoclonal DO-7; 1:500 dilution) was negative.
D ISC U SS IO N
A denohypophyseal neoplasms can be d ivided into three groups on the basis of the ir bio­
logic behavior: benign, invasive, and m alignant. The m ajority are benign, localized w ith in  the 
sella turcica or w ith  suprasellar expansion and w ith  sharply dem arcated borders. Five to 35% 
of the tum ours show macroscopic invasion in  dura, bone, nerves, or brain. These tum ours are 
term ed invasive adenomas (2-5). Shaffi and W rightson (6, 7) were the first authors, recognizing 
the invasive character of many p itu itary  adenomas, w ith  local invasion of the dura m ater and 
blood vessels, b u t w ithou t other clinical or histological signs of malignancy. Hardy (8) formu­
lated radiological criteria for p itu itary  tum our invasiveness: 1) intrasellar microadenomas, <10 
mm; 2) in trasellar macroadenomas, >10 mm; 3) adenomas w ith  local expansion; and 4) adeno­
mas w ith  extrasellar expansion. A lthough invasion in  surrounding structures indicates a more
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T a b le  I. Clinical and immunohistochemical characteristics of patients with metastasized ACTH-secreting adenohypophyseal tumours in literature.
Case Reference Presented clinically 
with
Biochemical 
characteristics of 
hormonal activity
Immunohistochemical 
staining of the primary 
tumour cq. métastasés
Site of métastasés
1. Cohen et al. (21 ) Cushing’s disease Liver
2. Forbes et al. (22) Cushing’s disease Liver
3. Sheldon et al. (23) Cushing’s disease Liver
4. Salassa et al. (24) Nelson’s syndrome Liver, spinal cord, cauda equina
5. Scholz et al. (25) Cushing’s disease, 
Sec. Hypogonadism, 
Sec. Hypothyroidism
Cervical lymph node
6. Queiroz et al. (26) Cushing’s disease, 
Diabetes insipidus
Liver
7. Moore et al. (27) Nelson’s syndrome Liver, cerebral cortex, spinal cord
8. Kaiser et al. (28) Nelson’s syndrome ACTH, b-MSH, b-END ACTH Liver, lung, mediastinum, bone
9. Papotti et al. (29) Nelson’s syndrome ACTH ACTH, b-HCG, b-END Subarachnoidal space,4th ventricle, brain stem
10. Gabrillove et al. (30) Nelson’s syndrome ACTH ACTH, a-MSH, b-LPH, b-END Spinal cord, cauda equina, heart, liver, pancreas
II. Nawata et al. (31 ) Cushing’s disease ACTH, CRH, b-LPH ACTH, CRH Liver, lung, olfactory bulb
12. Levesque et al. (32) Cushing’s disease ACTH, b-END ACTH Meninges, lymph nodes
13. Tonner et al. (33) Cushing’s disease ACTH ACTH Cerebellum, anterior fossa, subarachnoidal space
14. Frost et al. (34) Cushing’s disease,
Cauda equina syndrome
ACTH ACTH Spinal cord, cauda equina
15. Garrao et al. (35) Cushing’s disease ACTH ACTH Bone
16. Kemink et al. (this paper) Nelson’s syndrome ACTH ACTH, LH.TSH 1 ntrd u ral temporoparietal
b-MSH, beta-Melanocyte Stimulating Hormone; b-END, beta-Endorphin; b-LPH, beta-Lipotrophin
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agressive grow th potential, most of these tum ours do no t lead to d istan t metastases and are 
therefore generally no t considered to be m alignant. H istopathological features like cellular 
pleomorphism, nuclear atypia, cellularity, hem orrhage and necrosis, have been show n to be 
unreliable indicators of invasive behavior. In contrast, large tum our size and brisk mitotic activity 
do correlate w ith  aggressive grow th (5, 9, 10).
P ituitary carcinomas are distinguished from invasive adenomas by the presence of craniospinal 
and /or systemic metastases. Only few pathologic studies of m alignant adenohypophyseal 
tum ours have been undertaken  beyond the ligh t microscopic, u ltrastructural, and immuno- 
histochem ical levels. W hile a h igh  proliferative activ ity  as determ ined by the MIB-1 LI (10, 11) 
and the proliferating cell nuclear antigen (PCNA) index (12, 13) in  adenohypophyseal tum ours 
have been described by some authors to be indicators of m alignant progression, in  another 
study the MIB-1 LI did no t contribute to discrim inating invasive from  non-invasive adenomas 
(14). In our patient, the MIB-1 LI was m arked in  the biopsy tissue of 1969, somewhat lower in 
the tissue of 1985, and minimal in  the sellar and dural tum our tissue obtained by autopsy. The 
latter finding may be explained by differences in  the fixation-procedure (14). The prognostic 
relevance of the MIB-1 LI awaits fu rth e r elucidation.
Recently the expression of tum our suppressor genes and tum our transform ing genes has 
been show n to play a role in  p itu itary  tum origenesis (15, 16). In the study of Thapar et al. (17) 
overexpression of the p53 tum our suppressor gene was dem onstrated in  most p itu itary  carci­
nomas, in  a m inority  of invasive adenomas, b u t no t in  noninvasive adenomas. Our case 
illustrates th a t lack of p53 im m unoreactivity in  the adenohypophyseal tum our does no t rule out 
m alignant progression. For adenohypophyseal tum ours only one oncogene (Gsp) has been iden­
tified in  35-40% of som atotrophinom as (18). A lthough similar G protein gene m utations have 
been identified in  two out of 32 corticotroph adenomas, they appear to occur infrequently  in 
this type of tum our (19). Allelic deletion studies, using a PCR-based m icrosatellite polym or­
phism  analysis of DNA, have show n significant loss of heterozygosity in  p itu itary  tum ours. 
These DNA m icrodeletions were concentrated in  radiologically invasive tum ours com pared to 
non-invasive tum ours (15).
Up to 38%  of subjects adrenalectom ized for Cushing's disease subsequently  develop 
Nelson's syndrom e (1). The most obvious difference betw een the adenohypophyseal tum ours in 
Cushing's disease and those in  Nelson's syndrom e is the more aggressive grow th potential in  the 
latter, often resulting in  large and locally invasive tum ours (20). Nevertheless, p itu itary  carci­
noma in the context of Nelson's syndrom e is very rare (21-35; see Table 1 for review). Both 
in tradural and extracranial metastases of ACTH-producing carcinomas have been described 
(Table 1). Because in  older studies this technique was not available, only in  the more recent 
patients ACTH and /o r ACTH-related proteins have been dem onstrated in  the metastases by 
im m unohistochem istry (Table 1). In  literature, most patients w ith  m alignant ACTH-secreting 
tum ours showed m arked hyperpigm entation due to increased production of ACTH and related 
m elanotrophic peptides by the prim ary tum our and its metastases. In some cases hyper­
pigm entation was already present before adrenalectom y for Cushing's disease (21, 22), in  other 
cases hyperpigm entation developed only after adrenalectomy (22, 27-30; this case). The reduction 
of the elevated plasma cortisol levels by adrenalectom y and the subsequent physiological 
glucocorticoid replacem ent in  the la tter cases may have stim ulated the tum our cells not only to
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produce more ACTH b u t also to undergo increased cellular replication, eventually prom oting 
m alignant transform ation (28).
It is unlikely th a t m alignant transform ation of the adenohypophyseal tum our in  our 
patient was caused by irradiation. Radiation-induced intracranial neoplasm s are rare, the most 
common neoplasm s being meningiomas, gliomas, and sarcomas (36). In a study of Brada et al. 
(37), 334 patients w ith  p itu itary  adenom a treated w ith  conservative surgery and radiotherapy 
(median dose 45 Gy), were followed up for 3760 person years. Five patients developed a second 
brain  tum our: 2 had astrocytom a, 2 meningioma, and 1 meningeal sarcoma. No cases w ith  
m alignant transform ation of the ir p itu itary  adenom a were found.
W hile in  the study of Pernicone e t al.  (10), the interval from the initial diagnosis of p itu­
itary  adenoma to tha t of carcinoma ranged from 0.3 to 18.0 years, in  our patient the interval was 
even 34 years. The clinical significance of the occurrence of metastases of an adenohypophyseal 
tum our is variable. Of the 15 patients described by Pernicone et al. (10), 80% died of m etasta­
tic disease 7 days to 8 years after the diagnosis of carcinoma; of these, 66%  died w ith in  1 year. 
In many cases, including ours, the diagnosis of metastasized p itu itary  carcinoma was made only 
a t autopsy and the occurrence of metastases was not considered as contribu ting  to death 
(22-24, 26, 29). In  our case, the prim ary tum our caused extensive destruction  of the skull base 
in  the sellar region, thereby possibly creating a porte d 'en tree for microorganisms, leading to a 
fatal leptom eningitis and presum ably myocarditis.
It is unclear w hether or not prophylactic p itu itary  radiotherapy at the time of adrenalectomy 
can prevent Nelson's syndrom e. Jenkins et al. (38) reported  th a t prophylactic p itu itary  irradia­
tion  reduces the incidence of subsequent Nelson's syndrom e by 50% . They described 56 
patients adrenalectom ized for Cushing's disease, of whom  20 received prophylactic p itu itary  
radiotherapy. Of these 20 patients 5 (25%) developed Nelson's syndrom e, while 18 of the 36 
(50%) non-irradiated  patients developed this com plication. In  this study, Nelson's syndrom e 
was diagnosed in  the presence of hyperpigm entation and a plasma ACTH value greater than  
200 pmol/l, regardless of w hether a p itu itary  tum our was dem onstrated or not. W hen the 
effects of prophylactic radiotherapy were com pared in  the patients w ith  a p itu itary  tum our at 
the time of the diagnosis of Nelson's syndrom e (n=12), 4 patients of the 20 (20%) who received 
radiotherapy developed a tum our v s  8 of the 36 (22%) who did not. In  other studies p rophy­
lactic radiotherapy did no t prevent developm ent of Nelson's syndrom e in patients adrena­
lectomized for Cushing's disease (39-41). From these studies we conclude th a t prophylactic 
p itu itary  irradiation  has no t been proven to prevent Nelson's syndrom e after adrenalectom y for 
Cushing's disease.
Treatment of big pitu itary  macroadenomas, both neurosurgically and by irradiation, mostly 
provides only palliation. Increasing clinical awareness allied w ith recent improvements in  imaging 
techniques perm its earlier diagnosis of p itu itary  macroadenomas w ith  the corresponding ben­
efits of better control. Especially in  the case of invasive p itu itary  neoplasm s such as Nelson's 
tum ours, early and radical p itu itary  surgery is the treatm ent of choice. Conventional radio­
therapy has to be employed postoperatively in  all patients w ith  residual tum our or extrasellar 
extension (20). There is only little experience w ith  regard to cytotoxic chem otherapy in  the 
treatm ent of p itu itary  carcinomas. There are 2 case reports describing tum our regression by 
chem otherapy in  a TSH-secreting carcinoma (42) and in  a prolactin-secreting carcinoma (43),
PROGRESSION OF A NELSON’S ADENOMA TO PITUITARY CARCINOMA;A CASE REPORT AND REVIEW OF THE LITERATURE
bu t not in  ACTH-secreting p itu itary  carcinoma. N otw ithstanding cure rates approaching 70 to 
90% , Nelson's syndrom e shares w ith  Cushing's disease an inevitable tendency to recur over the 
long term , i.e., over periods 10 years and  longer. Life-long surveillance of these 
patients is essential for optim um  management.
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ABSTRACT
In 14 women, aged 47.2 ± 10.5 yr, bilaterally adrenalectom ized for Cushing's disease 13.6 
± 7 .7  y r  before, all on conventional doses of glucocorticoid and m ineralocorticoid substitution, 
body com position was studied w ith  regard to body fat, body fat d istribution , fat-free mass 
(FFM), and bone m ineral density. The data were compared w ith  those of 14 healthy women of 
similar age, body mass index, and menopausal state. Five different body com position m easure­
m ent m ethods were compared, i.e. body densitom etry by underw ater w eighing (UWW), total 
body w ater m easurem ent by deuterium  dilu tion  (D2O dilution), dual-energy x-ray absorptiom ­
etry  (DXA), bioelectrical im pedance spectrom etry (BIS), and skinfold m easurem ents, using a 
four-com ponent model (4C-model) as the reference method.
In the patients the percent body fat was significantly h igher than  th a t in  the controls as 
determ ined by all methods, whereas FFM was significantly lower w hen m easured w ith  the 4C- 
model, UWW, D2O dilution, DXA, or BIS. M easured by DXA, the percentage tru n k  fat, esti­
m ated as [fat mass of the tru n k  (g): total fat mass (g)] x 100%, was significantly h igher in  the 
patients than  in  the controls (39.3 ± 6.4%  and 29.9 ± 7.8% , respectively; P<0.001). M easured 
by DXA, there was no difference in  total bone m ineral density  betw een the groups. Differences 
betw een the 4C-model, UWW, D2O dilution, and DXA for determ ination of percent body fat 
were rather small. Skinfold m easurem ents and BIS results, however, deviated substantially  from 
the 4C-model.
The study indicates th a t adrenalectom ized patients on conventional glucocorticoid substi­
tu tion  have increased body fat percentages w ith  a centripetal fat d istribu tion  and lowered FFM, 
b u t norm al bone m ineral density. Furtherm ore, the study indicates th a t for clinical practice, 
DXA, D2O dilution, UWW, and the 4C-model can be used for determ ination of body composi­
tion  in  this patien t group, whereas the more convenient bedside methods, BIS and skinfold 
measurements, did no t give reliable results. We suppose th a t glucocorticoid overreplacem ent in 
adrenalectom ized patients m ight be the cause of the ir abnorm al body com position, although 
GH deficiency after p itu itary  surgery could have played a contribu tory  role in  some of the 
patients.
IN TR O D U C T IO N
Before the era of transsphenoidal p itu itary  surgery total adrenalectom y has been w idely 
used to treat p itu itary -dependen t Cushing's syndrom e. Today, total adrenalectom y is no longer 
the prim ary therapy of Cushing's disease, b u t there still rem ain patients in  whom  bilateral 
adrenalectom y is needed for cure of the disease, especially w hen p itu itary  surgery was unsuc­
cessful. It is the clinical im pression th a t patients bilaterally adrenalectom ized for treatm ent of 
Cushing's disease have an abnormal body com position. Body com position, however, has never 
been studied w ith  objective m ethods in  th is group of patients.
A variety  of m ethods for m easuring hum an body com position are available. M ost of these 
m ethods are based upon the tw o-com ponent model in  w hich the body consists of two chemi­
cally d istinct com partm ents, the fat and fat-free masses. In th is model it is assumed th a t the
C H A P T E R  5 So
Tab le  I . Clinical characteristics and therapy of the 14 patients bilaterally adrenalectomized for Cushing’s disease.
Patient
No.
Menopausal
State
Time after
A D X  (yr)
Pituitary surgery Peak GH level 
after arginine
(mU/L)
Daily
glucocorticoid
replacement
Daily
mineralocorticoid
replacement
Other medication3
1 Pre 25 No 59 CA (15.0 mg) F (0.06 mg) Ethinylestradiol(30|jg)/desogestrel( 150|jg)
2 Pre 17 No 21 CA (37.5 mg) F (0.09 mg)
3 Post 21 No 4 CA (25.0 mg) F (0.13 mg) ß-Blocker
4 Post 14 Before ADX NA CA (50.0 mg) F (0.19 mg) Levothyroxin, a-blocker
5 Pre 9 Before ADX 23 D (0.5 mg) F (0.19 mg) Ethin/lestradiol(30|jg)/desogestrel( 150|jg) 
Desmopressin
6 Pre 6 Before ADX 3 HC (20.0 mg) F (0.19 mg) Ethin/lestradiol(30|jg)/levonorgestrel( 150|jg)
7 Post 10 Before ADX 10 CA (37,5 mg) F (0.09 mg) Estradiol (1 mg)
8 Post 27 After ADX <2 CA (37,5 mg) F (0.06 mg) Levothyroxin
9 Post 16 No 11 CA (37,5 mg) F (0.06 mg) Conjugated Estrogen (0.625 mg)/ 
medroxyprogesteroneacetate ( 10 mg)
10 Post 27 Cryocoagulation 
Before ADX
11 P (5.0 mg) F (0.06 mg) Transdermal Estradiol (50 Mg)/ 
medroxyprogesteroneacetate ( 10 mg)
11 Pre 8 Before ADX 22 CA (37.5 mg) F (0.10 mg) Desmopressin
12 Post 15 BeforeADX 7 P (7.5 mg) F (0.09 mg)
13 Pre 2 Before ADX <2 CA (37.5 mg) F (0.19 mg) Levothyroxin, Ethinylestradiol (30 |jg)/ 
levonorgestrel (150 Mg),ACE inhibitor
14 Post 16 After ADX + RT <2 CA (50.0 mg) F (0.05 mg) Levothyroxin
ADX, Bilateral adrenalectomy; RT, pituitary radiotherarapy; CA, cortisone acetate; D, dexamethasone; HC, hydrocortisone; P, prednisone; F, 9-a-fluorohydrocortisone; NA, not available. aDoses are per day
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fat-free com partment has a density of 1.1 g/cc at 37 C and a water content of 0.73 L/kg, whereas 
fat, w hich is supposed to be anhydrous, has a density of 0.9 g/cc at 37 C (1). Examples of methods 
using the two-component model are measurement of whole body density by underw ater weighing 
(UWW), measurement of total body water by deuterium  dilution (D2O-dilution), dual-energy 
x-ray absorptiom etry (DXA), bioelectrical im pedance spectrom etry (BIS), and m easurem ent of 
skinfold thicknesses.
In the four-com ponent model (4C-model) the hum an body is d ivided into four chemically 
d istinct com partm ents: water, protein, bone mineral, and fat. This model overcomes uncertain­
ties concerning the hydration  fraction of the fat-free mass (FFM) and segregates protein from 
m ineral. Therefore, th is model circumvenes the need for some of the assum ptions inheren t to 
the tw o-com ponent model regarding proportions and densities of different com ponents of the 
FFM (2). One of the most reliable m ethods for determ ining body com position is th a t of Füller et 
al. (2), in  w hich a four-com ponent model is used, w hich combines results of densitom etry by 
UW W  w ith  those of m easurem ent of bone m ineral content by DXA, and total body w ater 
assessment by D2O -dilution (2, 3). The regional d istribu tion  of body fat is a critical variable to 
consider in  the clinical assessment of (former) Cushing's patients, as accum ulation of fat in  the 
central part of the body is associated w ith  an increased incidence of cardiovascular m orbidity  
and m ortality  (4).
In the present study we obtained body com position data, such as body fat, body fat 
d istribution , FFM, and bone m ineral density  (BMD), in  a group of women bilaterally adrena­
lectomized for Cushing's disease, all receiving conventional glucocorticoid and m ineralocorti­
coid substitu tion , and we com pared these data w ith  those of healthy women of similar age, 
body mass index, and m enopausal state. We com pared the relatively costly and com plicated 
m echanistic m ethods (UWW, D2O dilution, and DXA) w ith  the fast and inexpensive descriptive 
bedside body com position m easurem ent m ethods (BIS and skinfold) using the 4C-model (2) as 
the reference method.
SUBJECTS A N D  M ETH O D S
Sub jects
Fourteen women, aged 47.2 ± 10.5 y r  (mean ± SD; range, 28 - 60 yr) bilaterally adrena­
lectomized for p itu itary -dependen t Cushing's syndrom e 13.6 ± 7.7 y r  earlier (range, 2 - 27 yr) 
were studied. Clinical characteristics and medical therapy of these 14 patients are summ arized 
in  Table 1. E ight of them  were postm enopausal, and 6 were prem enopausal at the time of the 
study. Before adrenalectom y 7 of the 14 patients had undergone unsuccessful p itu itary  surgery, 
and 1 had undergone transsphenoidal cryocoagulation of the pituitary. Two others had un d er­
gone p itu itary  surgery because of Nelson's syndrom e after adrenalectomy, 18 and 11 y r  before 
this study; in  the la tter patient p itu itary  surgery was followed by radiotherapy w ith  a total dose 
of 46 Gy. All patients had conventional doses of glucocorticoid (cortisone acetate, n  = 10; 
hydrocortisone, n  = 1; prednisone, n  = 2; dexam ethasone, n  = 1) and m ineralocorticoid sub­
stitu tion  (9-alpha-fluorohydrocortisone, all). For com parison, the doses of the glucocorticoids 
were converted to hydrocortisone equivalents (30 mg hydrocortisone = 37.5 mg cortisone
C H A P T E R  5 g
Tab le 2. Physical characteristics of the 14 adrenalectomized women and their controls.
Adrenalectomized patients Controls
Subject no. Age (yr) Ht (m) Y/t(kg) BM I (kg/m1) Age (yr) Ht (m) W t  (kg) BMI (kg/m2)
1 44 1.59 59.7 23.6 40 1.63 56.4 21.2
2 Al 1.68 71.4 25.3 51 1.62 74.3 28.3
3 55 1.62 76.4 29.1 53 1.63 76.0 28.6
4 57 1.62 71.0 27.1 59 1.62 70.7 26.9
5 28 1.57 62.9 25.5 26 1.70 68.4 23.7a
6 35 1.75 62.2 20.3 37 1.75 59.6 19.4
7 55 1.61 61.2 23.6 57 1.58 55.0 22.0
8 51 1.71 71.6 24.5 48 1.70 75.8 26.2
9 52 1.64 63.2 23.5 55 1.63 65.1 24.5
10 58 1.70 69.1 23.9 58 1.61 64.1 24.7
11 35 1.63 54.3 20.4 34 1.67 55.2 19.8
12 60 1.66 70.3 25.5 57 1.69 72.1 25.3
13 33 1.58 57.5 23.0 31 1.70 59.5 20.6a
14 51 1.65 74.7 27.4 49 1.66 70.0 25.4
Mean (SD) 47.2 (10.5) 1.64 (0.05) 66.1 (6.8) 24.5 (2.5) 46.8 (1 l.l) 1.66 (0.05) 65.9 (7.7) 24.0 (3.0)
a Two of the controls used estrogens.
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acetate = 7.5 mg prednisone = 0.75 mg dexamethasone). The daily dose of hydrocortisone 
equivalent at the time of the study was 27.3 ± 7.9 mg (mean ± SD), and of 9-alpha-fluorohy- 
drocortisone 0.11 ± 0.06 mg. At the time of the study four patients were adequately substituted 
w ith  levothyroxine because of secondary hypothyroidism , seven used estrogens (as oral 
contraception or as replacem ent therapy), and two were treated w ith  desm opressin because of 
diabetes insipidus. To evaluate the presence of GH deficiency, in  13 of the 14 patients a stan­
dard arginine provocation test (0.5 g/kg arginine-HCl; maximal dose, 30 g) was perform ed. Peak 
plasma GH levels after arginine are given in  Table 1. None of the patients had received GH sub­
stitu tion  therapy. Three patients were treated for hypertension. Fourteen healthy female con­
trols, aged 46.8 ± 11.1 y r (mean ± SD; range, 26 - 59 yr), and m atched w ith  ind iv idual patients 
for age, body mass index (BMI) and m enopausal state, were recruited. Two of them  used estro­
gens as oral contraception. Patients and controls were well m atched for age, heigth, w eight, and 
BMI, respectively (Table 2).
The study was approved by the ethics committee of the U niversity Hospital of Nijmegen. 
All subjects gave inform ed consent after explanation of the aims and m ethods of the study.
Determination o f percent body fa t  (%BF) and FFM using the two-component model
Measurement o f whole body density by UW W . A fter m easuring body density  by UW W  it is 
possible to determ ine body fat and FFM from the m easured whole body density  (1). This tech­
nique uses determ ination of body volume according to Archim edes' principle, w hich states that 
the volume of an object subm erged in  w ater equals the volume of w ater the object displaced. If 
one measures w eight in  air and w eight in  water, the difference, corrected for the density  of the 
w ater corresponding to the w ater tem perature at the time of the underw ater weighing, is the 
apparent body volume. Patients and controls, therefore, were subm erged in  water, dressed in 
swim wear, for m easuring w eight in  w ater and body volume. The m easurem ent was perform ed 
in  the fasted state during  tidal volume respiration, and correction was made for residual lung 
volume during  submersion. Residual lung volume was m easured w ith  the helium  d ilu tion  tech­
nique using a lung volume meter.
Measurement o f total body water (TBW ) by D2O dilution. M easurem ent of TBW is a m ethod 
w hich allows determ ination of body fat and FFM, assum ing th a t w ater is no t present in  stored 
fat and th a t w ater occupies a relatively fixed fraction (73.2%) of the FFM (5, 6). TBW was deter­
m ined by the D2O dilu tion  m ethod, as described previously (7). Before the intake of a single 
oral dose of a know n am ount of deuterium , a urine sample was taken for deuterium  (back­
ground) m easurem ent. A fter an overnight equilibration  period of 10 hours (8), another urine 
sample was taken for deuterium  (enriched) m easurem ent. Subjects did no t eat or d rin k  between 
the time the deuterium  was taken and the enriched urine samples were obtained. D euterium  in 
urine was m easured by mass spectrom etry (7).
D XA. Total bone m ineral content (TBMC) and soft tissue com position of the body were 
m easured w ith  dual-energy x-ray absorptiom etry (model DPX, Lunar Corp., M adison, WI) as 
described previously (9). We used the m edium  scan speed (80 mm/s) w ith  a resolution of
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4.8x9.6 mm. For determ ination of soft tissue com position, total soft tissue (grams), fat tissue 
(grams), lean tissue (grams) and bone m ineral con ten t (grams) were m easured in  the total body 
and in  the trunk . Moreover, total BMD (TBMD; grams per cm2) was calculated by Lunar Corp. 
software (version 1.3z).
BIS. W ith  bioelectrical im pedance measurem ents of the body at different frequencies (BIS) 
it is possible to discrim inate betw een the extracellular w ater com partm ent (ECW) and the 
intracellular w ater com partm ent (ICW) of the body, as tissue im pedance at low frequencies is 
highly correlated w ith  the ECW and at h igh  frequencies w ith  the total body w ater com part­
m ent (TBW) (10). The prediction  of ECW and TBW using the im pedance of ECW and TBW 
depends on the underly ing theory. We used the general m ixture theory  based on em ulsion sci­
ences. This theory  includes properties of bo th  the conducting m aterial and the nonconducting  
m aterial in  the suspension. An extensive explanation of th is theory  is described by De Lorenzo 
et al. (10) as well as by Hanai (11). FFM can be estim ated from the results of BIS, assuming a 
fixed hydration  of the FFM of 0.73 L/kg. In patients and controls BIS was m easured w ith  a 
Xitron 4000 M ulti-Frequency Bio-Impedance A nalyzer (Xitron Technologies, San Diego, CA) at 
frequencies of 5 - 500 kHz, as decribed previously (10, 12). A tetrapolar arrangem ent of gel elec­
trodes was used, placed on hand, w rist, ankle, and foot at the rig h t side of the body.
Skin fo ld  thicknesses. Skinfold thicknesses were m easured to the nearest 0.2 mm at four 
sites, i.e. biceps, triceps, subscapular, and supra-iliac, w ith  a H oltain Ltd. caliper as described 
previously (1). Because body density  is not linearly related to sc fat mass, m athem atical trans­
form ation of the sum of skinfold thicknesses and correction for gender and age was perform ed 
as described by D urnin and Womersley (13) for prediction of %BF.
D eterm in a tio n  o f  % B F  a n d  F F M  using  the 4C -m odel
Body com position was also estim ated by the 4C-model according to Füller, com bining the 
measurem ents of body density  (UWW), total body w ater (D20 dilution) and bone mineral 
content (DXA). Classical tw o-com partm ent models (fat and FFM), such as underw ater weighing, 
are lim ited by assum ptions regarding the constancy of com position of the FFM. The 4C-model 
(fat, water, protein, and mineral), w hich is based on measurem ents obtained from densitom e­
try, D2O dilution, and DXA, overcomes uncertainties concerning the hydration  of the FFM and 
bone m ineral content. The 4C-model incorporates direct m easurem ent of TBMC, as well as the 
established m easurem ents of body density  and total body water. Densities of fat, protein, and 
TBM are still assumed as well as the ratio of osseous to nonosseous mineral. From this description 
it is evident tha t the calculations on body fat by UWW and D2O dilution are not completely inde­
pendent on the 4C-model. Differences in  outcome depend to a large extent on deviations from 
reference values w ith  respect to the hydration of FFM and to the bone mineral fraction of FFM.
Total body fat was calculated according to the formula: fat (kg) = 2.747 BV - 0.710 TBW 
+ 1.460 TBMC - 2.050 W t, where BV is body volume in  litres (from UWW), TBW is total body 
w ater volume in  litres (from D2O dilution), TBMC is total bone m ineral content in  kilograms 
(from DXA) and W t is body w eight in  kilograms (2).
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Table 3. Percent body fat (%BF), fat-free mass (FFM), and total bone mineral density (TBMD) in adrenalectomized patients and 
controls.
Method No. of pairs Patients
(mean±SD)
Controls
(mean±SD)
P value
% BF
UW W  (%) 11 41.7 ±5.6 31.1 ± 7.5 <0.005
D2O dilution (%) 12 39.8 ± 4.6 28.8 ± 6.5 <0.005
DXA (%) 14 39.6 ± 4.2 31.7 ±7.4 <0.005
4C model (%) 11 42.4 ± 4.5 31.7 ±6.7 <0.005
BIS (%) 14 45.9 ± 3.6 39.1 ±4.1 <0.005
Skinfolds (%) 14 33.6 ±4.1 30.5 ± 3.9 <0.05
FFM
UW W  (kg) 11 37.5 ± 2.4 43.7 ± 3.5 <0.01
D2O dilution (kg) 12 39.1 ± 3.1 45.7 ± 2.8 <0.005
DXA (kg) 14 39.8 ± 3.4 44.5 ± 2.2 <0.005
4C model (kg) 11 37.1 ± 2.5 43.3 ± 2.8 <0.01
BIS (kg) 14 35.6 ±3.1 39.9 ± 3.6 <0.01
Skinfolds (kg) 14 43.7 ± 3.2 45.6 ± 4.3 NS
Hydration of FFM (L/kg) 11 0.77 ± 0.02 0.76 ±0.01 NS
TBMD DXA (g/cm2) 14 1.09 ±0.09 1.11 ± 0.06 NS
UWW, Underwater weighing; D2O-dilution, deuterium dilution method; DXA, dual-energy x-ray absorptiometry; 4C model, four- 
component model; BIS, bioelectrical impedance spectrometry; skinfolds, skinfold measurements.
Table 4. Comparison of body composition techniques with the reference technique (4C model); regression analyses of the 
difference between respective methods and their mean.
R2 P Bias (average difference) Error (2 SD, 95 % CI) P
UW W NS -0.65 3.6 NS
D2O dilution NS .2-3. 2.4 <0.05
DXA NS -1.98 .85 NS
BIS 0.54 <0.0001
Skinfods 0.46 <0.0004
Given are the regression coefficient (R2) and P value.When there was no significant relation, bias (average difference between the 
methods) and error (2 SD or 95% CI) are presented. 4C model, Four-component model; UWW, underwater weighing; D2O-dilution, 
deuterium dilution method; DXA, dual-energy x-ray absorptiometry; BIS, bioelectrical impedance spectrometry; skinfolds, skinfold 
measurements. The statistically significant regression coefficients of BIS and skinfolds disclose a significant relation between the 
differences in percent body fat of the two methods compared to the 4C model and the size of the measurement.This relation is 
compatible with disagreement between methods.
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The density  of the FFM was calculated according to the formula: DFFM = (0.710 TBW + 
3.050 W t - 2.747 BV - 1.460 TBMC) /  (0.788 TBW +  2.276 W t - 2.050 BV - 1.621 TBMC); the 
abbreviations TBW, W t, BV, and TBMC are defined above (2).
The hydration  fraction of the FFM was calculated from the mass of TBW (from D2O dilu­
tion) and total body FFM, obtained from the 4C-model, according to the formula: hydration  
fraction = TBW /  (0.715 TBW + 3.070 W t - 2.765 BV - 1.469 TBMC); the abbreviations TBW, 
W t, BV, and TBMC are defined above (2).
D eterm ination o f  percent trunk fa t  (% T F )
We defined the fat mass of the tru n k  as the sc and the intraabdom inal fat mass of the tho ­
racic and abdom inal parts of the body. The %TF was estim ated as [fat mass of the tru n k  (g) /  
total fat mass (g)] x 100% , as m easured w ith  DXA as described above.
S ta tistica l analysis
W ilcoxon's signed rank  test was used to test significance of differences betw een adrena­
lectomized patients and m atched controls (P). Spearman rank  correlation coefficients were used 
to test relations betw een body fat com partm ents m easured by different m ethods (P*). Stepwise 
regression analysis was used to determ ine the relationships betw een factors supposed to be 
related to body fat d istribu tion . For assessing the agreement betw een different methods, the 
bias and lim its of agreement (error) betw een the different m ethods were calculated according to 
the m ethod described by Bland and A ltm an (14). All data are expressed as mean ± SD.
RESULTS
Percentage body fa t  and FFM
As show n in Table 3, the %BF in the patients was significantly h igher than  in  the controls, 
regardless of the m ethod used. Figure 1A shows th a t the %BF, as calculated by the 4C-model, 
was h igher in  the adrenalectom ized patients than  in  the ir control subjects. FFM in patients was 
significantly lower than  th a t in  controls w hen m easured w ith  the 4C-model, UWW, D2O dilu­
tion, DXA, or BIS. Skinfold m easurem ent failed to distinguish  the difference in  FFM betw een 
both  groups. In Fig. 1B the results of FFM, calculated by the 4C-model, are given for the ind i­
vidual patient-control pairs. The hydration  of the FFM in the patients (0.77 ± 0.02 L/kg, range, 
0.73 - 0.80) was no t different from  th a t in  controls (0.76 ± 0.01 L/kg, range, 0.74 - 0.78). There 
was no difference in  %BFDXA (39.3 ± 5.2%  and 39.7 ± 3.5% , respectively) or in  FFMDXA (40.8 
± 3 .1  and 38.2 ± 3.5 kg, respectively) betw een patients w ith  peak plasma GH levels after argi­
nine provocation of 10 mU/L or less and patients w ith  GH levels greater than  10 mU/L. Using 
a cut-off level for peak plasma GH of 15 mU/L after arginine provocation, there was also no 
difference in %BFDXA (38.9 ± 4.6% and 40.9 ± 3.8% , respectively) or in FFMDXA (40.9 ± 2.8 and
36.6 ± 3.0 kg, respectively) between the group w ith the lower and tha t w ith  the higher GH levels.
Regional fa t  distribution
M easured by DXA, %TF in the patients was significantly h igher than  in  the controls (39.3
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± 6.4% and 29.9 ± 7.8%, respectively; P<0.001). In all patient-control pairs, except one, %TF was 
higher in  the patient than  in the control subject (Fig. 1C). There was no statistically significant 
difference in  %TF (53.0 ± 4.8%  and 48.2 ± 7.0% , respectively) betw een patients w ith  a GH 
level of 10 mU/L or less and patients w ith  a GH level greater than  10 mU/L after arginine provo­
cation, or betw een patients w ith  a GH level of 15 mU/l or less and patients w ith  a GH level 
g rea ter th a n  15 m U/l (52.8 ± 4 .8%  and  46.0 ± 5 .7% , respectively). There was a 
statistically significant correlation betw een %TF and %BF in bo th  patients and controls 
(r=0.44; P*<0.02). However, in  a stepwise regression including the adrenalectom ized state and 
%BF as independen t variables, only the adrenalectom ized state (as a dum m y variable) appeared 
to be included (P<0.005), whereas %BF did not, stressing the difference betw een the adrena­
lectomized patients and the controls w ith  respect to body fat d istribu tion  [%TF /  %BF = 7.89 
x D + 0.1 x %BFdxa + 38.71; (D = dum m y variable for the adrenalectom ized state)].
Bone m ineral density
DXA measurement showed no difference in  total BMD between patients and healthy controls 
(Table 3 and Fig. 1D) and no statistically significant correlation between BMD and %BF or %TF.
Comparison o f  the d ifferent body composition m ethods
For com parison of the m ethods we pooled the data from patients and controls. To obtain 
inform ation about the agreement of two different methods, we plotted the difference between 
two m ethods against the ir mean (14). The 4C-model served as the reference m ethod. The com­
parisons revealed no significant correlations betw een the differences in  %BF betw een the 
4C-model and the mechanistic m ethods (UWW, D2O dilution, or DXA), on the one hand, and 
the size of the m easurem ent, on the other hand, whereas those from  the descriptive m ethods 
(BIS or skinfolds) were significantly negatively related to the average %BF (Fig. 2 A-E, and 
Table 4). The bias of the 4C-model w ith  the m ethods UW W  and DXA, estim ated by the average 
difference betw een methods, was not significantly different from  zero. The SD of the differences 
betw een the 4C-model and DXA, however, was relatively high. The bias of the 4C-model w ith  
D2O dilu tion  was greater (-3.2%), b u t the error betw een bo th  m ethods was relatively small 
(2SD, 2.4%). In the patien t group only, the bias of the 4C-model w ith  skinfold measurem ents 
was -9.9%  and the error betw een bo th  m ethods 6.6% , whereas the bias of the 4C-model w ith  
BIS was no t significant.
D ISCU SS IO N
In a group of 14 women adrenalectomized for Cushing's disease, conventionally substituted 
w ith  gluco- and m ineralocorticoids during  periods up to 27 yr, body com position differed 
impressively from th a t in  control women m atched for age, body mass index and menopausal 
state. The %BF m easured by the 4C-model as well as by five other m ethods was significantly 
h igher in  the former Cushing's patients. Correspondingly, FFM, an indicator of muscle mass, 
was significantly lower (approximately 10%) in  the adrenalectom ized patients. In  the patients 
body fat d istribu tion  was also significantly different from th a t in  controls, w ith  higher
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trunk fat %  (controls) , >TBMD g/cm2 (controls)
Figure 1. Percentages body fat (%BF; 1A) and FFM (FFM, 1B), calculated by the 4-component model of Füller, in 11 female 
adrenalectomized patients versus %BF and FFM in their individual controls matched for age, sex, BMI and menopausal state. 
Percentages trunk fat (%TF, 1C), defined as fat mass of the trunk (g) / total fat mass (g) measured by DXA, in 14 female adrena­
lectomized patients versus %TF in their individual controls.Total bone mineral density (TBMD, 1D) in 14 female adrenalectomized 
patients versus TBMD in their individual controls.
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Mean % BF
Figure 2. Difference in percentages body fat (%BF) between two methods (alternatives A-E against the four-component model 
according to Füller) plotted against the means. Indicated is the mean difference (bias) and 2 SD (error).
A. Underwater weighing, B. Deuterium dilution method, C. Dual-energy x-ray absorptiometry, D. Skinfold measurements, E. 
Bioelectrical impedance spectrometry.
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percentages of truncal fat in  the adrenalectom ized patients.
To determ ine w hich body com position m ethods give reliable results in  this specific patient 
group, we com pared five different m ethods using the 4C-model of Füller (2) as the reference 
m ethod. For determ ination of %BF the differences betw een the 4C-model and the mechanistic 
m ethods (UWW, D2O dilution, and DXA) were no t large. Of these m ethods the average differ­
ence was h ighest betw een the D2O d ilu tion  m ethod and the 4C-model (-3.2%). The relatively 
low %BF found w ith  the D2O dilu tion  m ethod can be explained by the rather h igh hydration  
of FFM we found in  this study. On the other hand, results from  the descriptive m ethods, skin­
fold m easurem ent and BIS, deviated substantially  from  the results using the 4C- model. W ith 
respect to the skinfold m easurem ent, this deviation probably can be a ttribu ted  to the peculiar 
body fat d istribu tion  in  the patients. As patients have relatively more truncal body fat, skin­
fold measurements, of w hich only the iliac is in  the truncal region, underestim ated %BF in the 
patient group. Plotting of the difference in  %BF betw een the skinfold and the 4C-model against 
the ir means showed a significant correlation betw een bo th  the difference and the mean. This 
discloses a disagreem ent betw een the methods. The h igher the mean %BF, the larger the 
discrepancy betw een the two methods. Comparison betw een the results from  BIS and the 
4C-model also reveals a significant correlation betw een the difference in  %BF by bo th  BIS and 
the 4C-model, on one hand, and the mean %BF, on the other hand. In  our study total body 
water volumes were calculated from a general m ixture theory (10, 11), using specific resistivities 
of the w ater com partm ents, ra ther than  applying the common procedure in  bioim pedance 
analyses of an em pirically determ ined regression equation. The disagreem ent betw een the 
results from BIS and the 4C-model can be explained by these specific resistivities. It is, however, 
im portant to realize tha t these coefficients do no t affect the correlation betw een the methods. 
The relation betw een the error and the mean of the m easurem ents can be caused by differences 
in  body shape or fat d istribu tion , as w ith  the skinfold measurem ents. On the other hand 
specific resistivities of the w ater com partm ents may be different betw een patients and controls. 
From these data we conclude th a t UWW, DXA, and D2O dilu tion can be used for assessing the 
%BF in adrenalectom ized patients. The two more convenient bedside methods, BIS and skin­
fold measurem ents, did not give reliable results.
Several explanations may be offered for the increased %BF and truncal obesity in  the 
former Cushing's patients. H ypothyroidism  as the cause of the increased %BF is unlikely. 
A lthough four patients had secondary hypothyroidism  after p itu itary  surgery, they were 
adequately substitu ted  w ith  levothyroxine, having plasma free T4 levels in  the norm al range. 
In the other patients euthyroidism  was docum ented. Furtherm ore, six patients were treated 
w ith  oral and one w ith  transderm al estrogens as contraceptive or replacement therapy, whereas 
in  the control group only two women used estrogens. It is unlikely, however, tha t the use of 
estrogens could be responsible for the centripetal obesity in  the patient group. In post­
menopausal women estrogen replacem ent therapy is no t associated w ith  w eight gain and 
central obesity (15, 16). In  fact, estrogen replacem ent reduces the increase of the waist to hip 
ratio after the m enopause (17). In prem enopausal women the use of m odern oral contraceptive 
agents, containing less than  50 ug estradiol, is also no t associated w ith  w eight gain (18, 19).
GH deficiency can cause increased body fat mass in  adults (20 - 22). As 10 of the 14 
patients had undergone p itu itary  surgery for Cushing's disease or Nelson's syndrom e, it is con­
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ceivable th a t some of them  were GH deficient. A t present, the biochemical criteria for the diag­
nosis of GH deficiency in  adulthood are no t firm ly established and are restricted  to individuals 
less than  50 y r  old (23, 24). For severe GH deficiency in  prem enopausal women, De Boer et al. 
(25) proposed to use a cut off level for plasma GH of less than  15 mU/L after provocation w ith  
arginine (0.5 g/kg BW). In  our study, only 4 of the 13 tested patients had an arginine-stimulated 
peak plasma GH level greater than  15 mU/L. It remains, however, uncertain  w hether the other 
patients are GH deficient, as 8 of them  were postm enopausal and older than  50 y r  of age. W ith 
aging a substantial decrease in  GH responsiveness is present (25), and there are no reliable 
criteria for GH deficiency in  this group. Furtherm ore, decreased spontaneous GH secretion and 
subnorm al GH responsiveness are characteristic findings in  obese subjects (25) as well as in 
subjects treated w ith  glucocorticoids, a t least in  h igh  doses (26, 27). However, w hen we used 
e ither a cut-off level of 15 mU/L or of 10 mU/L w ith  regard to the arginine-stim ulated peak 
plasma GH, there was no difference in  %BF and fat d istribu tion  betw een the groups w ith  the 
h igher and the lower GH responses. Therefore, although  it cannot be excluded th a t in  some 
patients GH deficiency may play a contribu tory  role, GH deficiency is unlikely to be the most 
im portant cause of the increased %BF and truncal obesity in  the adrenalectom ized patients.
In our opinion the truncal obesity in  the adrenalectom ized patients is most likely the result 
of glucocorticoid overreplacem ent. In patients w ith  Cushing's syndrom e, hypercortisolism  is 
associated w ith  an excess of visceral and sc abdom inal fat. It has been suggested th a t this is 
caused by the h igh  density  of glucocorticoid receptors in  this depot (28, 29). There is evidence 
th a t cortisol may exert its effect by raising lipoprotein lipase activity. In differentiated hum an 
adipocytes as well as in  hum an fat cells in vitro , glucocorticoids enhanced lipoprotein lipase 
activ ity  activity, and this effect was probably m ediated by glucocorticoid receptors (28). 
W ajchenberg et al. (30) studied body com position data determ ined by DXA and the abdom inal 
visceral fat com ponent determ ined by com puted tom ographic scanning, in  women w ith  
Cushing's disease and com pared these data w ith  those from obese women w ith  the same an thro­
pometric parameters. A lthough patients w ith  Cushing's disease had no increase in  total body 
fat, they had a h igher intraabdom inal fat area com pared to the obese subjects. The total lean 
tissue mass was slightly reduced in  the patients w ith  Cushing's disease com pared to th a t in  the 
obese subjects due to a significant decrease on the muscle of the legs and arms. Lönn et al. (31) 
reported  tha t p itu itary  surgery in  women w ith  Cushing's disease resulted in  a reduction  of the 
total body fat mass. Furtherm ore, a change of body fat d istribu tion  was dem onstrated by 
expressing regional fat mass depots as a percentage of the total body fat mass before and after 
treatm ent. A fter p itu itary  surgery, the visceral fat mass and sc fat mass of the tru n k  decreased, 
w hich was significantly different from the increase of the fat mass of the legs.
In the adrenalectom ized patients in  our study, the dosage of glucocorticoids, on the aver­
age, 27.3 mg hydrocortisone equivalents per day, although  conventionally considered as a near 
optim al am ount (32), still m ight be too h igh to resolve typical Cushing's symptoms, such as 
truncal obesity and muscle wasting. None of these 14 patients showed other clinical signs of 
overtreatm ent w ith  glucocorticoids. Unfortunately, we do no t have body com position data in 
un treated  Cushing's disease patients, nor have such data been reported  in  literature. Moreover, 
similar data in  patients successfully treated by p itu itary  adenomectom y are lacking.
O ther researchers also found argum ents for overreplacem ent w ith  glucocorticoids, in
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dosages similar to those used in  our study, in  patients w ith  prim ary or secondary adrenal 
insufficiency. Peacy et a l . (33) studied 32 patients on glucocorticoid therapy, 12 w ith  Addison's 
disease and 20 w ith  hypopituitarism . Aiming at peak serum  cortisol levels and 24-h u rinary  
free cortisol levels in  the norm al reference range and avoiding prolonged cortisol troughs, 88% 
of the patients required a reduction  of daily glucocorticoid dose and /o r a change in  glucocor­
ticoid regimen. The mean daily dose of hydrocortisone in  this group had to be reduced from
29.5 ± 1.2 to 20.8 ± 1 . 0  mg to achieve adequate serum  cortisol and urine free cortisol levels. 
H ow lett (34) surveyed case notes of 130 patients on glucocorticoid replacem ent therapy. 
Considering serum  cortisol and u rinary  free cortisol levels, he concluded th a t optim al replace­
m ent best m ight be achieved w ith  doses of 20 mg hydrocortisone in  3 d ivided doses. From these 
studies, unfortunately, no body com position data for the patients are available.
W hereas body composition in  the patients suggests overdosage of substituting glucocorti­
coids, bone density data did not differ betw een the substituted patients and the healthy controls. 
In  a recent study in  D utch Addisonians, using similar dosages of glucocorticoids as those used by 
our adrenalectomized women, BMD was significantly lower in  the male patients compared to the 
control subjects, whereas there was no difference in  BMD betw een female Addisonians and the 
controls (35). In  the men w ith  decreased BMD, the daily hydrocortisone dose per kg BW appeared 
significantly h igher than  in  men w ith  normal BMD. The researchers suggested th a t estrogen 
activity  in  the females might have prevented glucocorticoid-induced osteopenia. In the study by 
Peacey et al.  (33), BMD at the lum bar spine was significantly lower in  a group of 32 patients (13 
men and 19 women) receiving glucocorticoid replacement therapy than  in  age- and sex-matched 
controls. A weak, but significant, negative correlation was found between BMD and the daily 
dose of hydrocortisone, expressed as milligrams per kg. Moreover, patients w ith  higher serum 
cortisol and 24-h urinary  free cortisol levels had significantly lower osteocalcin levels. In  the 
patients whose glucocorticoid dose was reduced during the study, the osteocalcin concentration 
increased significantly, dem onstrating tha t even small changes in  cortisol replacement therapy 
may lead to a change in  bone formation. From their data it can be assumed tha t even mildly exces­
sive glucocorticoid replacement has adverse effects on bone formation and BMD, at least in  men. 
The risk of bone loss during long term  treatm ent w ith  standard replacement doses is another 
argument for adjustm ent of glucocorticoid therapy to the lowest acceptable dose.
In  conclusion, m easurem ents of body com position in  our adrenalectom ized patients 
receiving conventional glucocorticoid substitu tion  showed a m arkedly increased %BF w ith  a 
relatively h igh  am ount of truncal body fat and a decreased FFM, whereas BMD was normal. 
Comparison of body com position m easurem ent m ethods indicated th a t ra ther sophisticated 
methods, such as DXA, UWW, or D2O dilution, are necessary to reliably assess body composition 
in  these patients. More convenient bedside methods, such as BIS and skinfold measurements, 
d id not give reliable body com position data. A lthough we cannot exclude th a t GH deficiency 
m ight have played a role in  some patients, in  our opinion the centripetal obesity of the adrena- 
lectomized patients is most likely the result of glucocorticoid overreplacement.
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Before the era of transsphenoidal p itu itary  surgery total adrenalectom y has been w idely 
used to treat Cushing's disease (p itu itary-dependent bilateral adrenal hyperplasia). Nowadays 
total adrenalectom y is no longer the prim ary therapy of Cushing's disease. Nevertheless, in  the 
ligh t of the still lim ited results of p itu itary  surgery (cure rates varying from 60 to 90% ), and 
because the incidence of recurrences after prim ary successful p itu itary  surgery seems to 
increase w ith  a longer follow up, there rem ain many patients w ith  Cushing's disease who may 
benefit from bilateral adrenalectomy. In  this thesis the results of bilateral adrenalectom y as 
treatm ent for Cushing's disease were studied. Early postoperative m orbidity  and m ortality  after 
bilateral adrenalectomy in our hospital were described. The incidences of residual adrenocortical 
function  and of recurren t Cushing's disease after bilateral adrenalectom y were investigated. We 
studied the incidence of Nelson's syndrom e in  these patients and we determ ined w hich factors 
predict the developm ent of this syndrom e. Furtherm ore, the results of different treatm ent 
modalities in  patients w ith  Nelson's syndrom e were studied. Because of the clinical im pression 
th a t patients bilaterally adrenalectom ized for Cushing's disease have an abnorm al body compo­
sition, body com position was determ ined w ith  regard to body fat, body fat d istribution , fat-free 
mass and bone m ineral density, using different m easurem ent methods.
C h ap te r 1 contains a short in troduction  to the different forms of Cushing's syndrom e and 
reviews curren t knowledge of treatm ent modalities in  Cushing's disease. W hen, in  1912, 
H arvey Cushing first described a patien t w ith  the disease now  bearing his name, he was uncer­
tain  as to w hether the symptoms were attributable to pituitary, adrenal, pineal, or ovarian 
influences. In  1932, Cushing published a report on 12 patients w ith  similar symptoms. In this 
series, six of eight patients had p ituitary adenomas or an 'adenomatous-like' structure at autopsy. 
Cushing postulated th a t most patients w ith  features of chronic hypercortisolism  w ould have 
tum ors of the p itu itary  gland.
Nowadays, much more is know n about Cushing's syndrom e. Endogenous Cushing's syn­
drome is a clinical state resulting from prolonged, inappropriate endogenous secretion of corti­
sol and hence excess circulating free cortisol, characterized by loss of the norm al feedback 
mechanisms of the hypothalam o-pituitary-adrenal axis and the norm al circadian rhy thm  of 
cortisol secretion. The cause of Cushing's syndrom e may be excessive ACTH production  from 
the p itu itary  gland (Cushing's disease), ectopic ACTH secretion by a non-p itu itary  tum or (e.g., 
bronchial carcinoid tum or, small-cell lung cancer, m edullary thyroid carcinoma), or excessive 
secretion of cortisol by an adrenocortical adenom a or carcinoma. Alcohol abuse and depression 
may cause pseudo-Cushing's states, w hich may have a similar clinical presentation and clear 
evidence of hypercortisolism .
In the past the only effective treatm ent in  patients w ith  Cushing's disease was bilateral total 
adrenalectom y w ith  life-long suppletion of gluco- and m ineralocorticoids. Later on, in  the late 
seventies, new  treatm ent modalities were introduced, i.e., p itu itary  m icrosurgery and pitu itary  
irradiation. Drug therapy w ith  adrenal enzyme inhibitors, such as ketoconazole, m etyrapone, or 
am inoglutethim ide, given alone or in  com bination, are sometimes useful as adjunctive therapy.
Nowadays the treatm ent of choice for patients w ith  Cushing's disease is transsphenoidal 
m icroadenomectomy. This surgical technique has undergone a progressive evolution and the
SUMMARY
developm ent of surgical instrum entation  for endoscopic endonasal transsphenoidal p itu itary  
surgery has made th is operation cleaner, easier and faster . However, p itu itary  surgery is not 
successful in  all patients. Early clinical and biochemical remission of hypercortisolism  after sur­
gery occurs in  about 60-90% of patients, b u t recurrence of the disease may occur in  patients 
who were initially in  remission after surgery. Surgical m ortality  after transsphenoidal surgery 
for Cushing's disease is low (0-1.9%), while major m orbidity  has been reported  in  4.5%  of 
patients. P itu itary  insufficiency after transsphenoidal surgery seems to be determ ined by the 
ex ten t of surgery. Secondary hypogonadism  occurs in  3-48% , hypothyroidism  in 13-40% and 
persistent diabetes insipidus in  3-47% .
For patients w ith  Cushing's disease not cured by or relapsing after transsphenoidal sur­
gery, p itu itary  irradiation  nowadays is considered as the most appropriate second line treat­
m ent w ith  long-term  response rates varying from 46 to 67% . P itu itary  dysfunction  is the most 
common side effect of p itu itary  irradiation w ith  percentages of 50 to 57% for deficiency of 
grow th horm one, 7 to 33% for deficiency of gonadotropins, 12.5 to 14% for a deficiency of 
thyrotropin , and 3%  for a deficiency of corticotropin.
Currently, indications for bilateral adrenalectom y in patients w ith  Cushing's disease are (1) 
severe hypercortisolism , persisting after p itu itary  surgery, w hich is no t reversible w ith  adrenal 
enzyme inhibition , while requiring  prom pt reversal of symptoms, and (2) hypercortisolism , 
persisting despite p itu itary  surgery and radiotherapy, as alternative for long-term  treatm ent 
w ith  adrenal enzym e inhibitors. The consequences of total adrenalectom y are the need for life­
long replacem ent therapy w ith  gluco- and m ineralocorticoids, the risk of life-threatening acute 
adrenal insufficiency (Addisonian crisis) and the risk  of developm ent of Nelson's syndrome. 
Nowadays laparoscopic surgery is the preferred m ethod, since it showed excellent success rates, 
low perioperative m orbidity  and decreased hospital stay. However, persistence or recurrence of 
cortisol hypersecretion after bilateral adrenalectomy, due to adrenal rem nants or ectopic adre­
nal tissue, has been described.
In  C h ap te r 2 we described surgical techniques and early postoperative m orbidity  and 
m ortality  in  64 patients, bilaterally adrenalectom ized for Cushing's disease in  our hospital 
betw een 1962 and January  1st, 2002. In two patients adrenalectom y was perform ed by an ante­
rior transabdominal approach. Fifty-eight patients underw ent bilateral adrenalectomy by a lateral 
lum bar (retroperitoneal) approach via lumbotomy. In  five patients bilateral adrenalectom y was 
perform ed by a laparoscopic procedure via the transperitoneal lateral approach. In one of them  
the laparoscopic procedure had to be converted to open adrenalectom y by lum bar approach 
because of inadequate exposure of the adrenal gland.
The most common com plications after open adrenalectom y by the lateral lum bar 
approach, were pleura damage because of peroperative opening of the pleura (19%), throm ­
boembolic com plications (10%), and serious w ound infection and/or delayed w ound healing 
(28%). One of the 64 patients (1.6%) died due to massive pulm onary embolism, 9 days after 
bilateral adrenalectom y by lum bar approach. Of the 4 patients treated for Cushing's disease by 
laparoscopic bilateral adrenalectomy, none developed any perioperative m orbidity  or mortality.
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In C h ap te r 3 the incidence of residual, functioning adrenal tissue was investigated in  37 
patients, treated by total bilateral adrenalectom y for Cushing's disease in  our hospital (follow- 
up period, m edian and range, 8.3 and 0.1 - 18.9 years). Evidence of functioning cortisol pro­
ducing tissue (plasma cortisol level >50 nmol/L after stopping glucocorticoid and m ineralocor­
ticoid substitu tion  therapy for 24 hours) was found in  9 patients (24%). Plasma cortisol levels 
in  these 9 patients varied betw een 60 and 330 nmol/L (mean ± SD, 180 ± 100 nmol/L). Only in 
one patient signs and symptoms of recurren t Cushing's syndrom e were present. There was no 
difference in  plasma ACTH levels and duration  of follow up betw een the patients w ith  and 
w ithou t evidence of functioning cortisol producing tissue. In  all 9 patients detectable aldos­
terone levels indicated endogenous m ineralocorticoid production, whereas in  only one patient 
adrenaline was detectable in  the circulation. In  8 of the 9 patients suspected of functioning 
cortisol producing tissue we perform ed a stim ulation test w ith  synthetic ACTH (1-24). In 2 
patients plasma cortisol levels rose, in  6 they rem ained virtually  unchanged.
A lthough we found clinically relevant signs and sym ptom s of Cushing's syndrom e in only 
one patient, the relatively h igh  incidence of residual, functioning adrenal tissue after “to ta l” 
adrenalectom y for p itu itary -dependen t Cushing's syndrom e necessitates continuous surveil­
lance for recurren t Cushing's syndrom e. To avoid long-term  effects, substitu tion  therapy should 
be prescribed individually. There is no place for routine adm inistration of full replacem ent 
doses of glucocorticoids after total adrenalectomy.
A ddendum  to chapter 3. In  January  2002, ten  years after publication of the study described 
in  chapter 3, we review ed the medical records of the 9 patients w ith  residual functioning 
adrenocortical tissue. The patient w ith  recurren t Cushing's disease (patient 9) had died sud­
denly in  1993. He was know n w ith  hypertrophic obstructive cardiom yopathy for more than  10 
years.
Of the other 8 patients w ith  residual functioning adrenocortical tissue, one had died in 
1992 by unknow n cause (patient 5), and one was lost to follow-up (patient 4). In one patient 
(patient 2) glucocorticoid- and m ineralocorticoid suppletion had been stopped because of ade­
quately functioning adrenocortical tissue. She had repeatedly normal plasma cortisol responses 
after adm inistration of 0.25 mg of synthetic ACTH (1-24). Up till now she did not develop a 
recurren t Cushing's syndrom e. Five patients are treated  w ith  glucocorticoid- and m ineralocor­
ticoid suppletion up till now, and did not develop any signs or sym ptom s of recurren t Cushing's 
syndrome.
In C h ap te r 4 the developm ent of Nelson's syndrom e after bilateral adrenalectom y was 
investigated. We defined Nelson's syndrom e as the radiological evidence of a p itu itary  
m acroadenoma and fasting plasma ACTH levels of more than  200 pm ol/l after stopping gluco­
corticoid substitu tion  for at least 24 hours in  a patient bilaterally adrenalectom ized for 
Cushing's disease.
SUMMARY
C h ap te r 4.1 reviews the literature on Nelson's syndrom e. Nelson's tum ors differ from 
those before adrenalectom y by the ir sometimes aggressive grow th potential, whereas their 
ACTH secretion is much less suppressible by adm inistration of glucocorticoids than  in  the stage 
of Cushing's disease. In addition, at the level of the tum or cell Nelson's syndrom e differs to some 
degree from Cushing's disease. Recent research at the molecular level underscores the in trigu ­
ing possibility tha t somatic m utations in  the glucocorticoid receptor gene m ight contribute to 
its pathogenesis. The incidence of Nelson's syndrom e after adrenalectom y in various reports 
still remains a m atter of dispute, in  part explained by lack in  uniform ity of definition of the 
syndrom e. Because Nelson tum ors grow often locally invasive, neurosurgery, either trans- or 
suprasphenoidally, is the treatm ent of first choice. Postoperative radiotherapy is indicated in 
patients w ith  residual tum or and /o r extrasellar extension. Recent reports claim benefit from 
long-acting som atostatin analogues, although long-term  success remains to be awaited. 
N otw ithstanding im proved treatm ent results in  the last decade, Nelson's syndrom e shares w ith  
Cushing's disease the inevitable tendency to recur over the long term . Therefore life-long 
surveillance of these patients is essential for optim um  management.
In  C h ap te r 4.2 we investigated w hich factors may predict the developm ent of Nelson's 
syndrom e. Eight of 48 patients, bilaterally adrenalectom ized for p itu itary -dependen t Cushing's 
syndrom e 1 to 30 years earlier, developed Nelson's syndrom e 1.5 to 13 years (6.6 ± 4.3 years) 
after adrenalectomy. The mean age at adrenalectom y in the group of patients who developed 
Nelson's syndrom e was significantly lower than  th a t in  the group w ithou t the syndrom e (mean 
± SD, 26.0 ± 6.0 and 35.6 ± 11.7 years respectively, p<0.02). In the patients adrenalectom ized 
before the age of 35 years, 8 of 27 (30%) developed Nelson's syndrom e, whereas in  the patients 
older than  35 years no one did (p<0.02). No statistically significant differences betw een the two 
groups were found in  sex ratio, duration  of disease before adrenalectom y and duration  of 
follow-up thereafter. There were no statistically significant differences betw een bo th  groups in 
mean plasma cortisol and ACTH levels before adrenalectomy, cortisol suppressibility  after 8 and 
16 mg dexam ethasone or the cortisol responses to CRH, TRH and GnRH before adrenalectomy. 
We concluded th a t age at the time of adrenalectom y is an im portant predictive factor for devel­
opm ent of Nelson's syndrom e.
A ddendum  to chapter 4.2. January  1st, 2002, the incidence of Nelson's syndrom e has 
increased to 19 of 65 former Cushing patients (29%). The mean age at adrenalectom y in the 
group of patients who developed Nelson's syndrom e is still significantly lower than  in  the group 
w ithou t the syndrom e (mean ± SD, 30.6 ± 8.8 and 37.2 ± 12.2 years respectively, p<0.05). In 
the patients adrenalectom ized before the age of 35 years, 15 of 32 (47%) developed Nelson's 
syndrom e, whereas in  the patients older than  35 years 4 of 33 (12%) did so (p<0.02).
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In C h ap te r 4.3 the results of different treatm ent modalities for Nelson's syndrom e were 
analyzed. Therefore the medical reports of all Nelson's patients know n in our hospital at that 
time (15 women) were studied w ith  regard to treatm ent modalities and result of treatm ent. 
Clinical remission of Nelson's syndrom e was defined as a reduction  of tum or size to a diam eter 
of 10 mm or less and fasting plasma ACTH levels less than  200 pm ol/l after stopping glucocor­
ticoid substitu tion  for at least 24 hours.
E ight patients were initially followed w ithou t surgical or radiotherapeutical in tervention 
during  1 to 7 years. In  seven of them  plasma ACTH levels and tum or volumes increased 
progressively during  this rather short observation period, w ith  developm ent of extrasellar 
extension in  four patients. In one of these patients, who was planned for elective p itu itary  sur­
gery, massive pituitary hemorrhage occurred w hich was fatal despite emergency pituitary surgery.
Elective p itu itary  surgery was perform ed in  eleven patients, of w hom  three were operated 
tw ice. Clinical remission was docum ented in  five patients in  the first year after operation. In 
one patient postoperative MR-imaging revealed no residual tum or mass b u t the postoperative 
plasma ACTH level was still elevated. In  another patien t a residual intrasellar macroadenoma 
and an increased plasma ACTH level rem ained stable for 22 years. The rem aining four patients 
received postoperative radiotherapy because of residual tum or masses. Of these patients in  one 
a clinical remission was achieved. In two others relatively small residual intrasellar tum or masses 
remain, w ith  a fasting plasma ACTH level of more than  200 pm ol/l in  one of them . The fourth  
patient died of the consequences of progressive tum or growth.
In two patients radiotherapy as the only treatm ent for Nelson's syndrom e did not result in 
clinical remission.
We conclude tha t p itu itary  surgery of Nelson's macroadenomas is more successful w hen 
Nelson's adenomas are relatively small. P itu itary  surgery should be perform ed before extrasel­
lar expansion of the tum or occurs in  order to attain  long lasting remissions. P itu itary  irradia­
tion  should be perform ed postoperatively in  all patients w ith  residual tum or. Our data also 
illustrated  th a t in  patients w ith  Nelson's syndrom e plasma ACTH levels can reliably be used as 
an indirect approxim ation for tum or volume.
P itu itary  carcinomas are distinguished from invasive adenomas by the presence of cran­
iospinal and /or systemic metastases. P itu itary  carcinoma in the context of Nelson's syndrom e is 
very rare. C h ap te r 4.4 is a case report dealing w ith  a patient, who developed Nelson's syn­
drome one and a half after successful bilateral adrenalectom y for Cushing's disease. Despite 
p itu itary  surgery and radiotherapy the tum or showed invasive grow th, leading to visual dis­
turbance, paresis of the oculom otor nerve and, 34 years after adrenalectomy, to death by w ide­
spread pu ru len t leptom eningitis. A utopsy revealed a large adenohypophyseal carcinoma w ith  a 
metastasis attached to the dura, bo th  tum ors showing imm unocytochem ical staining for ACTH.
It was our clinical im pression th a t patients bilaterally adrenalectom ized for Cushing's dis­
ease have an abnorm al body com position. Body com position, however, has never been studied 
w ith  objective m ethods in  this group of patients. In C h ap te r 5 the body com position (body fat,
SUMMARY
body fat d istribution , fat-free mass, and bone m ineral density) was studied in  14 women, aged 
47.2 ± 10.5 years, bilaterally adrenalectom ized for Cushing's disease 13.6 ± 7.7 years before. All 
patients were on conventional doses of glucocorticoid and m ineralocorticoid substitu tion . The 
data were com pared w ith  those of 14 healthy women of similar age, body mass index and 
menopausal state. To determ ine w hich body com position m ethods give reliable results in  this 
specific patient group, we com pared five different methods, i.e. body densitom etry by un d er­
w ater w eighing (UWW), total body w ater m easurem ent by deuterium  d ilu tion  (D2 O dilution), 
dual-energy x-ray absorptiom etry (DXA), bioelectrical im pedance spectrom etry (BIS), and skin­
fold measurem ents, using a four-com ponent model (4C-model) as the reference method.
In the patients the percent body fat was significantly higher than  that in the controls as deter­
mined by all methods, whereas fat-free mass was significantly lower, when measured w ith  the 
4C-model, UWW, D2O dilution, DXA or BIS. M easured by DXA, percentage tru n k  fat - estimated 
as [fat mass of the tru n k  (g): total fat mass (g)] x 100% - was significantly h igher in  the patients 
than  in  the controls (39.3 ± 6.4%  and 29.9 ± 7.8% , respectively; P<0.001). M easured by DXA, 
there was no difference in  total bone m ineral density  betw een bo th  groups. Differences 
betw een the 4C-model, UWW, D2O dilu tion  and DXA for determ ination of %BF were rather 
small. Skinfold m easurem ents and BIS, however, deviated substantially  from the 4C-model, 
probably because of the peculiar body fat d istribu tion  of the patients.
The study indicated th a t adrenalectom ized patients on conventional glucocorticoid 
substitu tion  have increased body fat percentages w ith  a centripetal fat d istribu tion  and lowered 
fat-free mass, b u t norm al bone m ineral density. Furtherm ore, the study indicated tha t for 
clinical practice, DXA, D2O dilution, UWW, and the 4C-model can be used for determ ination of 
body com position in  th is patien t group, whereas the more convenient bedside methods, BIS and 
skinfold measurements, did not give reliable results. We supposed tha t glucocorticoid overre­
placement in  adrenalectom ized patients m ight be the cause of the ir abnormal body composition, 
although grow th horm one deficiency after p itu itary  surgery could have played a contribu tory  
role in  some of the patients.
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Voordat transsfenoïdale hypofyse m icrochirurgie mogelijk werd, was verw ijdering van de 
beide b ijnieren (bilaterale adrenalectomie) de eerste keus behandeling voor patiënten  met de 
ziekte van Cushing (hypofyse-afhankelijke bilaterale bijnierhyperplasie). Hoewel bilaterale 
adrenalectomie tegenwoordig niet meer de behandeling van eerste keus is voor deze groep, blijven 
er ook nu  nog patiënten  aangewezen op deze ingreep als behandeling voor de ziekte van 
Cushing, enerzijds om dat de behandelingsresultaten van hypofyse chirurgie beperk t zijn (gene- 
zingspercentages variëren van 60 to t 90%), en anderzijds om dat de incidentie van een recidief 
na eerdere geslaagde hypofyse chirurgie lijk t toe te nem en met de d u u r van de follow-up. Voor 
d it proefschrift w erden de resultaten  van bilaterale adrenalectom ie als behandeling voor de 
ziekte van Cushing bestudeerd. We beschreven de vroege postoperatieve m orbiditeit en mor­
talite it na bilaterale adrenalectom ie in  ons ziekenhuis. De incidentie van persisterende bijnier- 
horm oonproductie en van recidieven van de ziekte van Cushing na bilaterale adrenalectom ie 
w erden onderzocht. We bestudeerden de incidentie van het syndroom  van Nelson in  deze pati­
ëntengroep en onderzochten welke factoren de ontw ikkeling van d it syndroom  konden voor­
spellen. Voorts w erden de resultaten  van verschillende behandelingsvorm en bij patiënten  met 
het syndroom  van Nelson onderzocht. In verband m et he t feit dat patiënten  met de ziekte van 
Cushing, na geslaagde bilaterale adrenalectom ie, vaak een abnormale lichaam sbouw houden, 
w erd een onderzoek gedaan naar de lichaamssamenstelling in  deze patiën ten  groep. Daarvoor 
w erden m etingen van de lichaamssamenstelling verricht, m et name van de vetmassa, de 
vetverdeling, de vetvrije massa en de botm ineraaldichtheid, waarbij gebru ik  gem aakt w erd van 
verschillende m eetm ethoden.
H oofstuk  1 behelst een korte introductie van de verschillende vorm en van het Cushing 
syndroom en geeft een overzicht van de huidige stand van zaken betreffende de behandelings­
mogelijkheden van de ziekte van Cushing. Toen Harvey Cushing in  1912 voor het eerst een 
patiënt beschreef met het syndroom  dat nu zijn naam draagt, tw ijfelde hij of de sym ptom en 
w erden veroorzaakt door hypofysaire, adrenale, pineale of ovariële factoren. In  1932 publi­
ceerde Cushing een rapport betreffende 12 patiënten  met dezelfde sym ptom en. Bij 6 van de 8 
patiënten  bij wie obductie w erd verricht, vond hij adenom en of adenom ateuze structu ren  in  de 
hypofyse. Cushing veronderstelde dat bij de meeste patiën ten  met verschijnselen van chronisch 
hypercortisolism e een hypofysetum or aanwezig m oest zijn.
Tegenwoordig is er veel meer bekend over het syndroom  van Cushing. H et endogene 
Cushing syndroom  is het klinische gevolg van langdurige, overmatige secretie van cortisol, met 
een overmaat aan circulerend vrij cortisol als resultaat. Het verlies van de norm ale terugkop- 
pelingsm echanism en van de hypothalam us-hypofyse-bijnier as en van het normale circadiane 
ritm e van de cortisol secretie is karak teristiek  voor deze aandoening. Mogelijk oorzaken van het 
Cushing syndroom  zijn een overmatige ACTH productie door de hypofyse (ziekte van Cushing), 
ectopische ACTH secretie door een tum or gelegen bu iten  de hypofyse (zoals bijvoorbeeld bron- 
chiaal carcinoid, kleincellig bronchuscarcinoom , m edullair schildkliercarcinoom), of overmatige 
secretie van cortisol door een adenoom  of carcinoom van de bijnierschors. Alcohol abusus en 
depressie kunnen  een zogenaamd pseudo-Cushing syndroom  veroorzaken, met vergelijkbare 
klinische presentatie en een ev iden t hypercortisolism e.
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In  het verleden was bilaterale adrenalectom ie de enige effectieve behandeling voor pati­
ënten  met de ziekte van Cushing, m et als gevolg de noodzaak to t levenslange suppletie met 
gluco- en mineralocorticoiden. In  de zeventiger jaren w erden nieuwe behandelingsmogelijkheden 
geïntroduceerd, zoals hypofyse m icrochirurgie en hypofyse bestraling. M edicamenteuze thera­
pie m et bijnierenzym rem m ers, zoals ketoconazol, m etyrapon of am inoglutethim ide, als m ono­
therapie of in  com binatie, zijn soms zinvol als adjuvante therapie.
Tegenwoordig is transsfenoïdale m icrochirurgie van de hypofyse de behandeling van 
voorkeur. Deze chirurgische techniek  is in  de loop der tijd  sterk verbeterd en de ontw ikkeling 
van chirurgisch instrum entarium  voor endoscopische endonasale transsfenoïdale hypofyse 
chirurgie m aakte de ingreep schoner, gem akkelijker en sneller. Toch is deze behandeling niet 
in  alle gevallen succesvol. Na hypofyse chirurgie w ord t in  60 to t 90%  van de gevallen vroege 
klinische en biochemische remissie van hypercortisolism e bereikt, maar na aanvankelijk 
geslaagde chirurgie kunnen  recidieven van de aandoening optreden. De m ortaliteit na transs- 
fenoïdale chirurgie voor de ziekte van Cushing is laag (0-1,9%), terw ijl belangrijke m orbiditeit 
bij 4,5%  van de patiënten wordt beschreven. Hypofyse insufficiëntie na transsfenoïdale chirurgie 
lijk t te zijn gerelateerd aan de omvang van de operatie. Secundair hypogonadism e treed t op in 
3-48%, hypothyreoidie in  13-40% en perm anente diabetes insipidus in 3-47% van de patiënten.
W anneer de ziekte van Cushing niet geneest of recidiveert na transsfenoïdale chirurgie, 
w ord t radiotherapie van de hypofyse in  het algemeen als tw eede lijns behandeling toegepast 
met een genezingsresultaat op lange term ijn van 46 to t 67% . H ypofyse disfunctie is het meest 
voorkomende neveneffect van hypofysebestraling met percentages van 50 to t 57%  voor groei­
horm oon deficiëntie, 7 to t 33%  voor hypogonadotroop hypogonadisme, 12,5 to t 14% voor 
secundaire hypothyreoidie en 3%  voor deficiëntie van corticotroop horm oon.
De huidige indicaties voor bilaterale adrenalectom ie bij patiënten  met de ziekte van 
Cushing zijn (1) een ernstig  hypercortisolism e, persisterend na hypofysechirurgie en n ie t rever­
sibel onder bijnierenzym  remmers, terw ijl snelle verbetering van de sym ptom en gew enst is, en
(2) persisterend hypercortisolism e ondanks hypofyse chirurgie en radiotherapie, als alternatief 
voor langdurige behandeling met bijnierenzym  remmers.
De gevolgen van bilaterale adrenalectom ie zijn de noodzaak to t levenslange suppletie 
therapie met gluco- en m ineralocorticoiden, he t risico van levensbedreigende acute bijnierin- 
sufficiëntie (Addisonse crise) en het risico van de ontw ikkeling van het syndroom  van Nelson.
Tegenwoordig w orden adrenalectomieën bij voorkeur laparoscopisch verricht, omdat hiermee 
uitstekende resultaten w orden bereikt, met een lage perioperatieve morbiditeit en verkorting van 
de opnam eduur. Desalniettemin is persisterende dan wel recidiverende cortisol overproductie 
beschreven bij patiën ten  met een status na bilaterale adrenalectom ie, veroorzaakt door bijnier- 
resten of ectopisch bijnierweefsel.
In  H o o fd s tu k  2 beschreven wij de chirurgische technieken toegepast bij bilaterale 
adrenalectom ie en de vroege postoperatieve m orbiditeit en m ortaliteit bij 64 patiënten  met de 
ziekte van Cushing, die deze ingreep in  ons ziekenhuis ondergingen tussen 1962 en januari 
2002. Bij twee patiënten  w erd de adrenalectom ie verrich t via de anterieure transabdom inale 
route. A chtenvijftig patiënten  ondergingen bilaterale adrenalectom ie via de laterale lumbale
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(retroperitoneale) route middels lumbotomie. Bij de v ijf laatste patiënten werd een laparoscopische 
bilaterale adrenalectom ie verricht via de transperitoneale laterale route. Bij een van hen  moest 
de ingreep geconverteerd w orden to t een open adrenalectom ie via de lum bale route in  verband 
met onvoldoende overzicht over de bijnierregio.
De meest voorkomende complicaties na open adrenalectom ie via de laterale lumbale route 
w aren p leura laesies door peroperatieve beschadiging van de pleura (19%), throm boëm bolische 
complicaties (10%), en ernstige w ondinfecties en/of vertraagde w ondgenezing (28%). Een van 
de 64 patiënten  (1,6%) overleed aan de gevolgen van massale longembolieën, 9 dagen na bila­
terale adrenalectom ie via de lum bale route. Van de 4 patiënten, bij wie in  de studie periode een 
succesvolle laparoscopische bilaterale adrenalectom ie w erd verricht, ontw ikkelde niem and 
postoperatieve m orbiditeit of m ortaliteit.
In H o o fd s tu k  3 werd het onderzoek beschreven naar de incidentie van resterend functi­
onerend bijnierweefsel bij 37 patiënten die tevoren een totale adrenalectom ie hadden onder­
gaan in  ons ziekenhuis wegens de ziekte van Cushing (follow-up mediaan 8,3 jaar met een sprei­
ding van 0,1-18,9 jaar). Bij 9 patiënten  (24%) bestonden aanw ijzingen voor functioneel 
bijnierschors weefsel (plasma cortisol >50 nm o/l na het stoppen van glucocorticoid en m inera­
locorticoid substitu tie gedurende 24 uur). De plasma cortisol spiegels bij deze 9 patiënten  vari­
eerden van 60 to t 330 nm ol/l (gemiddelde ± SD, 180 ± 100 nmol/l). Slechts bij een patiënt waren 
klinische kenm erken van een recidief van de ziekte van Cushing aanwezig. Er w aren geen 
verschillen tussen de plasma ACTH spiegels of de duu r van de follow-up tussen patiënten met en 
zonder aanwijzingen voor de aanwezigheid van functionerend bijnierweefsel. Bij alle 9 patiënten 
was aldosteron in  de circulatie aantoonbaar, du idend  op endogene m ineralocorticoid productie. 
Bij slechts een patiënt kon aldosteron aangetoond w orden in  de circulatie. Bij 8 van de 9 pati­
ën ten  m et aantoonbare cortisol spiegels w erd een stim ulatietest met synthetisch  ACTH (1-24) 
verricht. Bij 2 van hen  steeg daarop de cortisol spiegel, bij 6 bleef deze nagenoeg onveranderd.
Alhoewel wij slechts bij een patiënt klinisch relevante kenm erken van een recidief van de 
ziekte van Cushing vonden, m aakte de relatief hoge incidentie van resterend functioneel 
bijnierweefsel, na 'totale ' adrenalectomie wegens de ziekte van Cushing, duidelijk dat conse­
quente controles noodzakelijk zijn ten  einde een recidief Cushing syndroom  tijdig op te  sporen. 
Ter voorkoming van overdosering, moet substitutie therapie altijd individueel gedoseerd worden. 
Er is geen plaats voor routinem atig voorschrijven van standaard doseringen glucocorticoiden 
na bilaterale adrenalectom ie.
A ddendum  bij H oo fdstuk  3. In januari 2002, 10 jaren  na publicatie van de studie zoals 
beschreven in  hoofdstuk 3, w erden de medische dossiers van de 9 patiënten  m et resterend 
functioneel bijnierschorsweefsel nog eens onderzocht. De enige patiënt met een recidief van de 
ziekte van Cushing (patiënt 9) bleek in  1993 plotseling te zijn overleden. Hij was reeds 10 jaar 
bekend met een hypertrofische obstructieve cardiomyopathie.
Van de andere 8 patiënten met resterend functioneel bijnierschorsweefsel was een overleden 
in  1992 door onbekende oorzaak (patiënt 5), en was een verdw enen u it controle (patiënt 4). Bij
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een patiën t (patiënt 2) was de glucocorticoid en de m ineralocorticoid substitu tie gestaakt in 
verband met adequaat functionerend bijnierschorsweefsel. Zij had bij herhaling een normale 
plasma cortisol respons na stimulatie met 0,25 mg synthetisch  ACTH (1-24). Tot nu  toe on tw ik­
kelde zij geen recidief Cushing syndroom . De 5 overige patiënten  w erden nog steeds behandeld 
met glucocorticoid en m ineralocorticoid substitu tie , en hadden geen van allen klinische 
kenm erken ontw ikkeld van een recidief Cushing syndroom .
In  H o o fd s tu k  4 w erd de ontw ikkeling van h e t syndroom  van Nelson na bilaterale 
adrenalectom ie onderzocht. Wij definieerden het syndroom  van Nelson als een radiologisch 
bewezen hypofysair macroadenoom met nuchtere plasma ACTH spiegels van meer dan 200 pmol/l 
na het stoppen van de glucocorticoid substitutie gedurende tenm inste 24 uur, bij patiënten die 
een bilaterale adrenalectom ie hadden ondergaan wegens de ziekte van Cushing.
In  H o o fd s tu k  4.1 w erd een overzicht gegeven van de litera tuur over het syndroom  van 
Nelson. De hypofyse tum oren bij d it ziektebeeld verschillen van die vóór adrenalectom ie door 
h u n  vaak agressieve groei, terw ijl h u n  ACTH secretie m inder suppressibel lijk t te zijn na toe­
diening van glucocorticoiden dan in  vergelijking met de situatie van voor adrenalectom ie. 
Daarnaast is er een verschil op celniveau tussen de tum orcellen bij he t syndroom  van Nelson 
en die bij de ziekte van Cushing. Recent onderzoek op moleculair niveau heeft aanw ijzingen 
opgeleverd voor het feit dat somatische mutaties van he t glucocorticoid receptor gen zouden 
kunnen  bijdragen aan de pathogenese van he t syndroom  van Nelson. De incidentie van het 
syndroom van Nelson na adrenalectomie blijft in  verschillende rapporten een punt van discussie, 
gedeeltelijk verklaard door verschillende definities van he t syndroom . Omdat Nelson tum oren 
vaak lokaal invasief groeien is neurochirurgie, transsfenoïdaal dan wel suprasfenoïdaal, de 
behandeling van eerste keus. Postoperatieve radiotherapie is geïndiceerd bij patiën ten  met 
resterend tum orweefsel en/of extrasellaire uitbreiding. In  de recente litera tuur w erd een 
gunstig  effect beschreven van langw erkende som atostatine analogen, alhoewel lange term ijn 
resultaten m oeten w orden afgewacht. O ndanks de verbeterde behandelingsresultaten in  het 
laatste decennium, delen het syndroom van Nelson en de ziekte van Cushing de onvermijdelijke 
tendens to t recidiveren op de lange term ijn. Daarom is levenslange controle van deze patiën­
tengroep noodzakelijk.
In  H o o fd s tu k  4.2 onderzochten wij welke factoren de ontw ikkeling van het syndroom  
van Nelson zouden kunnen  voorspellen. A cht van de 48 patiënten, die 1 to t 30 jaren  tevoren 
een bilaterale adrenalectom ie ondergingen wegens de ziekte van Cushing, ontw ikkelden het 
syndroom van Nelson 1,5 to t 13 (6,6 ± 4,3) jaar na adrenalectom ie. De gemiddelde leeftijd ten  
tijde van de adrenalectom ie van de groep patiënten die het syndroom  van Nelson ontw ikkelden 
was significant lager dan van de groep zonder Nelson (gemiddelde ± SD, 26,0 ± 6,0 en 35,6 ±
11,7 jaar resp.; p<0,02). Bij de patiënten  die een adrenalectom ie ondergingen voor de leeftijd 
van 35 jaar, ontw ikkelden 8 van de 27 (30%) het Nelson syndroom , terw ijl bij de patiënten  die
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ouder w aren dan 35 jaar ten  tijde van de adrenalectom ie, niem and d it syndroom  ontw ikkelde 
(p<0,02). Er w erden geen statistisch significante verschillen aangetoond tussen de beide groepen 
in  geslacht, d u u r van de ziekte van Cushing voor adrenalectom ie of d u u r van de follow-up 
daarna. Er w aren geen statistisch significante verschillen tussen  de beide groepen in  de 
gemiddelde plasma cortisol en ACTH spiegels voor adrenalectomie, de cortisol suppressibiliteit na 
8 en na 16 mg dexamethason of de cortisol respons na CRH, TRH of GnRH voor adrenalectomie. 
Wij concludeerden dat de leeftijd ten  tijde van adrenalectom ie een belangrijke voorspellende 
factor is voor de ontw ikkeling van het syndroom  van Nelson.
A ddendum  bij H oo fdstuk  4.2. Op 1 januari 2002 was de incidentie van h e t syndroom  van 
Nelson in  ons ziekenhuis opgelopen to t 19 van de 65 voormalige Cushing patiën ten  (29%). De 
gem iddelde leeftijd ten  tijde van adrenalectom ie was in  de groep patiënten  die he t syndroom  
van Nelson ontw ikkelden nog steeds lager dan in  de groep zonder Nelson (gemiddelde ± SD,
30,6 ± 8,8 en 37,2 ± 12,2 jaar resp.; p<0,05). Van de patiënten  die een adrenalectom ie onder­
gingen voor de leeftijd van 35 jaar ontw ikkelden 15 van de 32 (47%) het syndroom  van Nelson, 
terw ijl d it in  de groep ouder dan 35 jaar in  4 van de 33 (12%) gevallen voorkwam (p<0,02).
In H o o fd s tu k  4.3 w erden de resultaten van diverse behandelingsm ethoden voor het 
syndroom  van Nelson onderzocht. Daarvoor w erden de medische dossiers van alle op dat 
mom ent bekende en in  ons ziekenhuis behandelde Nelson patiën ten  (15 vrouwen) bestudeerd 
met betrekking to t de behandelingsm ethodes en de resultaten  van de behandeling. Klinische 
remissie van he t Nelson syndroom  w erd gedefinieerd als een reductie van de tum orgrootte to t 
een diam eter van 10 mm of m inder en nuchtere plasma ACTH spiegels van m inder dan 200 
pmol/l na het stoppen van de glucocorticoid suppletie gedurende tenm inste 24 uur.
A cht patiënten  w erden aanvankelijk expectatief vervolgd zonder chirurgische of radiothe­
rapeutische interventie gedurende 1 to t 7 jaar. Gedurende deze relatief korte observatie periode 
stegen de plasma ACTH spiegels bij 7 van hen  en nam  het tum or volume progressief toe met 
extrasellaire uitbreid ing bij 4 van hen. Bij een van deze patiënten, voor wie inmiddels electieve 
hypofyse chirurgie was gepland, ontstond een massale hypofyse bloeding welke haar, ondanks 
spoedoperatie, fataal werd.
Bij 11 patiënten  werd electieve hypofyse chirurgie uitgevoerd. Drie van hen w erden 
tweemaal geopereerd. Bij 5 van deze patiënten  w erd een klinische remissie bereik t in  het eer­
ste jaar na de operatie. Bij een patiënt toonde de postoperatieve MRI scan geen resterend tum or­
weefsel meer, maar bleef de postoperatieve ACTH spiegel verhoogd. Een andere patiën t behield 
een resterend intrasellair gelegen m acroadenoom en een verhoogde plasma ACTH spiegel, welke 
echter gedurende 22 jaren  stabiel bleven. De overige 4 patiënten  w erden na h u n  operatie 
behandeld met hypofysebestraling in  verband met resterend tumorweefsel. Bij een van deze 
patiënten werd een klinische remissie bereikt. Bij twee anderen resteerden relatief kleine intra- 
sellaire tum oren, met een nuchtere plasma ACTH spiegel van meer dan 200 pm ol/l bij een van 
hen. De vierde patiën t overleed aan de gevolgen van progressieve tum or groei.
Twee patiën ten  ondergingen radiotherapie van de hypofyse als enige behandeling voor
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het syndroom  van Nelson, zonder dat bij hen een klinische remissie w erd bereikt.
Wij concludeerden dat hypofyse chirurgie van adenom en bij het syndroom  van Nelson 
succesvoller is w anneer de adenom en relatief k lein zijn. Hypofyse chirurgie d ien t te w orden 
uitgevoerd voordat de tum or zich extrasellair heeft uitgebreid om lang durende remissies te 
kunnen  bereiken. Bij alle patiën ten  met resterend tum orweefsel is postoperatieve radiotherapie 
van de hypofyse geïndiceerd. Onze gegevens illustreren  verder dat de ACTH spiegels van pati­
ënten  met he t syndroom  van Nelson betrouw baar te gebruiken zijn voor indirecte schatting 
van h e t tum or volume.
Hypofyse carcinomen onderscheiden zich van invasieve adenom en door de vorm ing van 
craniospinale en /of system ische metastasen. H ypofyse carcinomen in  h e t kader van het syn­
droom van Nelson zijn zeer zeldzaam. H o o fd s tu k  4.4 is een case report betreffende een 
patiënte die het syndroom  van Nelson ontw ikkelde, anderhalf jaar na geslaagde bilaterale 
adrenalectom ie wegens de ziekte van Cushing. Ondanks hypofyse chirurgie en radiotherapie 
toonde de tum or invasieve groei, leidend to t visus stoornissen, parese van de nervus oculomo- 
torius en, 34 jaar na adrenalectom ie, to t overlijden ten  gevolge van een uitgebreide puru len te 
leptom eningitis. Autopsie toonde een groot carcinoom van de adenohypofyse met een metastase 
in  de dura. Beide tum or lokalisaties w aren positief voor ACTH.
In  onze groep bestond de klinische impressie dat patiënten, die een bilaterale adrenalec- 
tomie hadden ondergaan wegens de ziekte van Cushing, na de operatie een abnormale lichaams­
bouw  behielden. M etingen van de lichaamssamenstelling met objectieve m ethoden w aren in 
deze groep patiënten echter nooit verricht. In H oofdstuk  5 werd de lichaamssamenstelling 
(lichaamsvet, vetverdeling, vetvrije massa en bot mineraal dichtheid) bestudeerd van 14 vrouwen, 
in  de leeftijd van 47,2 ± 10,5 jaar, die 13,6 ± 7,7 jaar eerder een bilaterale adrenalectom ie had­
den ondergaan wegens de ziekte van Cushing. Alle patiënten  gebru ik ten  conventionele dose­
ringen glucocorticoid en m ineralocorticoid suppletie. H un gegevens w erden vergeleken m et die 
van 14 gezonde vrouw en van gelijke leeftijd, body mass index en menopauzale status. Om te 
beoordelen welke meetm ethodes voor de lichaamssamenstelling betrouw bare resultaten gaven 
in  deze specifieke patiëntengroep, vergeleken wij 5 verschillende methodes, te w eten lichaams 
densitom etrie door middel van onderw aterw eging (UWW), totale lichaam swater m eting door 
middel van de deuterium  verdunningsm ethode (D2O-dilutie), dual-energy x-ray absorptiom e­
try  (DXA), bioelectrische im pedantie spectrom etrie (BIS) en huidplooi m etingen, waarbij het 
zgn. V ier-com ponenten model (4C-model) als referentie m ethode w erd gebruikt.
Bij de patiënten was het percentage lichaamsvet, berekend met alle vijf methoden, significant 
hoger dan bij de controle personen, terw ijl de vetvrije massa, gem eten volgens het 
4C-model, de UWW, de D2O-dilutie, de DXA en de BIS, significant lager was bij de patiënten. 
Gemeten middels DXA, was het vetpercentage van de romp - berekend als [vetmassa van de 
rom p (g): totale vetmassa (g)] x 100% - significant hoger bij de patiënten  dan bij de controles 
(respectievelijk 39.3 ± 6,4%  en 29,9 ± 7,8% ; p<0,001). Gemeten middels DXA was er geen ver­
schil in  totale botm ineraal d ichtheid tussen beide groepen. De verschillen tussen het 4C-model,
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de UWW, de D2O-dilutie en de DXA voor de berekening van het percentage lichaamsvet waren 
relatief klein. Huidplooimetingen en BIS daarentegen verschilden fors van het 4C-model, mogelijk 
door de kenm erkende verdeling van lichaam svet bij de patiënten.
Deze studie toonde aan dat geadrenalectom eerde patiënten  tijdens conventionele gluco­
corticoid substitu tie een verhoogd percentage lichaam svet hebben, met een centripetale 
vetverdeling en een verm inderde vetvrije massa, maar een normale botm ineraal dichtheid. 
Voorts toonde de studie aan dat, voor de klinische praktijk , de DXA, de D2O-dilutie, de UW W  
en het 4C-model gebru ik t kunnen  w orden ter bepaling van de lichaamssamenstelling in  deze 
patiëntengroep, terw ijl de gem akkelijker bedside methodes, BIS en huidplooim etingen, geen 
betrouw bare resultaten  geven. Wij veronderstelden dat glucocorticoid overdosering, in  de 
groep patiënten  met een status na adrenalectom ie, de mogelijke oorzaak zou kunnen  zijn van 
hu n  abnormale lichaamssamenstelling, alhoewel groeihormoon deficiëntie na hypofyse chirurgie 
eveneens een bijdrage kan  hebben geleverd bij een aantal patiënten.
118
DANKW OORD
BILATERAL ADRENALECTOMY AS TREATMENT FOR CUSHING'S DISEASE
120
D A N K W O O R D
Nu dit proefschrift klaar is, is het tijd  om de vele mensen te bedanken die het mij mogelijk 
hebben gem aakt om d it w erk te verrichten. A llereerst bedank  ik  alle patiën ten  die, soms meer­
dere malen, bereid w aren mee te w erken aan mijn onderzoek. Een aantal van hen is zelfs met 
mij meegereisd naar M aastricht om zich, in  de gewelven van de afdeling Humane Biologie, in 
een groot bad onder w ater te laten dom pelen. Bedankt voor uw  levensverhalen, uw  bereidheid 
vele malen bloed af te staan voor diverse testen, en voor uw  vertrouw en in  mij als arts-assistent 
en later als in ternist.
Dank aan m ijn opleiders op de afdeling Endocriene Ziekten, professor Kloppenborg en 
professor Smals. Beiden hebben mij, elk op hun  eigen wijze, bijzonder weten te enthousiasmeren 
voor h e t vak Endocrinologie, en mij op vakkundige wijze gesteund en gestimuleerd to t het 
doen en beschrijven van d it prom otieonderzoek. Professor Kloppenborg, ik  dank  u voor uw  
raadgeving op m om enten dat ik  beslissingen m oest nem en over m ijn verdere carrière. Ik  weet 
dat ik  na uw  vertrek  van de afdeling uw  "zorgenkind" ben gebleven om dat dat proefschrift er 
maar n ie t kwam. H ier lig t het voor u. Professor Smals, bedank t voor uw  voortvarende begelei­
ding in  he t schrijven van de verschillende artikelen. Uw adequate en altijd snelle commentaar 
hebben de kw aliteit van de artikelen zeer zeker verhoogd. Toen ik  m ijn opleidingsplaats in  het 
aandachtsgebied Endocrinologie kon verdienen door het verrichten  van een diabetes onderzoek 
voor het Diabetes Fonds Nederland, heeft uw  enthousiaste idee voor een osteoporose onderzoek 
bij patiënten  met diabetes mellitus vervolgens geleid to t opmerkelijke resultaten . Uw stelling 
luidde immer: "Je k u n t het een doen en het ander n ie t laten." Ik denk  dat u bij uw  opm erking 
n ie t doelde op de com binatie k inderen  krijgen en promoveren, maar ik  heb hem  daar toch 
dankbaar voor gebruikt.
Dank aan m ijn promotor en co-promotor Ad Hermus en Gerlach Pieters voor het vertrouw en 
dat jullie in  mij hebben gesteld tijdens m ijn opleiding en prom otie-onderzoek. Ad, jij zag al 
vroeg een nieuwe endocrinoloog in  mij, toen je me destijds benaderde om onderzoek te komen 
doen bij die interessante groep Cushing patiënten, een groep patiënten  die je  na staat door je 
eigen onderzoek in  het verleden en voor wie je een grote rol speelt door je functie b innen hun  
patiëntenvereniging. Bedankt voor he t in itiëren  van dit onderzoek en je  kritische en stimule­
rende invloed tijdens de uitw erking ervan. Gerlach, van jou  leerde ik  zelfstandig te w orden in 
de patiëntenzorg en in  het onderwijs, zaken die me nog dagelijks van voordeel zijn. Bedankt 
voor je  altijd heldere en praktische adviezen met betrekking to t m ijn onderzoek.
De artsen van de afdeling Urologie bedank  ik  voor de uitstekende kw aliteit waarmee de 
chirurgische behandeling van de grote groep Cushing patiën ten  w erd verricht.
De medewerkers van het LEV-laboratorium (tegenwoordig afdeling ACE) w il ik  bedanken 
voor de vele horm oon bepalingen die w erden verricht in  het kader van d it onderzoek. 
Daarnaast kreeg ik  advies over statistiek, en w erden veel van de berekeningen ook daadwerke­
lijk door jullie verricht.
Jozet Frijns en W outer van M arken L ichtenbelt van de A fdeling Humane Biologie, 
U niversiteit M aastricht, zijn van onschatbare waarde geweest voor de m etingen van de 
lichaamssamenstelling en de berekeningen daarvan. Bedankt voor jullie voortvarende w erk­
wijze en de prettige ontvangst van mij en "mijn" patiënten.
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W il Straten, bedank t voor je eindeloze geduld w anneer ik  w eer eens m et com puter 
problem en kam pte en jou  hiermee op het secretariaat lastig viel door achter jouw  pc te kruipen.
Samen kw am en we er altijd wel weer uit.
Joop van den Bergh en M arie-Jose Pouwels bedank  ik  als mijn maatjes tijdens de opleiding 
op de Endo. H et was soms heel heilzaam om even te kunnen  praten  (of m opperen) met jullie 
omdat we samen in  hetzelfde schuitje zaten. H et doen van w etenschappelijk  onderzoek vergt 
naast kennis, inspiratie en doorzettingsverm ogen, immers ook he t vermogen de nodige portie 
tegenslag te verw erken. En dat gaat samen beter dan alleen.
H et diabetes team, Jos Lutterm an, Lammy Elving, Cees Tack, Gerald Vervoort, Petra van 
der Ven en Jannie de Best, dank ik voor de prettige sfeer waarin ik werd opgeleid in  dat andere 
deel van de Endocrinologie, de diabetes mellitus. Ook de verpleegkundigen op de afdeling 
Endocriene Ziekten en op de Poli Interne bedank ik  voor h u n  prettige samenwerking.
Familie en vrienden  wil ik  bedanken voor de interesse in  de voortgang van mijn onderzoek.
Ik vrees dat het wel eens heeft geleid to t enige ontrouw  in m ijn sociale contacten. Ik  beloof 
hierbij beterschap.
M ijn vader en m ijn m oeder wil ik  bedanken voor h u n  onuitputtelijke vertrouw en in  mij.
Jullie hebben me altijd gestim uleerd om aan die dingen te w erken die ik  graag w ilde bereiken.
Aan jullie draag ik  d it proefschrift dan ook op.
Lieve Aris, van he t begin to t he t einde was jij m ijn steun in  toeverlaat. Geen mens bij TNO 
weet zoveel van Cushing en Nelson als jij. Bedankt voor alle keren dat jij me w eer aan h e t w erk
zette en zelf de k inderen  opving. Zonder jou zou he t "een doen en he t ander n ie t laten" nooit -----
gelukt zijn. M aar nu kunnen  we weer een abonnem ent op de schouw burg nemen.
Lieve Vera, Daniel en Caroline, vanaf nu gaan we spelletjes doen op de computer.
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Linda Kemink w erd geboren op 7 augustus 1964 te Aalten. In  1982 behaalde zij het ein­
dexam en V.W.O. aan de Christelijke Scholengemeenschap te Aalten. In  dat zelfde jaar werd 
begonnen met de studie geneeskunde aan de Katholieke Universiteit te Nijmegen. Het doctoraal­
examen werd behaald in  1986 en h e t artsexam en in  1989. Direct aansluitend w erd begonnen aan 
de opleiding in terne geneeskunde in  het Academisch Ziekenhuis St. Radboud te Nijmegen 
(opleiders: Prof. Dr. A. van he t Laar en Prof. Dr. J.W.M. van der Meer). Op 1 ju n i 1995 w erd zij 
geregistreerd als in ternist.
Vanaf 1994 was zij verbonden aan de afdeling Endocriene Ziekten (hoofden: Prof. Dr. 
P.W.C. Kloppenborg en Prof. Dr. A.G.H. Smals). De opleiding to t endocrinoloog, welke in  1998 
werd afgerond (opleider: Prof. Dr. A.G.H. Smals), w erd gecom bineerd met he t onderzoek dat 
heeft geresulteerd in  d it proefschrift. In dezelfde periode w erd ook een onderzoek verrich t voor 
het Diabetes Fonds Nederland, waarbij de incidentie van osteoporose bij patiënten  met type 1 
diabetes mellitus werd onderzocht.
Sinds 1 januari 1999 is zij werkzaam  als internist-endocrinoloog in  h e t Jeroen Bosch 
Ziekenhuis, locatie Carolus (voorheen Carolus-Liduina Ziekenhuis) te 's-Hertogenbosch. Zij is 
getrouw d met Aris Lourens. Samen hebben ze drie k inderen, Vera, Daniel en Caroline.
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